data_6czt_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6czt _Structure_validation_residue.Date_analyzed 2019-04-12 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 N--CA 1.458 -0.601 0 N-CA-C 111.258 -0.324 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 66.3 tttp -64.77 132.44 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 109.02 -19.15 30.46 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 94.5 p -72.18 162.57 29.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 111.208 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -141.42 150.34 42.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.253 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -119.21 148.34 43.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.164 -175.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.8 p -146.8 133.79 14.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 176.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -98.6 120.82 39.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.212 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.56 91.22 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 174.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -88.86 125.09 34.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.169 -176.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -95.07 102.89 14.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.203 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -90.65 2.41 55.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -177.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -102.01 -175.29 27.87 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -178.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -111.63 28.85 8.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 111.189 -177.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -150.71 157.08 42.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.168 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -62.06 135.36 57.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.215 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 88.1 mt -114.39 141.11 48.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.218 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.71 106.82 17.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.19 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.427 HG22 HG13 ' A' ' 88' ' ' VAL . 96.7 t -92.91 130.46 41.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.141 -174.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.4 t -157.51 117.85 3.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 174.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.6 t -105.46 119.6 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.216 -176.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.04 -113.15 4.04 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -114.85 8.72 16.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.806 0.336 . . . . 0.0 111.21 177.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.6 m -103.41 126.46 50.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.223 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.0 t -81.42 125.32 30.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.165 174.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 81.8 mt -113.46 176.42 5.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.224 -175.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -75.94 147.29 39.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.166 -175.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -70.68 154.42 41.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 177.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 90.8 t -115.28 133.83 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.124 -178.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -71.41 159.37 85.74 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.231 -175.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -53.38 133.64 53.91 Favored 'Trans proline' 0 N--CA 1.458 -0.603 0 C-N-CA 121.752 1.635 . . . . 0.0 111.217 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.8 mt 52.07 34.38 13.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.221 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.89 -163.17 11.74 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.6 p -162.48 159.54 25.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.82 0.343 . . . . 0.0 111.167 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -145.65 129.64 17.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.164 176.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.18 134.29 33.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.203 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -128.4 160.9 30.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.241 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -141.37 147.66 38.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.234 -177.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -132.16 139.95 48.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.195 175.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.512 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 60.7 tp -71.84 -48.08 11.51 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.186 179.262 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.512 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 41.5 Cg_endo -83.44 117.12 2.39 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.694 1.596 . . . . 0.0 111.268 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.03 164.36 29.73 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.735 1.624 . . . . 0.0 111.139 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.8 -175.04 23.95 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 177.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 96' ' ' LYS . 29.5 t -84.37 126.36 33.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.782 0.325 . . . . 0.0 111.181 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -130.06 156.54 44.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.189 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 95.6 m -89.74 99.86 12.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 174.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.91 85.11 7.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 -175.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -80.42 124.35 28.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.178 176.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.427 HG13 HG22 ' A' ' 58' ' ' VAL . 51.7 t -127.79 84.65 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.176 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.18 -109.34 2.85 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -86.24 -12.56 49.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.756 0.312 . . . . 0.0 111.16 -176.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.91 157.08 18.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.185 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.3 t -157.02 114.11 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.178 176.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.97 141.13 34.85 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.148 -175.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -77.27 67.51 7.67 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.688 1.592 . . . . 0.0 111.218 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.8 t -74.51 116.82 17.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.175 -176.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 88.5 tttt -84.37 126.9 33.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.269 175.078 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 89.1 mt -104.47 95.86 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.179 -177.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -70.63 150.31 95.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.211 174.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.09 144.91 53.73 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.691 1.594 . . . . 0.0 111.209 -178.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 59.27 45.75 13.73 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.195 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 45.7 t -151.41 144.65 24.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.201 -177.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 25.3 m-85 -101.93 150.55 23.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.222 176.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -132.26 145.73 51.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.199 176.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 94.0 m -122.68 119.09 29.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.173 171.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.7 tp -110.38 111.73 23.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.137 -176.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 97.7 t -85.2 114.15 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.217 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.4 t -105.51 109.76 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.208 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -113.18 103.35 55.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.21 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -57.62 117.81 4.57 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.672 1.581 . . . . 0.0 111.183 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.49 84.06 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 176.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -127.09 -134.6 4.0 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -129.96 116.36 17.96 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 120.738 0.304 . . . . 0.0 111.209 -178.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -76.52 159.4 35.84 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.693 1.596 . . . . 0.0 111.225 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -145.09 120.94 10.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.262 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 57.6 tp -96.19 129.87 43.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.238 174.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.3 t -118.67 122.96 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.233 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -84.5 137.78 33.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 176.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -139.91 74.59 31.59 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.228 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_exo . . . . . 0 C--O 1.2 -1.39 0 C-N-CA 121.73 1.62 . . . . 0.0 111.165 178.949 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_exo . . . . . 0 N--CA 1.458 -0.609 0 N-CA-C 111.186 -0.351 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.9 tptp -57.55 118.71 5.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.211 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.88 -15.99 47.55 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -179.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 29.7 t -91.76 141.28 28.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.735 0.302 . . . . 0.0 111.21 -178.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.24 146.73 38.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 176.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -114.87 110.9 20.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.17 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.417 ' HB ' ' HB2' ' A' ' 76' ' ' PHE . 65.6 t -115.75 127.94 73.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.225 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.4 ttm180 -120.5 113.4 20.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.16 177.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.43 152.6 23.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 176.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -136.6 132.51 35.19 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.21 -178.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -93.1 98.03 11.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.274 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.0 5.6 48.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.231 -177.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.44 -164.34 33.22 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -177.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 -124.76 34.77 4.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.777 0.322 . . . . 0.0 111.209 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.6 p -159.06 -179.31 7.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -55.38 125.24 19.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 177.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . 0.424 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 37.3 tp -70.43 126.8 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -112.96 81.4 1.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 90.2 t -134.11 135.28 54.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 -178.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 64' ' ' SER . 42.8 t -110.98 116.12 30.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.132 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 64.8 t -106.54 101.48 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.197 -171.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.91 -110.12 3.27 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 176.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.4 p -101.7 -6.58 23.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.784 0.326 . . . . 0.0 111.185 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.9 m -120.68 115.83 24.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.18 -176.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 59' ' ' SER . 69.6 m -79.62 144.16 34.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.217 177.141 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 64.6 tp -115.81 115.74 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.183 -175.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -130.93 170.97 13.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.24 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 37.3 t0 55.23 59.54 3.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.171 178.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.424 ' HB ' ' HB3' ' A' ' 56' ' ' LEU . 94.4 t -122.01 125.15 72.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.225 176.248 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -69.92 154.68 94.48 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.186 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -52.98 135.92 59.62 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.675 1.583 . . . . 0.0 111.212 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 53.3 mt 67.34 21.72 9.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.186 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -93.26 -168.25 38.82 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 175.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.7 p -162.99 167.83 21.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.792 0.329 . . . . 0.0 111.224 -177.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.7 t -155.53 136.88 14.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 177.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -99.9 144.23 29.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.21 -177.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.417 ' HB2' ' HB ' ' A' ' 46' ' ' VAL . 73.7 m-85 -128.47 150.33 50.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.249 179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -123.39 119.96 31.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 -179.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -123.29 95.68 4.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.184 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.481 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 63.5 tp -61.23 -48.6 91.15 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.17 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.481 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 49.2 Cg_endo -80.0 118.92 3.81 Favored 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 121.723 1.616 . . . . 0.0 111.206 177.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.54 166.49 25.7 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 121.752 1.635 . . . . 0.0 111.178 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.85 -173.38 26.21 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.3 t -83.36 121.27 26.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.787 0.327 . . . . 0.0 111.227 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -121.43 146.79 46.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.192 176.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.8 m -101.64 125.66 48.33 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.203 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -101.46 98.45 8.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.211 172.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -79.28 118.27 21.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.188 -174.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 54.1 t -119.53 78.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.175 -178.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 70.06 -111.2 3.68 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.15 -4.67 48.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.81 0.338 . . . . 0.0 111.169 177.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.9 mm-40 -109.66 172.63 6.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.4 p -158.28 156.11 30.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.115 177.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 87.3 mt -117.46 132.46 23.55 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.18 179.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -78.04 70.28 7.14 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 121.735 1.623 . . . . 0.0 111.209 177.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.4 t -80.02 82.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.227 -169.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -67.38 113.15 5.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.223 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 73.8 mt -95.99 117.1 29.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.211 -174.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -100.19 152.73 37.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.253 172.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -56.71 131.55 46.29 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 121.701 1.601 . . . . 0.0 111.163 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 63.67 23.59 13.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 172.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 44.0 t -104.02 148.51 26.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.227 175.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -105.61 139.27 40.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.196 -176.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -133.53 142.82 48.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.162 -178.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.8 m -120.69 127.58 52.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.179 173.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 68.7 mt -109.94 97.22 6.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.236 -179.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.8 t -92.12 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 -177.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.3 t -101.69 106.78 17.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.143 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 55.1 tp60 -115.07 104.95 53.54 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.253 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -55.72 139.45 83.4 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.709 1.606 . . . . 0.0 111.146 177.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 103.98 -19.83 42.63 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -142.41 -153.86 6.01 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.33 149.79 36.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.832 0.349 . . . . 0.0 111.231 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -72.08 153.45 57.41 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.665 1.577 . . . . 0.0 111.188 179.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.1 mm-40 -107.93 143.44 36.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.215 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 54.7 tp -120.34 111.7 18.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.234 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.5 t -109.01 118.55 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.232 177.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -109.46 138.13 46.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.209 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -126.17 118.5 23.57 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.226 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo . . . . . 0 C--O 1.2 -1.411 0 C-N-CA 121.694 1.596 . . . . 0.0 111.242 178.455 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo . . . . . 0 N--CA 1.458 -0.574 0 N-CA-C 111.133 -0.372 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -57.16 122.62 12.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.211 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 114.98 -23.1 11.83 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 38.8 t -63.42 130.55 44.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.786 0.327 . . . . 0.0 111.152 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -114.67 146.71 40.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.209 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -125.38 138.94 54.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.196 -176.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.8 t -116.64 112.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.164 173.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -89.6 106.0 18.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.227 -176.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.62 145.57 30.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.235 178.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -125.61 128.92 48.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.244 178.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -85.78 95.39 9.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.35 9.6 30.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.207 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.78 -169.43 33.88 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -179.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -106.85 9.37 30.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.78 0.324 . . . . 0.0 111.213 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.2 p -159.53 178.97 9.33 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.232 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -60.42 126.39 27.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.162 175.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 82.3 mt -110.7 147.3 34.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.22 -176.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -79.05 85.08 5.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.174 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.3 t -115.65 128.08 73.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.125 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.0 p -150.66 156.03 40.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 173.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.2 t -129.87 123.68 57.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.232 -178.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 66.2 -112.73 5.15 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.5 p -114.36 7.22 16.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.835 0.35 . . . . 0.0 111.247 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.8 m -99.57 119.71 38.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.173 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 85.6 p -87.51 169.94 11.77 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.202 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.9 tp -158.14 134.9 9.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.159 178.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -149.62 179.51 7.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.193 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.2 t0 60.48 45.7 10.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.154 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.9 t -106.55 119.21 55.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.184 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.92 152.94 86.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.191 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_exo -53.66 133.68 55.01 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 121.709 1.606 . . . . 0.0 111.196 177.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 55.3 mt 66.86 21.07 10.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.224 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -96.67 -167.37 33.61 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 174.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 90.4 p -159.41 161.22 35.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 111.201 -178.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.1 t -160.91 141.72 11.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 177.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.66 132.49 39.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.235 -175.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -91.95 121.56 33.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.188 169.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -95.26 116.67 29.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.17 -174.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -126.1 94.45 4.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.241 175.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.489 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 55.3 tp -56.99 -49.83 91.71 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.201 177.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.489 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 42.4 Cg_endo -80.16 124.77 5.56 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.692 1.595 . . . . 0.0 111.162 174.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -75.19 164.9 32.14 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.655 1.57 . . . . 0.0 111.284 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.22 -172.42 24.67 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.6 t -86.07 128.1 34.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 111.144 -176.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -130.62 146.1 52.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.232 174.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 96.8 m -96.31 115.61 27.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 -176.099 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -83.27 94.18 7.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.228 177.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.7 tp60 -78.95 120.22 23.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 178.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.7 t -131.53 100.47 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.99 -119.31 13.03 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -96.2 -2.61 45.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.744 0.307 . . . . 0.0 111.179 178.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -110.19 170.06 8.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.23 -179.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 97.1 p -152.07 154.01 35.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.204 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.3 tp -144.1 107.68 4.93 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.413 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 85.3 Cg_endo -74.28 144.09 32.6 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 121.747 1.631 . . . . 0.0 111.202 178.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.3 p -149.42 135.41 11.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -85.57 122.65 29.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.239 173.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -94.09 113.35 25.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.259 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -71.57 147.34 92.24 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.214 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -53.81 129.12 32.5 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 121.66 1.573 . . . . 0.0 111.203 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 38.3 t0 55.42 62.94 2.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.229 177.052 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 85.5 p -145.6 165.61 28.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.212 178.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -122.54 147.29 46.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.251 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -131.62 144.46 51.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.256 176.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 86.8 m -105.68 119.7 39.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.155 176.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 59.8 tp -112.85 119.91 39.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.242 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.48 113.71 41.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.155 -178.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.7 t -91.63 97.55 11.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.248 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 57.5 tp60 -113.51 106.65 54.01 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.183 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_exo -56.46 144.04 85.3 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.69 1.593 . . . . 0.0 111.14 177.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 91.02 21.66 35.2 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 176.17 -169.62 42.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 178.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -88.14 150.4 47.22 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.807 0.337 . . . . 0.0 111.215 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -71.99 149.3 52.74 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.685 1.59 . . . . 0.0 111.18 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -106.98 148.66 28.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.224 179.047 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.0 tt -139.9 131.2 26.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 -175.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 86.9 t -122.99 129.14 75.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.266 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.62 136.72 37.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.229 178.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -139.68 76.32 29.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.231 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_exo . . . . . 0 C--O 1.2 -1.376 0 C-N-CA 121.681 1.587 . . . . 0.0 111.24 178.761 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo . . . . . 0 N--CA 1.457 -0.626 0 N-CA-C 111.189 -0.35 . . . . 0.0 111.189 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.7 tptp -59.42 119.18 6.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.165 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -1.02 60.07 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 174.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 56.7 p -105.22 -177.08 3.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.239 -177.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.19 154.51 51.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.216 178.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 74.1 t80 -130.44 132.01 45.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.153 -177.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 63.4 t -119.59 126.77 75.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.278 -175.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 85.9 mtt85 -99.81 177.06 5.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.189 170.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' A' ' 105' ' ' LEU . . . -148.24 155.72 41.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.22 -179.049 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 72.1 t80 -162.76 117.15 1.74 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.117 172.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -67.01 107.82 2.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.232 176.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -122.74 25.93 8.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.217 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -95.85 -157.34 31.83 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 47.7 p-10 -114.43 29.58 7.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.279 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.7 p -163.1 162.44 25.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.35 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -85.3 130.37 34.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.223 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . 0.507 ' C ' HD12 ' A' ' 56' ' ' LEU . 4.2 pp -157.35 162.66 39.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.231 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -98.28 148.26 23.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.148 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 99.5 t -127.13 135.33 63.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.197 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 86.8 p -153.96 166.7 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.221 177.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 8.4 p -148.72 129.93 5.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.164 176.314 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 62.98 -113.71 6.17 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 -178.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.8 p -112.8 10.84 19.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.982 0.42 . . . . 0.0 111.292 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.9 m -97.08 119.84 36.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.226 -178.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 28.8 t -81.39 123.28 28.43 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.193 172.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.1 mt -107.25 169.64 8.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.188 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -151.14 177.36 10.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.123 175.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -65.12 119.94 11.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.219 -175.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 89.9 t -106.41 119.47 55.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.153 173.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.93 145.47 92.68 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 -177.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -52.2 133.94 48.95 Favored 'Trans proline' 0 C--N 1.328 -0.538 0 C-N-CA 121.617 1.545 . . . . 0.0 111.203 177.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 69.3 mt 65.8 23.38 11.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.212 -178.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.71 -166.02 12.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.4 t -166.26 151.91 8.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.884 0.373 . . . . 0.0 111.146 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.1 t -143.79 140.74 30.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.255 177.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -70.04 128.82 37.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.197 -175.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -131.57 163.81 27.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.241 174.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -63.1 125.35 23.73 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 175.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -76.93 144.42 38.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.229 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.2 mt -120.56 140.16 29.97 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.195 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 34.9 Cg_exo -57.99 160.48 15.4 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.699 1.599 . . . . 0.0 111.219 171.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.86 151.13 62.56 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 121.599 1.533 . . . . 0.0 111.188 176.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.48 -157.37 25.64 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.6 t -103.38 109.01 20.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.803 0.335 . . . . 0.0 111.141 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -121.45 109.69 15.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.204 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 87.6 m -64.31 129.06 38.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.235 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -102.7 162.88 12.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.174 176.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -129.23 131.97 47.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.138 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -128.56 101.25 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 173.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.56 -116.18 7.67 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -174.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -99.6 1.32 43.57 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.699 0.285 . . . . 0.0 111.168 177.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.45 170.91 7.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.226 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.9 p -144.01 157.37 44.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.215 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.8 tp -154.42 114.03 2.46 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 -178.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 78.3 Cg_exo -55.0 125.23 18.49 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 121.634 1.556 . . . . 0.0 111.261 175.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 87.3 t -108.06 115.72 49.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.249 177.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -80.95 116.62 21.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 175.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.3 mt -103.23 114.99 29.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.264 -178.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -95.12 149.31 36.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 175.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -54.48 133.22 55.39 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.664 1.576 . . . . 0.0 111.339 177.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 55.81 60.59 3.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.213 178.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 83.3 p -146.95 160.37 42.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.229 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -128.83 143.47 50.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.162 -177.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -132.51 154.72 49.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.288 -177.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 87.6 m -128.75 120.78 27.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 170.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 48' ' ' ALA . 70.2 tp -104.04 112.96 26.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.121 -178.386 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 33.0 m -117.39 157.95 18.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.189 -176.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 80.5 p -90.36 159.68 16.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.156 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 93.9 mm-40 -124.74 155.96 69.06 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 173.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -50.53 127.99 22.23 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.731 1.621 . . . . 0.0 111.188 177.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 104.61 -9.69 48.69 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -172.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 83.39 42.72 7.76 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -108.66 145.82 32.42 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 111.165 -175.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.5 152.78 30.21 Favored 'Trans proline' 0 C--N 1.328 -0.552 0 C-N-CA 121.643 1.562 . . . . 0.0 111.24 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 68.3 tp60 -151.59 107.69 3.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.22 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 60.6 tp -92.55 118.87 31.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.187 -177.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 67.2 t -121.88 113.12 37.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.241 176.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -66.45 129.14 38.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.202 177.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.21 73.55 25.83 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo . . . . . 0 C--O 1.201 -1.336 0 C-N-CA 121.817 1.678 . . . . 0.0 111.124 178.273 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo . . . . . 0 N--CA 1.459 -0.523 0 N-CA-C 111.212 -0.342 . . . . 0.0 111.212 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -61.36 129.98 43.86 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.193 175.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.92 3.43 55.91 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 89.3 p -87.97 162.15 17.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.813 0.339 . . . . 0.0 111.116 174.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.33 148.15 24.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.19 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -120.12 138.82 53.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.188 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.6 p -148.16 144.09 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.173 -179.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.9 ptt180 -142.93 153.2 42.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.252 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -94.01 155.06 17.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.215 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -135.23 130.62 35.51 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.209 175.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 55.7 t-20 -102.67 93.71 5.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.204 -176.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.33 70.69 7.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.229 177.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.62 177.78 40.89 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -97.88 -7.04 31.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.808 0.337 . . . . 0.0 111.145 -175.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 34.8 t -99.88 135.84 40.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.164 178.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.1 mp0 -61.77 140.49 58.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.172 176.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.0 mt -124.8 144.89 50.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.171 -175.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -106.37 111.05 23.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.244 174.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.97 166.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.192 -177.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.6 p -148.01 158.24 43.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 51.2 t -127.04 85.6 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.243 174.246 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.97 -111.74 4.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -84.86 -12.61 53.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.771 0.319 . . . . 0.0 111.166 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.3 m -84.47 126.24 33.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.25 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.8 t -103.4 119.44 38.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.192 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.6 mt -125.11 67.5 1.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.173 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -91.42 158.82 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.251 -172.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 36.6 t0 55.31 60.49 3.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.213 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.1 t -82.55 130.77 35.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.203 176.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -61.55 147.08 88.92 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -171.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 71.3 Cg_exo -54.89 129.23 34.09 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.657 1.571 . . . . 0.0 111.178 178.252 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 86.4 mt 50.74 33.53 8.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -177.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -124.84 -162.03 11.25 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.5 p -148.64 166.42 28.37 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.743 0.306 . . . . 0.0 111.34 -177.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.4 t -137.95 100.96 4.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.235 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -76.93 150.85 35.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.201 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -142.82 127.81 18.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 174.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -116.42 178.6 4.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.183 -178.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 64.46 32.41 11.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.234 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 61.4 tp -102.16 115.26 64.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.084 -179.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -54.88 128.33 30.02 Favored 'Trans proline' 0 N--CA 1.457 -0.624 0 C-N-CA 121.787 1.658 . . . . 0.0 111.179 176.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_exo -56.14 146.48 70.45 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 121.692 1.595 . . . . 0.0 111.225 176.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 156.32 -175.44 33.99 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.8 t -85.78 125.07 32.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.786 0.327 . . . . 0.0 111.107 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -130.24 143.66 50.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.181 176.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 96.0 m -98.3 110.57 23.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.206 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -75.58 151.13 37.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 177.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 72.6 tp60 -134.91 117.16 15.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.204 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.3 t -127.37 106.5 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.196 173.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.78 -110.14 3.31 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -115.45 18.16 16.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.889 0.376 . . . . 0.0 111.191 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.0 tp60 -126.91 117.05 21.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -90.01 155.6 18.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.29 176.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 97.1 mt -141.2 85.12 12.23 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.142 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 59.4 Cg_exo -55.35 129.25 34.18 Favored 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 121.677 1.585 . . . . 0.0 111.189 174.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -146.71 135.35 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.235 -177.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -86.65 123.72 32.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.188 173.078 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.6 mt -100.02 103.01 14.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.271 -178.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -73.68 155.62 88.99 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.188 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.3 149.79 63.98 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 121.782 1.655 . . . . 0.0 111.197 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 55.01 45.23 26.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.13 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -151.58 147.48 26.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.272 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -106.38 140.51 39.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.197 -175.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -129.64 142.17 50.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.273 177.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.5 m -120.6 126.46 50.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.277 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 62.3 tp -94.49 98.91 11.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 176.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.5 t -78.42 106.15 8.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.115 -178.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 92.6 p -101.82 162.85 12.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -154.42 133.28 7.11 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.112 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.75 101.97 0.12 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 121.717 1.612 . . . . 0.0 111.121 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 71.67 22.54 78.66 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 176.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -118.43 -167.63 14.04 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.37 124.32 43.31 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 120.814 0.34 . . . . 0.0 111.251 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -75.49 157.96 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 121.611 1.541 . . . . 0.0 111.265 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -141.37 127.38 19.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.197 -175.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 95.5 mt -76.06 133.98 40.18 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.207 172.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 90.0 t -128.37 125.31 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.228 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.38 135.87 38.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.142 175.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 81.4 mt-10 -128.92 150.55 75.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -178.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo . . . . . 0 C--O 1.201 -1.349 0 C-N-CA 121.585 1.523 . . . . 0.0 111.231 178.002 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo . . . . . 0 N--CA 1.457 -0.64 0 N-CA-C 111.238 -0.332 . . . . 0.0 111.238 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -80.24 163.09 24.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.158 177.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 113.64 -20.25 18.13 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -176.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.3 t -154.68 140.59 18.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 0.0 111.165 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.1 151.48 24.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.173 176.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -114.9 139.6 49.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.182 -173.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.9 p -140.45 140.39 34.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.131 -178.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 42.1 ttm180 -111.42 112.44 24.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.171 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.56 123.83 33.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.187 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -110.56 134.81 52.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -100.28 104.18 15.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.189 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.65 4.01 53.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.284 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -97.21 -171.28 33.67 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -102.92 2.67 35.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.888 0.375 . . . . 0.0 111.199 178.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.9 p -149.01 167.73 25.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.294 177.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -53.95 122.15 9.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.231 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 90.1 mt -107.12 140.18 40.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -105.84 144.65 32.28 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.231 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.6 p -140.05 137.26 38.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 41.2 t -102.09 105.52 16.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.158 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 61.7 t -102.14 94.15 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.229 -176.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.16 -109.65 3.01 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -175.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.7 p -103.33 -7.42 21.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.752 0.31 . . . . 0.0 111.23 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.7 m -120.06 118.61 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.34 -175.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.3 p -89.13 154.63 20.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.251 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.4 mt -120.0 149.03 42.82 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.18 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 32.4 p30 -158.66 -174.9 5.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -178.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.3 t0 63.07 46.19 4.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.22 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.1 t -117.49 121.6 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.231 174.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -70.59 145.99 93.26 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.136 -175.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_exo -53.36 131.49 43.65 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.619 1.546 . . . . 0.0 111.285 177.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 65.9 mt 66.42 20.17 10.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.169 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.63 -166.93 12.19 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 173.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 84.7 p -155.7 165.08 37.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.724 0.297 . . . . 0.0 111.215 -179.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -149.58 143.21 25.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.147 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -93.01 138.59 31.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 -178.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -129.69 161.43 30.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.255 -178.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.424 ' O ' ' HB2' ' A' ' 78' ' ' PHE . 63.4 pttt -158.02 -155.77 0.52 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.24 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 77' ' ' LYS . 50.0 m-85 68.35 33.09 4.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.138 -173.342 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 56.0 tp -134.85 116.67 12.59 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.216 -176.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -51.67 133.83 45.41 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 121.618 1.545 . . . . 0.0 111.286 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -55.47 147.81 55.83 Favored 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 121.77 1.647 . . . . 0.0 111.217 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.16 -171.91 30.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.0 t -103.59 124.74 49.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.796 0.331 . . . . 0.0 111.21 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -127.33 140.52 52.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.243 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 90.6 m -80.4 117.54 21.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -92.26 108.31 19.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.197 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -85.14 113.8 21.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.254 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.9 t -122.66 103.09 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.215 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.65 -118.94 12.44 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -98.29 -0.55 43.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.741 0.305 . . . . 0.0 111.21 177.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.5 mm-40 -109.01 168.35 9.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.085 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.6 p -149.08 153.8 38.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.253 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.2 tp -151.76 114.91 3.0 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.273 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -57.37 131.41 44.58 Favored 'Trans proline' 0 C--N 1.326 -0.608 0 C-N-CA 121.613 1.542 . . . . 0.0 111.118 174.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.7 t -123.81 118.49 54.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.223 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -86.31 124.54 32.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 172.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 84.2 mt -118.54 139.03 52.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.175 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -114.82 155.68 45.99 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.32 -176.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -80.08 -19.92 9.08 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 121.788 1.658 . . . . 0.0 111.211 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -92.93 -30.57 15.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.193 -173.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.1 t -126.16 -158.76 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.145 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -149.42 159.23 44.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.192 176.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -126.85 141.72 51.74 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.203 177.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.4 m -102.16 118.23 36.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.147 -176.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.2 tp -99.52 113.31 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.0 t -81.69 99.29 4.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 177.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -85.22 123.41 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 -176.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -91.43 152.5 43.73 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.232 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.82 68.31 7.21 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.683 1.589 . . . . 0.0 111.24 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.49 -7.37 53.75 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -96.15 -166.41 34.13 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.329 -0.708 . . . . 0.0 111.329 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -87.79 127.73 56.94 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 120.877 0.37 . . . . 0.0 111.16 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -75.88 160.31 37.38 Favored 'Trans proline' 0 N--CA 1.457 -0.634 0 C-N-CA 121.683 1.589 . . . . 0.0 111.232 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -129.02 118.55 22.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.233 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 50.3 tp -85.39 128.03 34.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.18 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.7 126.73 72.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.143 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.76 73.18 5.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.137 179.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -67.59 129.99 93.32 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.234 -178.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo . . . . . 0 C--O 1.2 -1.42 0 C-N-CA 121.628 1.552 . . . . 0.0 111.161 178.262 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo . . . . . 0 N--CA 1.457 -0.666 0 N-CA-C 111.206 -0.344 . . . . 0.0 111.206 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -63.66 122.8 17.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.175 -176.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.63 5.56 78.24 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 175.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 69.8 m -117.84 160.65 21.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.842 0.353 . . . . 0.0 111.058 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.37 146.75 24.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.262 177.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -115.67 130.9 57.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.209 175.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 91.5 t -128.07 131.83 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 176.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -115.09 104.94 12.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.202 173.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.5 147.27 32.28 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.209 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -138.4 133.88 33.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.064 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -99.2 105.22 17.24 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.255 -178.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -96.22 24.3 5.83 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.204 -174.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -125.08 -165.05 12.02 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -115.3 27.33 9.44 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.756 0.313 . . . . 0.0 111.219 -179.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 44.8 t -146.6 130.33 17.04 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.199 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -59.91 131.3 50.44 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.12 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.8 mt -116.1 146.99 41.78 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.195 -174.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -89.38 111.13 21.91 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.217 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.6 t -96.07 134.32 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.157 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 83.8 p -156.76 167.37 30.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.239 173.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.08 130.57 5.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 178.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.33 -114.11 6.51 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -114.04 9.11 17.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.5 m -99.87 118.48 36.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.177 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.6 t -78.32 123.95 27.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.236 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 84.2 mt -106.4 173.55 6.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.303 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -73.11 144.9 46.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.217 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.86 150.64 45.58 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.223 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -117.63 123.4 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.106 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -72.82 159.96 84.05 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.2 -178.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_exo -52.69 125.64 18.59 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.713 1.609 . . . . 0.0 111.239 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.3 mt 65.18 22.07 12.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.108 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -112.29 -172.66 18.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 175.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.9 p -152.24 164.16 37.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.855 0.359 . . . . 0.0 111.171 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.9 t -149.39 124.95 10.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.213 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -83.6 137.7 33.7 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.315 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -127.41 118.35 23.92 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.215 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -113.25 168.42 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.19 -177.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 63.81 31.96 13.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.148 174.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 96.5 mt -86.22 125.88 66.66 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.268 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -55.71 116.04 2.88 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.639 1.559 . . . . 0.0 111.227 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -59.87 147.67 91.62 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.714 1.609 . . . . 0.0 111.175 175.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.97 -161.99 27.51 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.3 t -103.29 109.69 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.766 0.317 . . . . 0.0 111.249 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -132.78 155.31 49.14 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.345 -177.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 94.9 m -88.83 117.61 27.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.168 178.517 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -93.23 114.15 26.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.245 -179.223 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.3 tt0 -107.71 131.99 53.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.232 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.04 105.68 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 172.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 81.51 -106.66 2.64 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -174.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -113.02 -24.48 9.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.773 0.321 . . . . 0.0 111.133 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -98.72 154.0 18.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.277 -177.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 86.7 p -150.76 148.17 28.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.304 -178.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 87.6 mt -143.0 141.18 19.03 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.247 174.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 61.1 Cg_exo -55.97 137.09 77.92 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 121.65 1.567 . . . . 0.0 111.136 175.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 31.7 m -127.45 150.72 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.237 176.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.74 115.73 30.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.282 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 88.4 mt -107.68 100.04 9.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.204 -177.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -88.35 147.12 39.31 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.184 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.78 149.14 53.75 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 121.74 1.627 . . . . 0.0 111.188 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 59.98 43.26 14.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 81.9 p -147.95 161.17 41.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.176 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -114.93 144.74 43.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.196 -175.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -133.85 147.68 51.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.169 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 99.5 m -118.14 129.86 55.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.154 169.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 46.8 tp -114.95 101.41 8.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.185 -173.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 90.7 t -100.04 128.27 52.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.265 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.5 t -148.91 150.86 33.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.107 -176.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -153.48 159.0 32.65 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.232 176.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -54.98 123.72 14.5 Favored 'Trans proline' 0 C--N 1.328 -0.543 0 C-N-CA 121.688 1.592 . . . . 0.0 111.161 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.85 -20.01 47.51 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.204 -0.759 . . . . 0.0 111.204 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -111.08 -171.76 19.45 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -124.06 155.58 67.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 111.178 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -56.58 120.24 7.99 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.594 1.529 . . . . 0.0 111.28 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 60.3 tp60 -104.12 112.43 25.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.186 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 35.7 tp -77.23 129.26 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.222 178.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.4 t -115.92 114.03 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.094 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -76.24 132.91 40.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.214 -178.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 76.7 mt-10 -139.38 76.13 31.9 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.258 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo . . . . . 0 C--O 1.199 -1.45 0 C-N-CA 121.67 1.58 . . . . 0.0 111.183 179.466 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo . . . . . 0 N--CA 1.456 -0.687 0 N-CA-C 111.217 -0.34 . . . . 0.0 111.217 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -62.19 115.36 4.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.191 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.66 4.27 57.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 28.9 t -65.41 131.24 45.93 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.816 0.341 . . . . 0.0 111.177 -179.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.38 145.74 43.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.171 173.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -124.43 135.66 53.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.221 -174.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 67.4 t -124.32 124.81 69.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.241 170.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -110.49 111.7 23.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.199 176.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.11 149.33 29.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.258 175.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -148.42 132.34 17.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.272 177.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.441 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 58.5 t-20 -91.32 99.55 12.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.71 5.13 50.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 -175.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.97 -171.95 37.21 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -178.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -115.21 26.22 10.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.198 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -151.37 164.71 36.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.207 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -79.08 128.97 33.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.19 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.82 148.98 51.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.23 -177.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -85.24 128.71 34.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.217 176.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.9 t -122.78 130.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.204 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 42.1 t -136.46 123.26 21.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.229 -178.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 80.7 t -126.46 107.46 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 178.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.5 -116.48 5.78 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -102.26 -6.86 22.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.194 -176.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.3 m -115.54 136.08 53.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.133 -177.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -142.52 157.79 44.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.139 -174.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.8 tp -137.8 119.72 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.089 175.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -88.53 150.43 23.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.238 -175.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 54.51 59.41 4.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.229 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -75.99 120.82 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.12 148.41 97.89 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.227 -173.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -52.11 132.57 43.83 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.728 1.619 . . . . 0.0 111.196 176.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.8 mt 66.59 21.2 10.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.89 -171.15 43.36 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 174.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.1 p -159.77 166.61 30.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.327 . . . . 0.0 111.243 -176.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.8 t -157.89 118.77 3.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.213 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -88.79 139.03 30.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.228 -176.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -121.05 93.84 4.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.149 172.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -98.15 154.89 17.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.243 -164.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 67.0 33.73 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.175 166.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 97.5 mt -84.02 137.89 40.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.185 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -72.12 150.2 53.51 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.704 1.603 . . . . 0.0 111.234 175.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_exo -57.19 145.0 88.98 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 121.8 1.667 . . . . 0.0 111.192 178.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.27 -172.18 28.57 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.4 t -94.6 134.92 36.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.227 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 -125.82 151.18 47.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.195 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.6 m -95.26 118.97 32.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.196 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -108.7 96.02 6.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.216 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -94.9 130.51 41.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.214 -178.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.1 t -127.91 119.45 51.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.229 168.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.89 -110.02 3.24 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -178.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -108.16 -9.58 15.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.76 0.314 . . . . 0.0 111.177 -175.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -113.49 160.27 18.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 -176.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 95.5 p -147.69 148.46 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 90.4 mt -135.39 150.04 71.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.23 177.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.04 146.6 32.7 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.665 1.577 . . . . 0.0 111.129 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 89.4 t -124.78 126.37 71.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.189 177.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -99.11 111.94 24.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.131 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.8 mt -106.39 135.57 47.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.241 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -113.79 162.26 23.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.114 -177.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -51.91 123.28 12.07 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.781 1.654 . . . . 0.0 111.198 175.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 56.02 64.73 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 77.0 p -140.87 157.57 45.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.219 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -118.75 161.2 20.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.197 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.44 149.87 22.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.236 -175.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 97.7 m -127.42 134.73 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.208 179.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 63.6 tp -116.02 111.73 20.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.141 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.461 ' HB ' ' HB3' ' A' ' 114' ' ' GLN . 85.9 t -103.38 123.96 57.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.117 -175.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.441 ' HB2' ' HA ' ' A' ' 50' ' ' ASN . 67.8 m -84.91 127.6 34.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.236 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -98.37 148.77 34.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_exo -52.02 131.75 40.13 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.657 1.572 . . . . 0.0 111.179 176.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.95 -10.45 57.1 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -177.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.74 67.87 1.34 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 178.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.54 130.93 13.62 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-O 120.768 0.318 . . . . 0.0 111.303 175.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.61 148.86 33.55 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.742 1.628 . . . . 0.0 111.181 -178.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . 0.461 ' HB3' ' HB ' ' A' ' 106' ' ' VAL . 49.7 tt0 -126.01 125.04 42.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 171.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 94.3 mt -85.51 118.45 25.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.264 -175.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 82.9 t -125.9 112.52 30.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.306 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -86.37 136.24 33.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.258 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -100.8 152.78 37.93 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.17 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo . . . . . 0 C--O 1.201 -1.374 0 C-N-CA 121.741 1.628 . . . . 0.0 111.209 -178.562 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo . . . . . 0 N--CA 1.458 -0.595 0 N-CA-C 111.248 -0.328 . . . . 0.0 111.248 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -62.06 124.43 20.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 176.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 107.14 -1.61 35.26 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' SER . . . . . 0.441 ' O ' ' N ' ' A' ' 100' ' ' ASP . 86.0 p -68.59 161.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 111.159 -178.645 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -158.23 148.88 20.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.202 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -125.98 142.62 51.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.228 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.21 126.96 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 175.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -110.48 100.42 9.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.199 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.28 148.15 50.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.186 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -145.65 131.15 18.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.163 178.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.4 t-20 -93.95 100.06 12.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 178.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -88.72 4.23 48.05 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.189 -173.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -99.64 -169.19 30.01 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -176.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 -115.32 22.74 13.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.78 0.324 . . . . 0.0 111.161 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 82.5 p -147.04 168.89 20.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.232 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.42 ' HA ' ' O ' ' A' ' 68' ' ' VAL . 99.7 mt-10 -77.17 139.61 39.97 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.179 -173.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -115.93 147.9 40.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -106.41 111.51 24.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.211 173.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.6 m -128.44 166.09 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.208 -175.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.2 t -152.97 120.3 5.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.161 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 85.8 t -123.63 125.64 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.146 -173.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.61 -116.46 7.43 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -114.03 9.22 17.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.797 0.332 . . . . 0.0 111.231 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.3 m -121.8 115.22 22.25 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.206 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 67.5 m -84.95 149.43 25.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 54.3 tp -144.71 94.45 2.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.149 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -92.9 159.19 15.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.277 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 61.51 48.3 5.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.289 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 55' ' ' GLU . 99.2 t -72.0 118.91 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.273 178.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -64.02 145.79 97.7 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.267 -174.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_exo -52.95 130.69 39.02 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 121.717 1.611 . . . . 0.0 111.248 177.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 59.1 mt 66.17 21.31 11.13 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.177 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.32 177.99 39.77 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 175.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 87.0 p -156.1 164.71 38.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.758 0.314 . . . . 0.0 111.179 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.2 t -161.38 127.37 3.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.192 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -88.21 137.34 32.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.197 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -119.72 134.17 55.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.217 176.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -104.2 122.9 46.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.17 -171.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -111.07 133.67 53.26 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.207 173.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.492 ' HB2' ' HD3' ' A' ' 80' ' ' PRO . 96.3 mt -89.82 -45.52 0.41 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.275 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.492 ' HD3' ' HB2' ' A' ' 79' ' ' LEU . 22.5 Cg_endo -90.0 143.95 4.19 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 121.73 1.62 . . . . 0.0 111.225 -178.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_endo -76.48 162.85 32.86 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.689 1.592 . . . . 0.0 111.162 173.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.37 -118.45 1.28 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 177.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 87.1 p -166.59 162.61 16.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.812 0.339 . . . . 0.0 111.188 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -160.01 136.11 8.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.23 177.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 92.0 m -87.42 111.64 21.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.226 178.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.06 146.26 28.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.223 -176.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.4 tp60 -88.96 120.98 30.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 46.7 t -125.12 80.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.82 -115.3 7.4 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 -176.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.11 -3.24 51.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.86 0.362 . . . . 0.0 111.192 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -107.93 178.04 4.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.208 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -148.97 159.04 44.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.22 176.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.9 tp -135.02 110.94 10.95 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.154 -177.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -71.83 82.48 1.23 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.766 1.644 . . . . 0.0 111.165 176.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.4 t -75.05 118.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.162 -175.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -80.98 132.71 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 171.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 64.9 mt -111.79 90.64 3.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.25 -175.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -72.18 146.22 89.41 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.166 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_exo -54.32 124.33 15.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.761 1.64 . . . . 0.0 111.185 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 43' ' ' SER . 80.7 m-20 54.25 63.11 2.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.128 175.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.1 p -144.4 157.12 44.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.252 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -108.26 150.81 26.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.175 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -136.73 151.98 49.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 177.315 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 97.8 m -121.58 137.11 54.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.211 173.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.533 ' C ' HD23 ' A' ' 105' ' ' LEU . 7.1 tt -115.7 104.33 11.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.66 122.34 56.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.199 -178.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 90.5 p -142.82 162.73 34.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.199 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -159.82 159.24 27.52 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.257 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -56.49 125.04 17.73 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 121.739 1.626 . . . . 0.0 111.179 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 87.63 -0.14 84.63 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 174.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -120.28 -168.04 13.62 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -124.35 153.59 68.95 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.78 0.324 . . . . 0.0 111.269 179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -69.73 136.59 33.47 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.726 1.617 . . . . 0.0 111.252 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -112.31 125.63 54.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.218 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 58.3 tp -86.77 122.23 30.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 79.8 t -111.42 118.64 57.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 175.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -80.16 132.78 35.98 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.134 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 73.4 mt-10 -139.64 75.06 32.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.217 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo . . . . . 0 C--O 1.201 -1.339 0 C-N-CA 121.685 1.59 . . . . 0.0 111.228 179.339 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo . . . . . 0 N--CA 1.455 -0.769 0 CA-C-O 120.927 0.303 . . . . 0.0 111.318 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.23 130.1 45.3 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.126 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.24 -20.1 26.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -177.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 81.1 p -96.7 166.86 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.823 0.344 . . . . 0.0 111.152 177.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.54 150.76 21.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.272 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -119.06 132.36 56.02 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 97.2 t -129.32 138.25 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -127.56 95.31 4.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 178.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.85 151.29 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.148 177.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -137.57 134.6 35.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.151 179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -92.97 93.96 8.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.191 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.95 11.36 25.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.218 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.51 -167.35 36.69 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 74.8 m-20 -116.1 24.59 11.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.742 0.306 . . . . 0.0 111.152 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 84.8 p -157.01 163.24 39.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.196 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 mp0 -64.76 137.11 57.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.233 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -121.56 150.65 41.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.197 -177.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -101.2 119.99 39.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 173.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 97.7 t -115.99 128.65 73.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.984 -172.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.3 t -134.86 106.33 6.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.143 177.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.9 t -108.42 114.12 45.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.16 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.57 -111.5 4.02 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 95.9 p -100.62 -5.0 27.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 111.227 178.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 69.7 p -87.44 166.41 14.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 -176.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 43.6 t -163.93 126.29 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.231 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 68.5 tp -135.3 118.51 16.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -94.92 156.25 16.42 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.207 -175.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 61.49 49.23 5.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.214 173.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.3 t -74.85 121.11 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.272 175.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -64.8 147.81 97.77 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.206 -170.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -52.94 131.9 44.71 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.637 1.558 . . . . 0.0 111.295 177.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 67.7 mt 65.68 21.56 11.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.167 178.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -99.14 -170.04 30.78 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 174.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 96.1 p -149.91 162.03 41.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.761 0.315 . . . . 0.0 111.16 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.3 t -140.55 108.04 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.174 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -81.44 137.65 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -120.47 100.5 7.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.212 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -96.99 169.13 10.04 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.157 176.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 55.36 41.22 31.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 55.2 tp -106.58 116.53 58.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.239 -177.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.71 121.56 9.77 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.642 1.562 . . . . 0.0 111.236 -178.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.12 150.56 64.62 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 121.676 1.584 . . . . 0.0 111.214 176.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.04 172.08 19.07 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.6 t -84.84 113.12 21.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.778 0.323 . . . . 0.0 111.169 176.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -128.75 147.92 50.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.157 -178.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.5 m -93.86 95.17 8.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.237 172.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -78.82 146.19 33.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.164 -176.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.1 tp60 -112.64 104.52 12.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.069 173.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.97 93.74 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 71.42 -118.59 7.32 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -100.81 4.14 42.64 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.816 0.341 . . . . 0.0 111.155 -177.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -129.25 117.62 21.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.16 -177.191 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 31.1 t -69.35 131.15 44.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.157 172.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 84.3 mt -131.85 82.61 59.57 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.257 -178.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -70.92 143.62 45.71 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.766 1.644 . . . . 0.0 111.188 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.0 p -161.05 142.27 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 -176.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 59.8 tttm -79.29 119.1 21.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.212 173.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.9 mt -102.49 98.47 8.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.204 -173.376 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -78.52 152.91 78.62 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.201 173.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.46 148.91 61.57 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 121.787 1.658 . . . . 0.0 111.214 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 57.83 45.13 19.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.187 179.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.3 t -151.44 145.52 25.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -103.21 132.31 49.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.299 -174.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -123.9 107.32 11.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.267 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 96.7 m -83.87 125.52 32.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.089 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 89.8 mt -112.5 91.24 3.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.209 -178.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.4 t -82.81 117.06 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.097 177.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.7 t -112.9 133.55 54.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.261 178.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 -140.77 94.15 8.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.156 -176.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -57.56 119.51 6.81 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 121.79 1.66 . . . . 0.0 111.245 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 84.99 5.44 86.08 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -128.04 -133.08 3.66 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -136.36 121.0 12.87 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.715 0.293 . . . . 0.0 111.234 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.69 163.31 34.04 Favored 'Trans proline' 0 C--N 1.327 -0.586 0 C-N-CA 121.757 1.638 . . . . 0.0 111.167 178.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.3 tp60 -145.57 124.83 12.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.258 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.3 mp -102.24 131.22 48.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.191 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.1 t -130.45 120.69 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.238 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.21 132.78 42.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.23 176.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -130.96 149.26 73.23 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.205 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo . . . . . 0 C--O 1.199 -1.44 0 C-N-CA 121.641 1.561 . . . . 0.0 111.135 177.544 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.785 0.326 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.32 145.97 88.73 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.214 177.349 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -73.39 144.47 36.6 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 121.705 1.603 . . . . 0.0 111.258 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 66.3 tttp -64.77 132.44 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 109.02 -19.15 30.46 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 94.5 p -72.18 162.57 29.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 111.208 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -141.42 150.34 42.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.253 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -119.21 148.34 43.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.164 -175.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.8 p -146.8 133.79 14.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 176.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -98.6 120.82 39.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.212 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.56 91.22 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 174.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -88.86 125.09 34.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.169 -176.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -95.07 102.89 14.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.203 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -90.65 2.41 55.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -177.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -102.01 -175.29 27.87 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -178.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -111.63 28.85 8.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 111.189 -177.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -150.71 157.08 42.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.168 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -62.06 135.36 57.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.215 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 88.1 mt -114.39 141.11 48.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.218 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.71 106.82 17.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.19 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.427 HG22 HG13 ' A' ' 88' ' ' VAL . 96.7 t -92.91 130.46 41.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.141 -174.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.4 t -157.51 117.85 3.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 174.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.6 t -105.46 119.6 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.216 -176.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.04 -113.15 4.04 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -114.85 8.72 16.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.806 0.336 . . . . 0.0 111.21 177.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.6 m -103.41 126.46 50.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.223 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.0 t -81.42 125.32 30.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.165 174.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 81.8 mt -113.46 176.42 5.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.224 -175.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -75.94 147.29 39.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.166 -175.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -70.68 154.42 41.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 177.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 90.8 t -115.28 133.83 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.124 -178.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -71.41 159.37 85.74 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.231 -175.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -53.38 133.64 53.91 Favored 'Trans proline' 0 N--CA 1.458 -0.603 0 C-N-CA 121.752 1.635 . . . . 0.0 111.217 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.8 mt 52.07 34.38 13.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.221 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.89 -163.17 11.74 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.6 p -162.48 159.54 25.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.82 0.343 . . . . 0.0 111.167 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -145.65 129.64 17.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.164 176.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.18 134.29 33.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.203 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -128.4 160.9 30.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.241 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -141.37 147.66 38.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.234 -177.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -132.16 139.95 48.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.195 175.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.512 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 60.7 tp -71.84 -48.08 11.51 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.186 179.262 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.512 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 41.5 Cg_endo -83.44 117.12 2.39 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.694 1.596 . . . . 0.0 111.268 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.03 164.36 29.73 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.735 1.624 . . . . 0.0 111.139 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.8 -175.04 23.95 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 177.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 96' ' ' LYS . 29.5 t -84.37 126.36 33.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.782 0.325 . . . . 0.0 111.181 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -130.06 156.54 44.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.189 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 95.6 m -89.74 99.86 12.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 174.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.91 85.11 7.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 -175.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -80.42 124.35 28.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.178 176.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.427 HG13 HG22 ' A' ' 58' ' ' VAL . 51.7 t -127.79 84.65 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.176 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.18 -109.34 2.85 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -86.24 -12.56 49.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.756 0.312 . . . . 0.0 111.16 -176.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.91 157.08 18.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.185 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.3 t -157.02 114.11 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.178 176.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.97 141.13 34.85 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.148 -175.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -77.27 67.51 7.67 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.688 1.592 . . . . 0.0 111.218 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.8 t -74.51 116.82 17.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.175 -176.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 88.5 tttt -84.37 126.9 33.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.269 175.078 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 89.1 mt -104.47 95.86 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.179 -177.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -70.63 150.31 95.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.211 174.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.09 144.91 53.73 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.691 1.594 . . . . 0.0 111.209 -178.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 59.27 45.75 13.73 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.195 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 45.7 t -151.41 144.65 24.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.201 -177.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 25.3 m-85 -101.93 150.55 23.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.222 176.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -132.26 145.73 51.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.199 176.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 94.0 m -122.68 119.09 29.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.173 171.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.7 tp -110.38 111.73 23.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.137 -176.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 97.7 t -85.2 114.15 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.217 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.4 t -105.51 109.76 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.208 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -113.18 103.35 55.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.21 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -57.62 117.81 4.57 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.672 1.581 . . . . 0.0 111.183 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.49 84.06 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 176.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -127.09 -134.6 4.0 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -129.96 116.36 17.96 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 120.738 0.304 . . . . 0.0 111.209 -178.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -76.52 159.4 35.84 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.693 1.596 . . . . 0.0 111.225 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -145.09 120.94 10.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.262 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 57.6 tp -96.19 129.87 43.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.238 174.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.3 t -118.67 122.96 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.233 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -84.5 137.78 33.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 176.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -139.91 74.59 31.59 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.228 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_exo . . . . . 0 C--O 1.2 -1.39 0 C-N-CA 121.73 1.62 . . . . 0.0 111.165 178.949 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 96.5 mm-40 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.883 0.373 . . . . 0.0 111.19 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.79 148.32 75.78 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.205 178.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_exo -55.86 151.77 39.06 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.742 1.628 . . . . 0.0 111.186 176.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.9 tptp -57.55 118.71 5.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.211 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.88 -15.99 47.55 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -179.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 29.7 t -91.76 141.28 28.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.735 0.302 . . . . 0.0 111.21 -178.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.24 146.73 38.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 176.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -114.87 110.9 20.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.17 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.417 ' HB ' ' HB2' ' A' ' 76' ' ' PHE . 65.6 t -115.75 127.94 73.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.225 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.4 ttm180 -120.5 113.4 20.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.16 177.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.43 152.6 23.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 176.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -136.6 132.51 35.19 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.21 -178.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -93.1 98.03 11.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.274 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.0 5.6 48.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.231 -177.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.44 -164.34 33.22 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -177.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 -124.76 34.77 4.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.777 0.322 . . . . 0.0 111.209 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.6 p -159.06 -179.31 7.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -55.38 125.24 19.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 177.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . 0.424 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 37.3 tp -70.43 126.8 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -112.96 81.4 1.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 90.2 t -134.11 135.28 54.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 -178.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 64' ' ' SER . 42.8 t -110.98 116.12 30.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.132 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 64.8 t -106.54 101.48 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.197 -171.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.91 -110.12 3.27 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 176.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.4 p -101.7 -6.58 23.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.784 0.326 . . . . 0.0 111.185 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.9 m -120.68 115.83 24.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.18 -176.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 59' ' ' SER . 69.6 m -79.62 144.16 34.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.217 177.141 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 64.6 tp -115.81 115.74 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.183 -175.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -130.93 170.97 13.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.24 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 37.3 t0 55.23 59.54 3.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.171 178.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.424 ' HB ' ' HB3' ' A' ' 56' ' ' LEU . 94.4 t -122.01 125.15 72.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.225 176.248 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -69.92 154.68 94.48 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.186 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -52.98 135.92 59.62 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.675 1.583 . . . . 0.0 111.212 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 53.3 mt 67.34 21.72 9.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.186 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -93.26 -168.25 38.82 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 175.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.7 p -162.99 167.83 21.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.792 0.329 . . . . 0.0 111.224 -177.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.7 t -155.53 136.88 14.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 177.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -99.9 144.23 29.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.21 -177.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.417 ' HB2' ' HB ' ' A' ' 46' ' ' VAL . 73.7 m-85 -128.47 150.33 50.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.249 179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -123.39 119.96 31.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 -179.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -123.29 95.68 4.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.184 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.481 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 63.5 tp -61.23 -48.6 91.15 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.17 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.481 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 49.2 Cg_endo -80.0 118.92 3.81 Favored 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 121.723 1.616 . . . . 0.0 111.206 177.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.54 166.49 25.7 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 121.752 1.635 . . . . 0.0 111.178 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.85 -173.38 26.21 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.3 t -83.36 121.27 26.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.787 0.327 . . . . 0.0 111.227 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -121.43 146.79 46.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.192 176.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.8 m -101.64 125.66 48.33 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.203 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -101.46 98.45 8.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.211 172.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -79.28 118.27 21.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.188 -174.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 54.1 t -119.53 78.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.175 -178.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 70.06 -111.2 3.68 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.15 -4.67 48.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.81 0.338 . . . . 0.0 111.169 177.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.9 mm-40 -109.66 172.63 6.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.4 p -158.28 156.11 30.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.115 177.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 87.3 mt -117.46 132.46 23.55 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.18 179.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -78.04 70.28 7.14 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 121.735 1.623 . . . . 0.0 111.209 177.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.4 t -80.02 82.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.227 -169.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -67.38 113.15 5.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.223 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 73.8 mt -95.99 117.1 29.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.211 -174.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -100.19 152.73 37.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.253 172.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -56.71 131.55 46.29 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 121.701 1.601 . . . . 0.0 111.163 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 63.67 23.59 13.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 172.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 44.0 t -104.02 148.51 26.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.227 175.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -105.61 139.27 40.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.196 -176.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -133.53 142.82 48.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.162 -178.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.8 m -120.69 127.58 52.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.179 173.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 68.7 mt -109.94 97.22 6.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.236 -179.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.8 t -92.12 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 -177.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.3 t -101.69 106.78 17.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.143 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 55.1 tp60 -115.07 104.95 53.54 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.253 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -55.72 139.45 83.4 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.709 1.606 . . . . 0.0 111.146 177.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 103.98 -19.83 42.63 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -142.41 -153.86 6.01 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.33 149.79 36.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.832 0.349 . . . . 0.0 111.231 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -72.08 153.45 57.41 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.665 1.577 . . . . 0.0 111.188 179.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.1 mm-40 -107.93 143.44 36.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.215 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 54.7 tp -120.34 111.7 18.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.234 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.5 t -109.01 118.55 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.232 177.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -109.46 138.13 46.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.209 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -126.17 118.5 23.57 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.226 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo . . . . . 0 C--O 1.2 -1.411 0 C-N-CA 121.694 1.596 . . . . 0.0 111.242 178.455 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 . . . . . 0 CA--C 1.523 -0.072 0 CA-C-O 120.84 0.352 . . . . 0.0 111.235 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -73.88 148.66 87.3 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.234 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -55.52 140.1 82.89 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 121.726 1.618 . . . . 0.0 111.133 177.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -57.16 122.62 12.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.211 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 114.98 -23.1 11.83 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 38.8 t -63.42 130.55 44.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.786 0.327 . . . . 0.0 111.152 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -114.67 146.71 40.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.209 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -125.38 138.94 54.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.196 -176.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.8 t -116.64 112.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.164 173.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -89.6 106.0 18.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.227 -176.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.62 145.57 30.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.235 178.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -125.61 128.92 48.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.244 178.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -85.78 95.39 9.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.35 9.6 30.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.207 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.78 -169.43 33.88 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -179.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -106.85 9.37 30.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.78 0.324 . . . . 0.0 111.213 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.2 p -159.53 178.97 9.33 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.232 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -60.42 126.39 27.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.162 175.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 82.3 mt -110.7 147.3 34.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.22 -176.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -79.05 85.08 5.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.174 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.3 t -115.65 128.08 73.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.125 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.0 p -150.66 156.03 40.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 173.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.2 t -129.87 123.68 57.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.232 -178.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 66.2 -112.73 5.15 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.5 p -114.36 7.22 16.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.835 0.35 . . . . 0.0 111.247 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.8 m -99.57 119.71 38.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.173 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 85.6 p -87.51 169.94 11.77 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.202 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.9 tp -158.14 134.9 9.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.159 178.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -149.62 179.51 7.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.193 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.2 t0 60.48 45.7 10.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.154 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.9 t -106.55 119.21 55.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.184 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.92 152.94 86.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.191 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_exo -53.66 133.68 55.01 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 121.709 1.606 . . . . 0.0 111.196 177.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 55.3 mt 66.86 21.07 10.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.224 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -96.67 -167.37 33.61 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 174.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 90.4 p -159.41 161.22 35.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 111.201 -178.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.1 t -160.91 141.72 11.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 177.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.66 132.49 39.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.235 -175.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -91.95 121.56 33.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.188 169.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -95.26 116.67 29.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.17 -174.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -126.1 94.45 4.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.241 175.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.489 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 55.3 tp -56.99 -49.83 91.71 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.201 177.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.489 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 42.4 Cg_endo -80.16 124.77 5.56 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.692 1.595 . . . . 0.0 111.162 174.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -75.19 164.9 32.14 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.655 1.57 . . . . 0.0 111.284 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.22 -172.42 24.67 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.6 t -86.07 128.1 34.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 111.144 -176.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -130.62 146.1 52.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.232 174.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 96.8 m -96.31 115.61 27.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 -176.099 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -83.27 94.18 7.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.228 177.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.7 tp60 -78.95 120.22 23.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 178.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.7 t -131.53 100.47 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.99 -119.31 13.03 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -96.2 -2.61 45.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.744 0.307 . . . . 0.0 111.179 178.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -110.19 170.06 8.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.23 -179.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 97.1 p -152.07 154.01 35.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.204 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.3 tp -144.1 107.68 4.93 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.413 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 85.3 Cg_endo -74.28 144.09 32.6 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 121.747 1.631 . . . . 0.0 111.202 178.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.3 p -149.42 135.41 11.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -85.57 122.65 29.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.239 173.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -94.09 113.35 25.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.259 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -71.57 147.34 92.24 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.214 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -53.81 129.12 32.5 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 121.66 1.573 . . . . 0.0 111.203 178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 38.3 t0 55.42 62.94 2.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.229 177.052 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 85.5 p -145.6 165.61 28.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.212 178.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -122.54 147.29 46.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.251 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -131.62 144.46 51.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.256 176.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 86.8 m -105.68 119.7 39.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.155 176.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 59.8 tp -112.85 119.91 39.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.242 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.48 113.71 41.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.155 -178.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.7 t -91.63 97.55 11.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.248 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 57.5 tp60 -113.51 106.65 54.01 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.183 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_exo -56.46 144.04 85.3 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.69 1.593 . . . . 0.0 111.14 177.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 91.02 21.66 35.2 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 176.17 -169.62 42.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 178.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -88.14 150.4 47.22 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.807 0.337 . . . . 0.0 111.215 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -71.99 149.3 52.74 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.685 1.59 . . . . 0.0 111.18 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -106.98 148.66 28.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.224 179.047 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.0 tt -139.9 131.2 26.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 -175.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 86.9 t -122.99 129.14 75.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.266 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.62 136.72 37.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.229 178.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -139.68 76.32 29.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.231 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_exo . . . . . 0 C--O 1.2 -1.376 0 C-N-CA 121.681 1.587 . . . . 0.0 111.24 178.761 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.798 0.332 . . . . 0.0 111.206 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.56 149.87 86.47 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.223 176.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -53.8 144.25 55.53 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.726 1.618 . . . . 0.0 111.189 176.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.7 tptp -59.42 119.18 6.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.165 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -1.02 60.07 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 174.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 56.7 p -105.22 -177.08 3.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.239 -177.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.19 154.51 51.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.216 178.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 74.1 t80 -130.44 132.01 45.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.153 -177.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 63.4 t -119.59 126.77 75.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.278 -175.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 85.9 mtt85 -99.81 177.06 5.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.189 170.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' A' ' 105' ' ' LEU . . . -148.24 155.72 41.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.22 -179.049 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 72.1 t80 -162.76 117.15 1.74 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.117 172.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -67.01 107.82 2.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.232 176.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -122.74 25.93 8.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.217 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -95.85 -157.34 31.83 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 47.7 p-10 -114.43 29.58 7.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.279 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.7 p -163.1 162.44 25.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.35 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -85.3 130.37 34.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.223 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . 0.507 ' C ' HD12 ' A' ' 56' ' ' LEU . 4.2 pp -157.35 162.66 39.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.231 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -98.28 148.26 23.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.148 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 99.5 t -127.13 135.33 63.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.197 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 86.8 p -153.96 166.7 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.221 177.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 8.4 p -148.72 129.93 5.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.164 176.314 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 62.98 -113.71 6.17 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 -178.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.8 p -112.8 10.84 19.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.982 0.42 . . . . 0.0 111.292 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.9 m -97.08 119.84 36.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.226 -178.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 28.8 t -81.39 123.28 28.43 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.193 172.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.1 mt -107.25 169.64 8.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.188 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -151.14 177.36 10.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.123 175.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -65.12 119.94 11.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.219 -175.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 89.9 t -106.41 119.47 55.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.153 173.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.93 145.47 92.68 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 -177.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -52.2 133.94 48.95 Favored 'Trans proline' 0 C--N 1.328 -0.538 0 C-N-CA 121.617 1.545 . . . . 0.0 111.203 177.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 69.3 mt 65.8 23.38 11.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.212 -178.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.71 -166.02 12.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.4 t -166.26 151.91 8.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.884 0.373 . . . . 0.0 111.146 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.1 t -143.79 140.74 30.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.255 177.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -70.04 128.82 37.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.197 -175.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -131.57 163.81 27.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.241 174.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -63.1 125.35 23.73 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 175.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -76.93 144.42 38.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.229 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.2 mt -120.56 140.16 29.97 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.195 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 34.9 Cg_exo -57.99 160.48 15.4 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.699 1.599 . . . . 0.0 111.219 171.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.86 151.13 62.56 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 121.599 1.533 . . . . 0.0 111.188 176.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.48 -157.37 25.64 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.6 t -103.38 109.01 20.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.803 0.335 . . . . 0.0 111.141 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -121.45 109.69 15.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.204 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 87.6 m -64.31 129.06 38.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.235 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -102.7 162.88 12.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.174 176.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -129.23 131.97 47.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.138 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -128.56 101.25 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 173.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.56 -116.18 7.67 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -174.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -99.6 1.32 43.57 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.699 0.285 . . . . 0.0 111.168 177.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.45 170.91 7.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.226 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.9 p -144.01 157.37 44.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.215 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.8 tp -154.42 114.03 2.46 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 -178.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 78.3 Cg_exo -55.0 125.23 18.49 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 121.634 1.556 . . . . 0.0 111.261 175.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 87.3 t -108.06 115.72 49.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.249 177.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -80.95 116.62 21.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 175.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.3 mt -103.23 114.99 29.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.264 -178.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -95.12 149.31 36.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 175.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -54.48 133.22 55.39 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.664 1.576 . . . . 0.0 111.339 177.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 55.81 60.59 3.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.213 178.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 83.3 p -146.95 160.37 42.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.229 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -128.83 143.47 50.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.162 -177.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -132.51 154.72 49.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.288 -177.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 87.6 m -128.75 120.78 27.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 170.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 48' ' ' ALA . 70.2 tp -104.04 112.96 26.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.121 -178.386 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 33.0 m -117.39 157.95 18.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.189 -176.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 80.5 p -90.36 159.68 16.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.156 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 93.9 mm-40 -124.74 155.96 69.06 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 173.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -50.53 127.99 22.23 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.731 1.621 . . . . 0.0 111.188 177.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 104.61 -9.69 48.69 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -172.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 83.39 42.72 7.76 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -108.66 145.82 32.42 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 111.165 -175.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.5 152.78 30.21 Favored 'Trans proline' 0 C--N 1.328 -0.552 0 C-N-CA 121.643 1.562 . . . . 0.0 111.24 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 68.3 tp60 -151.59 107.69 3.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.22 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 60.6 tp -92.55 118.87 31.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.187 -177.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 67.2 t -121.88 113.12 37.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.241 176.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -66.45 129.14 38.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.202 177.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.21 73.55 25.83 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo . . . . . 0 C--O 1.201 -1.336 0 C-N-CA 121.817 1.678 . . . . 0.0 111.124 178.273 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 . . . . . 0 CA--C 1.524 -0.055 0 CA-C-O 120.806 0.336 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.407 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . . . -70.75 146.35 93.32 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.12 178.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 39' ' ' ALA . 71.6 Cg_exo -55.93 141.14 86.29 Favored 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 121.678 1.585 . . . . 0.0 111.212 179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -61.36 129.98 43.86 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.193 175.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.92 3.43 55.91 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 89.3 p -87.97 162.15 17.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.813 0.339 . . . . 0.0 111.116 174.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.33 148.15 24.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.19 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -120.12 138.82 53.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.188 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.6 p -148.16 144.09 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.173 -179.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.9 ptt180 -142.93 153.2 42.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.252 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -94.01 155.06 17.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.215 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -135.23 130.62 35.51 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.209 175.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 55.7 t-20 -102.67 93.71 5.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.204 -176.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.33 70.69 7.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.229 177.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.62 177.78 40.89 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -97.88 -7.04 31.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.808 0.337 . . . . 0.0 111.145 -175.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 34.8 t -99.88 135.84 40.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.164 178.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.1 mp0 -61.77 140.49 58.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.172 176.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.0 mt -124.8 144.89 50.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.171 -175.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -106.37 111.05 23.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.244 174.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.97 166.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.192 -177.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.6 p -148.01 158.24 43.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 51.2 t -127.04 85.6 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.243 174.246 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.97 -111.74 4.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -84.86 -12.61 53.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.771 0.319 . . . . 0.0 111.166 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.3 m -84.47 126.24 33.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.25 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.8 t -103.4 119.44 38.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.192 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.6 mt -125.11 67.5 1.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.173 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -91.42 158.82 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.251 -172.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 36.6 t0 55.31 60.49 3.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.213 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.1 t -82.55 130.77 35.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.203 176.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -61.55 147.08 88.92 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -171.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 71.3 Cg_exo -54.89 129.23 34.09 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.657 1.571 . . . . 0.0 111.178 178.252 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 86.4 mt 50.74 33.53 8.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -177.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -124.84 -162.03 11.25 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.5 p -148.64 166.42 28.37 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.743 0.306 . . . . 0.0 111.34 -177.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.4 t -137.95 100.96 4.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.235 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -76.93 150.85 35.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.201 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -142.82 127.81 18.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 174.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -116.42 178.6 4.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.183 -178.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 64.46 32.41 11.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.234 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 61.4 tp -102.16 115.26 64.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.084 -179.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -54.88 128.33 30.02 Favored 'Trans proline' 0 N--CA 1.457 -0.624 0 C-N-CA 121.787 1.658 . . . . 0.0 111.179 176.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_exo -56.14 146.48 70.45 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 121.692 1.595 . . . . 0.0 111.225 176.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 156.32 -175.44 33.99 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.8 t -85.78 125.07 32.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.786 0.327 . . . . 0.0 111.107 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -130.24 143.66 50.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.181 176.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 96.0 m -98.3 110.57 23.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.206 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -75.58 151.13 37.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 177.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 72.6 tp60 -134.91 117.16 15.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.204 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.3 t -127.37 106.5 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.196 173.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.78 -110.14 3.31 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -115.45 18.16 16.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.889 0.376 . . . . 0.0 111.191 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.0 tp60 -126.91 117.05 21.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -90.01 155.6 18.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.29 176.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 97.1 mt -141.2 85.12 12.23 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.142 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 59.4 Cg_exo -55.35 129.25 34.18 Favored 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 121.677 1.585 . . . . 0.0 111.189 174.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -146.71 135.35 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.235 -177.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -86.65 123.72 32.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.188 173.078 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.6 mt -100.02 103.01 14.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.271 -178.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -73.68 155.62 88.99 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.188 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.3 149.79 63.98 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 121.782 1.655 . . . . 0.0 111.197 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 55.01 45.23 26.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.13 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -151.58 147.48 26.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.272 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -106.38 140.51 39.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.197 -175.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -129.64 142.17 50.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.273 177.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.5 m -120.6 126.46 50.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.277 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 62.3 tp -94.49 98.91 11.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 176.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.5 t -78.42 106.15 8.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.115 -178.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 92.6 p -101.82 162.85 12.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -154.42 133.28 7.11 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.112 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.75 101.97 0.12 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 121.717 1.612 . . . . 0.0 111.121 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 71.67 22.54 78.66 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 176.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -118.43 -167.63 14.04 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.37 124.32 43.31 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 120.814 0.34 . . . . 0.0 111.251 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -75.49 157.96 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 121.611 1.541 . . . . 0.0 111.265 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -141.37 127.38 19.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.197 -175.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 95.5 mt -76.06 133.98 40.18 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.207 172.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 90.0 t -128.37 125.31 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.228 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.38 135.87 38.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.142 175.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 81.4 mt-10 -128.92 150.55 75.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -178.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo . . . . . 0 C--O 1.201 -1.349 0 C-N-CA 121.585 1.523 . . . . 0.0 111.231 178.002 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.6 tt0 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.744 0.307 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.406 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . . . -80.67 152.55 72.55 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.118 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 39' ' ' ALA . 77.8 Cg_exo -56.99 134.99 68.16 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.645 1.564 . . . . 0.0 111.238 178.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -80.24 163.09 24.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.158 177.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 113.64 -20.25 18.13 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -176.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.3 t -154.68 140.59 18.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 0.0 111.165 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.1 151.48 24.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.173 176.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -114.9 139.6 49.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.182 -173.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.9 p -140.45 140.39 34.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.131 -178.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 42.1 ttm180 -111.42 112.44 24.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.171 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.56 123.83 33.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.187 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -110.56 134.81 52.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -100.28 104.18 15.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.189 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.65 4.01 53.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.284 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -97.21 -171.28 33.67 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -102.92 2.67 35.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.888 0.375 . . . . 0.0 111.199 178.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.9 p -149.01 167.73 25.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.294 177.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -53.95 122.15 9.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.231 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 90.1 mt -107.12 140.18 40.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -105.84 144.65 32.28 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.231 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.6 p -140.05 137.26 38.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 41.2 t -102.09 105.52 16.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.158 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 61.7 t -102.14 94.15 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.229 -176.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.16 -109.65 3.01 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -175.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.7 p -103.33 -7.42 21.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.752 0.31 . . . . 0.0 111.23 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.7 m -120.06 118.61 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.34 -175.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.3 p -89.13 154.63 20.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.251 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.4 mt -120.0 149.03 42.82 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.18 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 32.4 p30 -158.66 -174.9 5.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -178.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.3 t0 63.07 46.19 4.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.22 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.1 t -117.49 121.6 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.231 174.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -70.59 145.99 93.26 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.136 -175.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 82.6 Cg_exo -53.36 131.49 43.65 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.619 1.546 . . . . 0.0 111.285 177.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 65.9 mt 66.42 20.17 10.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.169 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.63 -166.93 12.19 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 173.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 84.7 p -155.7 165.08 37.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.724 0.297 . . . . 0.0 111.215 -179.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -149.58 143.21 25.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.147 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -93.01 138.59 31.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 -178.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -129.69 161.43 30.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.255 -178.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.424 ' O ' ' HB2' ' A' ' 78' ' ' PHE . 63.4 pttt -158.02 -155.77 0.52 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.24 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 77' ' ' LYS . 50.0 m-85 68.35 33.09 4.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.138 -173.342 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 56.0 tp -134.85 116.67 12.59 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.216 -176.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -51.67 133.83 45.41 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 121.618 1.545 . . . . 0.0 111.286 179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -55.47 147.81 55.83 Favored 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 121.77 1.647 . . . . 0.0 111.217 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.16 -171.91 30.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.0 t -103.59 124.74 49.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.796 0.331 . . . . 0.0 111.21 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -127.33 140.52 52.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.243 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 90.6 m -80.4 117.54 21.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -92.26 108.31 19.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.197 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -85.14 113.8 21.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.254 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.9 t -122.66 103.09 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.215 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.65 -118.94 12.44 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -98.29 -0.55 43.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.741 0.305 . . . . 0.0 111.21 177.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.5 mm-40 -109.01 168.35 9.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.085 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.6 p -149.08 153.8 38.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.253 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.2 tp -151.76 114.91 3.0 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.273 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -57.37 131.41 44.58 Favored 'Trans proline' 0 C--N 1.326 -0.608 0 C-N-CA 121.613 1.542 . . . . 0.0 111.118 174.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.7 t -123.81 118.49 54.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.223 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -86.31 124.54 32.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 172.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 84.2 mt -118.54 139.03 52.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.175 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -114.82 155.68 45.99 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.32 -176.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -80.08 -19.92 9.08 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 121.788 1.658 . . . . 0.0 111.211 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -92.93 -30.57 15.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.193 -173.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.1 t -126.16 -158.76 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.145 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -149.42 159.23 44.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.192 176.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -126.85 141.72 51.74 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.203 177.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.4 m -102.16 118.23 36.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.147 -176.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.2 tp -99.52 113.31 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.0 t -81.69 99.29 4.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 177.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -85.22 123.41 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 -176.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -91.43 152.5 43.73 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.232 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.82 68.31 7.21 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.683 1.589 . . . . 0.0 111.24 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.49 -7.37 53.75 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -96.15 -166.41 34.13 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.329 -0.708 . . . . 0.0 111.329 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -87.79 127.73 56.94 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 120.877 0.37 . . . . 0.0 111.16 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -75.88 160.31 37.38 Favored 'Trans proline' 0 N--CA 1.457 -0.634 0 C-N-CA 121.683 1.589 . . . . 0.0 111.232 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -129.02 118.55 22.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.233 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 50.3 tp -85.39 128.03 34.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.18 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.7 126.73 72.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.143 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.76 73.18 5.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.137 179.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -67.59 129.99 93.32 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.234 -178.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo . . . . . 0 C--O 1.2 -1.42 0 C-N-CA 121.628 1.552 . . . . 0.0 111.161 178.262 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.804 0.335 . . . . 0.0 111.243 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.439 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . . . -70.39 146.25 94.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.271 177.476 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 39' ' ' ALA . 74.0 Cg_exo -56.98 140.46 92.49 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 121.671 1.58 . . . . 0.0 111.206 178.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -63.66 122.8 17.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.175 -176.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.63 5.56 78.24 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 175.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 69.8 m -117.84 160.65 21.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.842 0.353 . . . . 0.0 111.058 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.37 146.75 24.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.262 177.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -115.67 130.9 57.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.209 175.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 91.5 t -128.07 131.83 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 176.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -115.09 104.94 12.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.202 173.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.5 147.27 32.28 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.209 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -138.4 133.88 33.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.064 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -99.2 105.22 17.24 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.255 -178.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -96.22 24.3 5.83 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.204 -174.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -125.08 -165.05 12.02 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -115.3 27.33 9.44 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.756 0.313 . . . . 0.0 111.219 -179.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 44.8 t -146.6 130.33 17.04 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.199 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -59.91 131.3 50.44 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.12 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.8 mt -116.1 146.99 41.78 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.195 -174.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -89.38 111.13 21.91 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.217 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.6 t -96.07 134.32 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.157 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 83.8 p -156.76 167.37 30.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.239 173.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.08 130.57 5.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 178.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.33 -114.11 6.51 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -114.04 9.11 17.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.5 m -99.87 118.48 36.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.177 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.6 t -78.32 123.95 27.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.236 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 84.2 mt -106.4 173.55 6.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.303 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -73.11 144.9 46.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.217 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.86 150.64 45.58 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.223 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -117.63 123.4 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.106 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -72.82 159.96 84.05 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.2 -178.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_exo -52.69 125.64 18.59 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.713 1.609 . . . . 0.0 111.239 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.3 mt 65.18 22.07 12.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.108 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -112.29 -172.66 18.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 175.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.9 p -152.24 164.16 37.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.855 0.359 . . . . 0.0 111.171 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.9 t -149.39 124.95 10.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.213 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -83.6 137.7 33.7 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.315 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -127.41 118.35 23.92 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.215 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -113.25 168.42 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.19 -177.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 63.81 31.96 13.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.148 174.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 96.5 mt -86.22 125.88 66.66 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.268 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -55.71 116.04 2.88 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.639 1.559 . . . . 0.0 111.227 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -59.87 147.67 91.62 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.714 1.609 . . . . 0.0 111.175 175.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.97 -161.99 27.51 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.3 t -103.29 109.69 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.766 0.317 . . . . 0.0 111.249 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -132.78 155.31 49.14 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.345 -177.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 94.9 m -88.83 117.61 27.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.168 178.517 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -93.23 114.15 26.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.245 -179.223 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.3 tt0 -107.71 131.99 53.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.232 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.04 105.68 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 172.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 81.51 -106.66 2.64 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -174.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -113.02 -24.48 9.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.773 0.321 . . . . 0.0 111.133 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -98.72 154.0 18.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.277 -177.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 86.7 p -150.76 148.17 28.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.304 -178.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 87.6 mt -143.0 141.18 19.03 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.247 174.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 61.1 Cg_exo -55.97 137.09 77.92 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 121.65 1.567 . . . . 0.0 111.136 175.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 31.7 m -127.45 150.72 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.237 176.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.74 115.73 30.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.282 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 88.4 mt -107.68 100.04 9.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.204 -177.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -88.35 147.12 39.31 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.184 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.78 149.14 53.75 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 121.74 1.627 . . . . 0.0 111.188 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 59.98 43.26 14.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 81.9 p -147.95 161.17 41.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.176 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -114.93 144.74 43.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.196 -175.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -133.85 147.68 51.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.169 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 99.5 m -118.14 129.86 55.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.154 169.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 46.8 tp -114.95 101.41 8.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.185 -173.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 90.7 t -100.04 128.27 52.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.265 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.5 t -148.91 150.86 33.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.107 -176.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -153.48 159.0 32.65 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.232 176.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -54.98 123.72 14.5 Favored 'Trans proline' 0 C--N 1.328 -0.543 0 C-N-CA 121.688 1.592 . . . . 0.0 111.161 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.85 -20.01 47.51 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.204 -0.759 . . . . 0.0 111.204 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -111.08 -171.76 19.45 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -124.06 155.58 67.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 111.178 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -56.58 120.24 7.99 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.594 1.529 . . . . 0.0 111.28 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 60.3 tp60 -104.12 112.43 25.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.186 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 35.7 tp -77.23 129.26 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.222 178.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.4 t -115.92 114.03 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.094 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -76.24 132.91 40.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.214 -178.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 76.7 mt-10 -139.38 76.13 31.9 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.258 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo . . . . . 0 C--O 1.199 -1.45 0 C-N-CA 121.67 1.58 . . . . 0.0 111.183 179.466 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.2 tp60 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.798 0.332 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.415 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . . . -74.26 149.47 86.93 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.182 177.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 39' ' ' ALA . 77.9 Cg_exo -55.51 143.38 78.38 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 121.778 1.652 . . . . 0.0 111.217 177.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -62.19 115.36 4.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.191 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.66 4.27 57.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 28.9 t -65.41 131.24 45.93 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.816 0.341 . . . . 0.0 111.177 -179.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.38 145.74 43.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.171 173.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -124.43 135.66 53.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.221 -174.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 67.4 t -124.32 124.81 69.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.241 170.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -110.49 111.7 23.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.199 176.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.11 149.33 29.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.258 175.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -148.42 132.34 17.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.272 177.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.441 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 58.5 t-20 -91.32 99.55 12.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.71 5.13 50.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 -175.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.97 -171.95 37.21 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -178.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -115.21 26.22 10.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.198 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -151.37 164.71 36.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.207 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -79.08 128.97 33.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.19 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.82 148.98 51.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.23 -177.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -85.24 128.71 34.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.217 176.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.9 t -122.78 130.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.204 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 42.1 t -136.46 123.26 21.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.229 -178.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 80.7 t -126.46 107.46 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 178.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.5 -116.48 5.78 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -102.26 -6.86 22.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.194 -176.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.3 m -115.54 136.08 53.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.133 -177.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -142.52 157.79 44.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.139 -174.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.8 tp -137.8 119.72 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.089 175.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -88.53 150.43 23.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.238 -175.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 54.51 59.41 4.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.229 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -75.99 120.82 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.12 148.41 97.89 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.227 -173.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -52.11 132.57 43.83 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.728 1.619 . . . . 0.0 111.196 176.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.8 mt 66.59 21.2 10.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.89 -171.15 43.36 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 174.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.1 p -159.77 166.61 30.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.327 . . . . 0.0 111.243 -176.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.8 t -157.89 118.77 3.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.213 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -88.79 139.03 30.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.228 -176.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -121.05 93.84 4.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.149 172.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -98.15 154.89 17.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.243 -164.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 67.0 33.73 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.175 166.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 97.5 mt -84.02 137.89 40.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.185 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -72.12 150.2 53.51 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.704 1.603 . . . . 0.0 111.234 175.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_exo -57.19 145.0 88.98 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 121.8 1.667 . . . . 0.0 111.192 178.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.27 -172.18 28.57 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.4 t -94.6 134.92 36.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.227 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 -125.82 151.18 47.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.195 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.6 m -95.26 118.97 32.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.196 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -108.7 96.02 6.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.216 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -94.9 130.51 41.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.214 -178.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.1 t -127.91 119.45 51.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.229 168.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.89 -110.02 3.24 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -178.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -108.16 -9.58 15.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.76 0.314 . . . . 0.0 111.177 -175.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -113.49 160.27 18.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 -176.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 95.5 p -147.69 148.46 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 90.4 mt -135.39 150.04 71.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.23 177.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.04 146.6 32.7 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.665 1.577 . . . . 0.0 111.129 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 89.4 t -124.78 126.37 71.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.189 177.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -99.11 111.94 24.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.131 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.8 mt -106.39 135.57 47.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.241 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -113.79 162.26 23.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.114 -177.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -51.91 123.28 12.07 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.781 1.654 . . . . 0.0 111.198 175.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 56.02 64.73 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 77.0 p -140.87 157.57 45.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.219 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -118.75 161.2 20.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.197 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.44 149.87 22.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.236 -175.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 97.7 m -127.42 134.73 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.208 179.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 63.6 tp -116.02 111.73 20.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.141 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.461 ' HB ' ' HB3' ' A' ' 114' ' ' GLN . 85.9 t -103.38 123.96 57.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.117 -175.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.441 ' HB2' ' HA ' ' A' ' 50' ' ' ASN . 67.8 m -84.91 127.6 34.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.236 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -98.37 148.77 34.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_exo -52.02 131.75 40.13 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.657 1.572 . . . . 0.0 111.179 176.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.95 -10.45 57.1 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -177.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.74 67.87 1.34 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 178.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.54 130.93 13.62 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-O 120.768 0.318 . . . . 0.0 111.303 175.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.61 148.86 33.55 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.742 1.628 . . . . 0.0 111.181 -178.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . 0.461 ' HB3' ' HB ' ' A' ' 106' ' ' VAL . 49.7 tt0 -126.01 125.04 42.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 171.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 94.3 mt -85.51 118.45 25.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.264 -175.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 82.9 t -125.9 112.52 30.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.306 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -86.37 136.24 33.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.258 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -100.8 152.78 37.93 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.17 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo . . . . . 0 C--O 1.201 -1.374 0 C-N-CA 121.741 1.628 . . . . 0.0 111.209 -178.562 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.82 0.343 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.2 145.36 88.32 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.156 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -75.72 155.63 39.68 Favored 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 121.653 1.569 . . . . 0.0 111.248 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -62.06 124.43 20.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 176.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 107.14 -1.61 35.26 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.441 ' O ' ' N ' ' A' ' 100' ' ' ASP . 86.0 p -68.59 161.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 111.159 -178.645 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -158.23 148.88 20.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.202 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -125.98 142.62 51.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.228 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.21 126.96 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 175.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -110.48 100.42 9.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.199 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.28 148.15 50.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.186 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -145.65 131.15 18.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.163 178.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.4 t-20 -93.95 100.06 12.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 178.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -88.72 4.23 48.05 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.189 -173.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -99.64 -169.19 30.01 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -176.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 -115.32 22.74 13.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.78 0.324 . . . . 0.0 111.161 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 82.5 p -147.04 168.89 20.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.232 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.42 ' HA ' ' O ' ' A' ' 68' ' ' VAL . 99.7 mt-10 -77.17 139.61 39.97 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.179 -173.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -115.93 147.9 40.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -106.41 111.51 24.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.211 173.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.6 m -128.44 166.09 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.208 -175.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.2 t -152.97 120.3 5.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.161 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 85.8 t -123.63 125.64 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.146 -173.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.61 -116.46 7.43 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -114.03 9.22 17.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.797 0.332 . . . . 0.0 111.231 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.3 m -121.8 115.22 22.25 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.206 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 67.5 m -84.95 149.43 25.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 54.3 tp -144.71 94.45 2.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.149 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -92.9 159.19 15.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.277 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 61.51 48.3 5.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.289 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 55' ' ' GLU . 99.2 t -72.0 118.91 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.273 178.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -64.02 145.79 97.7 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.267 -174.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_exo -52.95 130.69 39.02 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 121.717 1.611 . . . . 0.0 111.248 177.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 59.1 mt 66.17 21.31 11.13 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.177 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.32 177.99 39.77 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 175.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 87.0 p -156.1 164.71 38.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.758 0.314 . . . . 0.0 111.179 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.2 t -161.38 127.37 3.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.192 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -88.21 137.34 32.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.197 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -119.72 134.17 55.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.217 176.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -104.2 122.9 46.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.17 -171.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -111.07 133.67 53.26 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.207 173.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.492 ' HB2' ' HD3' ' A' ' 80' ' ' PRO . 96.3 mt -89.82 -45.52 0.41 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.275 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.492 ' HD3' ' HB2' ' A' ' 79' ' ' LEU . 22.5 Cg_endo -90.0 143.95 4.19 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 121.73 1.62 . . . . 0.0 111.225 -178.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_endo -76.48 162.85 32.86 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.689 1.592 . . . . 0.0 111.162 173.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.37 -118.45 1.28 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 177.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 87.1 p -166.59 162.61 16.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.812 0.339 . . . . 0.0 111.188 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -160.01 136.11 8.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.23 177.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 92.0 m -87.42 111.64 21.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.226 178.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.06 146.26 28.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.223 -176.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.4 tp60 -88.96 120.98 30.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 46.7 t -125.12 80.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.82 -115.3 7.4 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 -176.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.11 -3.24 51.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.86 0.362 . . . . 0.0 111.192 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -107.93 178.04 4.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.208 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -148.97 159.04 44.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.22 176.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.9 tp -135.02 110.94 10.95 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.154 -177.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -71.83 82.48 1.23 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.766 1.644 . . . . 0.0 111.165 176.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.4 t -75.05 118.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.162 -175.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -80.98 132.71 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 171.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 64.9 mt -111.79 90.64 3.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.25 -175.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -72.18 146.22 89.41 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.166 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_exo -54.32 124.33 15.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.761 1.64 . . . . 0.0 111.185 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 43' ' ' SER . 80.7 m-20 54.25 63.11 2.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.128 175.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.1 p -144.4 157.12 44.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.252 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -108.26 150.81 26.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.175 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -136.73 151.98 49.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 177.315 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 97.8 m -121.58 137.11 54.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.211 173.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.533 ' C ' HD23 ' A' ' 105' ' ' LEU . 7.1 tt -115.7 104.33 11.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.66 122.34 56.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.199 -178.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 90.5 p -142.82 162.73 34.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.199 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -159.82 159.24 27.52 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.257 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -56.49 125.04 17.73 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 121.739 1.626 . . . . 0.0 111.179 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 87.63 -0.14 84.63 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 174.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -120.28 -168.04 13.62 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -124.35 153.59 68.95 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.78 0.324 . . . . 0.0 111.269 179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -69.73 136.59 33.47 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.726 1.617 . . . . 0.0 111.252 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -112.31 125.63 54.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.218 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 58.3 tp -86.77 122.23 30.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 79.8 t -111.42 118.64 57.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 175.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -80.16 132.78 35.98 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.134 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 73.4 mt-10 -139.64 75.06 32.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.217 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo . . . . . 0 C--O 1.201 -1.339 0 C-N-CA 121.685 1.59 . . . . 0.0 111.228 179.339 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 . . . . . 0 CA--C 1.522 -0.117 0 CA-C-O 120.928 0.394 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.27 145.91 88.8 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.11 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.9 78.07 1.81 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 121.637 1.558 . . . . 0.0 111.318 178.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.23 130.1 45.3 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.126 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.24 -20.1 26.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -177.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 81.1 p -96.7 166.86 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.823 0.344 . . . . 0.0 111.152 177.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.54 150.76 21.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.272 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -119.06 132.36 56.02 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 97.2 t -129.32 138.25 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -127.56 95.31 4.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 178.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.85 151.29 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.148 177.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -137.57 134.6 35.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.151 179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -92.97 93.96 8.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.191 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.95 11.36 25.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.218 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.51 -167.35 36.69 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 74.8 m-20 -116.1 24.59 11.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.742 0.306 . . . . 0.0 111.152 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 84.8 p -157.01 163.24 39.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.196 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 mp0 -64.76 137.11 57.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.233 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -121.56 150.65 41.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.197 -177.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -101.2 119.99 39.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 173.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 97.7 t -115.99 128.65 73.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.984 -172.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.3 t -134.86 106.33 6.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.143 177.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.9 t -108.42 114.12 45.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.16 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.57 -111.5 4.02 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 95.9 p -100.62 -5.0 27.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 111.227 178.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 69.7 p -87.44 166.41 14.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 -176.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 43.6 t -163.93 126.29 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.231 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 68.5 tp -135.3 118.51 16.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -94.92 156.25 16.42 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.207 -175.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 61.49 49.23 5.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.214 173.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.3 t -74.85 121.11 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.272 175.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -64.8 147.81 97.77 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.206 -170.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -52.94 131.9 44.71 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.637 1.558 . . . . 0.0 111.295 177.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 67.7 mt 65.68 21.56 11.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.167 178.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -99.14 -170.04 30.78 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 174.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 96.1 p -149.91 162.03 41.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.761 0.315 . . . . 0.0 111.16 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.3 t -140.55 108.04 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.174 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -81.44 137.65 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -120.47 100.5 7.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.212 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -96.99 169.13 10.04 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.157 176.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 55.36 41.22 31.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 55.2 tp -106.58 116.53 58.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.239 -177.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.71 121.56 9.77 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.642 1.562 . . . . 0.0 111.236 -178.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.12 150.56 64.62 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 121.676 1.584 . . . . 0.0 111.214 176.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.04 172.08 19.07 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.6 t -84.84 113.12 21.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.778 0.323 . . . . 0.0 111.169 176.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -128.75 147.92 50.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.157 -178.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.5 m -93.86 95.17 8.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.237 172.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -78.82 146.19 33.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.164 -176.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.1 tp60 -112.64 104.52 12.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.069 173.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.97 93.74 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 71.42 -118.59 7.32 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -100.81 4.14 42.64 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.816 0.341 . . . . 0.0 111.155 -177.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -129.25 117.62 21.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.16 -177.191 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 31.1 t -69.35 131.15 44.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.157 172.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 84.3 mt -131.85 82.61 59.57 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.257 -178.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -70.92 143.62 45.71 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.766 1.644 . . . . 0.0 111.188 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.0 p -161.05 142.27 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 -176.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 59.8 tttm -79.29 119.1 21.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.212 173.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.9 mt -102.49 98.47 8.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.204 -173.376 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -78.52 152.91 78.62 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.201 173.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.46 148.91 61.57 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 121.787 1.658 . . . . 0.0 111.214 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 57.83 45.13 19.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.187 179.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.3 t -151.44 145.52 25.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -103.21 132.31 49.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.299 -174.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -123.9 107.32 11.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.267 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 96.7 m -83.87 125.52 32.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.089 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 89.8 mt -112.5 91.24 3.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.209 -178.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.4 t -82.81 117.06 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.097 177.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.7 t -112.9 133.55 54.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.261 178.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 -140.77 94.15 8.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.156 -176.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -57.56 119.51 6.81 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 121.79 1.66 . . . . 0.0 111.245 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 84.99 5.44 86.08 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -128.04 -133.08 3.66 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -136.36 121.0 12.87 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.715 0.293 . . . . 0.0 111.234 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.69 163.31 34.04 Favored 'Trans proline' 0 C--N 1.327 -0.586 0 C-N-CA 121.757 1.638 . . . . 0.0 111.167 178.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.3 tp60 -145.57 124.83 12.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.258 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.3 mp -102.24 131.22 48.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.191 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.1 t -130.45 120.69 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.238 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.21 132.78 42.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.23 176.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -130.96 149.26 73.23 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.205 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo . . . . . 0 C--O 1.199 -1.44 0 C-N-CA 121.641 1.561 . . . . 0.0 111.135 177.544 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 N--CA 1.458 -0.601 0 N-CA-C 111.258 -0.324 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 66.3 tttp -64.77 132.44 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 109.02 -19.15 30.46 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 94.5 p -72.18 162.57 29.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 111.208 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -141.42 150.34 42.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.253 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -119.21 148.34 43.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.164 -175.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.8 p -146.8 133.79 14.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 176.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -98.6 120.82 39.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.212 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.56 91.22 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 174.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -88.86 125.09 34.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.169 -176.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -95.07 102.89 14.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.203 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -90.65 2.41 55.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -177.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -102.01 -175.29 27.87 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -178.261 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -111.63 28.85 8.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 111.189 -177.227 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -150.71 157.08 42.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.168 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -62.06 135.36 57.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.215 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 88.1 mt -114.39 141.11 48.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.218 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.71 106.82 17.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.19 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.426 HG22 HG13 ' A' ' 88' ' ' VAL . 96.7 t -92.91 130.46 41.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.141 -174.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.4 t -157.51 117.85 3.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 174.793 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.6 t -105.46 119.6 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.216 -176.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.04 -113.15 4.04 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -114.85 8.72 16.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.806 0.336 . . . . 0.0 111.21 177.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.6 m -103.41 126.46 50.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.223 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.0 t -81.42 125.32 30.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.165 174.199 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 81.8 mt -113.46 176.42 5.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.224 -175.619 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -75.94 147.29 39.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.166 -175.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -70.68 154.42 41.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 177.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 90.8 t -115.28 133.83 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.124 -178.412 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -71.41 159.37 85.74 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.231 -175.663 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -53.38 133.64 53.91 Favored 'Trans proline' 0 N--CA 1.458 -0.603 0 C-N-CA 121.752 1.635 . . . . 0.0 111.217 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.8 mt 52.07 34.38 13.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.221 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.89 -163.17 11.74 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.6 p -162.48 159.54 25.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.82 0.343 . . . . 0.0 111.167 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -145.65 129.64 17.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.164 176.304 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.18 134.29 33.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.203 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -128.4 160.9 30.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.241 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -141.37 147.66 38.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.234 -177.075 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -132.16 139.95 48.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.195 175.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.533 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 60.7 tp -71.84 -48.08 11.51 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.186 179.262 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.533 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 41.5 Cg_endo -83.44 117.12 2.39 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.694 1.596 . . . . 0.0 111.268 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.03 164.36 29.73 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.735 1.624 . . . . 0.0 111.139 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.8 -175.04 23.95 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 177.487 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 96' ' ' LYS . 29.5 t -84.37 126.36 33.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.782 0.325 . . . . 0.0 111.181 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -130.06 156.54 44.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.189 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 95.6 m -89.74 99.86 12.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 174.728 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.91 85.11 7.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 -175.127 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -80.42 124.35 28.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.178 176.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.426 HG13 HG22 ' A' ' 58' ' ' VAL . 51.7 t -127.79 84.65 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.176 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.18 -109.34 2.85 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -86.24 -12.56 49.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.756 0.312 . . . . 0.0 111.16 -176.076 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.91 157.08 18.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.185 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.3 t -157.02 114.11 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.178 176.594 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.97 141.13 34.85 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.148 -175.469 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -77.27 67.51 7.67 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.688 1.592 . . . . 0.0 111.218 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.8 t -74.51 116.82 17.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.175 -176.296 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 88.5 tttt -84.37 126.9 33.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.269 175.078 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 89.1 mt -104.47 95.86 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.179 -177.153 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -70.63 150.31 95.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.211 174.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.09 144.91 53.73 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.691 1.594 . . . . 0.0 111.209 -178.39 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 59.27 45.75 13.73 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.195 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 45.7 t -151.41 144.65 24.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.201 -177.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 25.3 m-85 -101.93 150.55 23.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.222 176.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -132.26 145.73 51.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.199 176.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 94.0 m -122.68 119.09 29.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.173 171.324 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.7 tp -110.38 111.73 23.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.137 -176.186 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 97.7 t -85.2 114.15 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.217 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.4 t -105.51 109.76 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.208 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -113.18 103.35 55.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.21 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -57.62 117.81 4.57 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.672 1.581 . . . . 0.0 111.183 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.49 84.06 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 176.367 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -127.09 -134.6 4.0 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.47 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -129.96 116.36 17.96 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 120.738 0.304 . . . . 0.0 111.209 -178.71 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -76.52 159.4 35.84 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.693 1.596 . . . . 0.0 111.225 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -145.09 120.94 10.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.262 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 57.6 tp -96.19 129.87 43.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.238 174.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.3 t -118.67 122.96 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.233 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -84.5 137.78 33.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 176.313 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -139.91 74.59 31.59 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.228 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_exo . . . . . 0 C--O 1.2 -1.39 0 C-N-CA 121.73 1.62 . . . . 0.0 111.165 178.949 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_exo . . . . . 0 N--CA 1.458 -0.609 0 N-CA-C 111.186 -0.351 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.9 tptp -57.55 118.71 5.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.211 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.88 -15.99 47.55 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -179.093 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 29.7 t -91.76 141.28 28.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.735 0.302 . . . . 0.0 111.21 -178.001 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.24 146.73 38.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 176.172 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -114.87 110.9 20.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.17 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 76' ' ' PHE . 65.6 t -115.75 127.94 73.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.225 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.4 ttm180 -120.5 113.4 20.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.16 177.488 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.43 152.6 23.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 176.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -136.6 132.51 35.19 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.21 -178.187 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -93.1 98.03 11.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.274 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.0 5.6 48.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.231 -177.386 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.44 -164.34 33.22 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -177.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 -124.76 34.77 4.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.777 0.322 . . . . 0.0 111.209 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.6 p -159.06 -179.31 7.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -55.38 125.24 19.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 177.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.437 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 37.3 tp -70.43 126.8 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -112.96 81.4 1.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 90.2 t -134.11 135.28 54.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 -178.161 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 64' ' ' SER . 42.8 t -110.98 116.12 30.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.132 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 64.8 t -106.54 101.48 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.197 -171.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.91 -110.12 3.27 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 176.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.4 p -101.7 -6.58 23.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.784 0.326 . . . . 0.0 111.185 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.9 m -120.68 115.83 24.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.18 -176.041 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 59' ' ' SER . 69.6 m -79.62 144.16 34.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.217 177.141 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 64.6 tp -115.81 115.74 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.183 -175.651 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -130.93 170.97 13.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.24 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 37.3 t0 55.23 59.54 3.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.171 178.59 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 56' ' ' LEU . 94.4 t -122.01 125.15 72.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.225 176.248 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -69.92 154.68 94.48 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.186 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -52.98 135.92 59.62 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.675 1.583 . . . . 0.0 111.212 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 53.3 mt 67.34 21.72 9.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.186 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -93.26 -168.25 38.82 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 175.427 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.7 p -162.99 167.83 21.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.792 0.329 . . . . 0.0 111.224 -177.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.7 t -155.53 136.88 14.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 177.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -99.9 144.23 29.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.21 -177.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.415 ' HB2' ' HB ' ' A' ' 46' ' ' VAL . 73.7 m-85 -128.47 150.33 50.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.249 179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -123.39 119.96 31.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 -179.156 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -123.29 95.68 4.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.184 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.503 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 63.5 tp -61.23 -48.6 91.15 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.17 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.503 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 49.2 Cg_endo -80.0 118.92 3.81 Favored 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 121.723 1.616 . . . . 0.0 111.206 177.247 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.54 166.49 25.7 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 121.752 1.635 . . . . 0.0 111.178 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.85 -173.38 26.21 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.3 t -83.36 121.27 26.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.787 0.327 . . . . 0.0 111.227 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -121.43 146.79 46.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.192 176.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.8 m -101.64 125.66 48.33 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.203 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -101.46 98.45 8.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.211 172.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -79.28 118.27 21.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.188 -174.634 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 54.1 t -119.53 78.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.175 -178.43 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 70.06 -111.2 3.68 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.15 -4.67 48.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.81 0.338 . . . . 0.0 111.169 177.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.9 mm-40 -109.66 172.63 6.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.4 p -158.28 156.11 30.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.115 177.029 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 87.3 mt -117.46 132.46 23.55 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.18 179.051 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -78.04 70.28 7.14 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 121.735 1.623 . . . . 0.0 111.209 177.23 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.4 t -80.02 82.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.227 -169.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -67.38 113.15 5.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.223 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 73.8 mt -95.99 117.1 29.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.211 -174.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -100.19 152.73 37.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.253 172.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -56.71 131.55 46.29 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 121.701 1.601 . . . . 0.0 111.163 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 63.67 23.59 13.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 172.404 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 44.0 t -104.02 148.51 26.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.227 175.068 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -105.61 139.27 40.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.196 -176.721 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -133.53 142.82 48.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.162 -178.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.8 m -120.69 127.58 52.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.179 173.37 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 68.7 mt -109.94 97.22 6.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.236 -179.115 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.8 t -92.12 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 -177.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.3 t -101.69 106.78 17.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.143 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 55.1 tp60 -115.07 104.95 53.54 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.253 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -55.72 139.45 83.4 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.709 1.606 . . . . 0.0 111.146 177.083 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 103.98 -19.83 42.63 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -142.41 -153.86 6.01 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.33 149.79 36.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.832 0.349 . . . . 0.0 111.231 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -72.08 153.45 57.41 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.665 1.577 . . . . 0.0 111.188 179.428 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.1 mm-40 -107.93 143.44 36.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.215 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 54.7 tp -120.34 111.7 18.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.234 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.5 t -109.01 118.55 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.232 177.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -109.46 138.13 46.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.209 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -126.17 118.5 23.57 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.226 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo . . . . . 0 C--O 1.2 -1.411 0 C-N-CA 121.694 1.596 . . . . 0.0 111.242 178.455 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo . . . . . 0 N--CA 1.458 -0.574 0 N-CA-C 111.133 -0.372 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -57.16 122.62 12.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.211 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 114.98 -23.1 11.83 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.443 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 38.8 t -63.42 130.55 44.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.786 0.327 . . . . 0.0 111.152 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -114.67 146.71 40.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.209 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -125.38 138.94 54.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.196 -176.353 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.8 t -116.64 112.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.164 173.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -89.6 106.0 18.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.227 -176.354 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.62 145.57 30.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.235 178.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -125.61 128.92 48.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.244 178.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -85.78 95.39 9.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.35 9.6 30.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.207 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.78 -169.43 33.88 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -179.06 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -106.85 9.37 30.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.78 0.324 . . . . 0.0 111.213 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.2 p -159.53 178.97 9.33 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.232 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -60.42 126.39 27.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.162 175.328 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 82.3 mt -110.7 147.3 34.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.22 -176.093 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -79.05 85.08 5.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.174 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.3 t -115.65 128.08 73.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.125 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.0 p -150.66 156.03 40.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 173.291 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.2 t -129.87 123.68 57.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.232 -178.156 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 66.2 -112.73 5.15 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.405 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.5 p -114.36 7.22 16.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.835 0.35 . . . . 0.0 111.247 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.8 m -99.57 119.71 38.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.173 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 85.6 p -87.51 169.94 11.77 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.202 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.9 tp -158.14 134.9 9.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.159 178.056 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -149.62 179.51 7.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.193 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.2 t0 60.48 45.7 10.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.154 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.9 t -106.55 119.21 55.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.184 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.92 152.94 86.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.191 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_exo -53.66 133.68 55.01 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 121.709 1.606 . . . . 0.0 111.196 177.115 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 55.3 mt 66.86 21.07 10.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.224 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -96.67 -167.37 33.61 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 174.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 90.4 p -159.41 161.22 35.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 111.201 -178.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.1 t -160.91 141.72 11.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 177.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.66 132.49 39.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.235 -175.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -91.95 121.56 33.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.188 169.719 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -95.26 116.67 29.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.17 -174.311 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -126.1 94.45 4.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.241 175.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.513 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 55.3 tp -56.99 -49.83 91.71 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.201 177.004 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.513 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 42.4 Cg_endo -80.16 124.77 5.56 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.692 1.595 . . . . 0.0 111.162 174.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -75.19 164.9 32.14 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.655 1.57 . . . . 0.0 111.284 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.22 -172.42 24.67 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.6 t -86.07 128.1 34.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 111.144 -176.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -130.62 146.1 52.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.232 174.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.8 m -96.31 115.61 27.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -83.27 94.18 7.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.228 177.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.7 tp60 -78.95 120.22 23.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 178.32 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.7 t -131.53 100.47 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.99 -119.31 13.03 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -96.2 -2.61 45.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.744 0.307 . . . . 0.0 111.179 178.464 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -110.19 170.06 8.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.23 -179.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 97.1 p -152.07 154.01 35.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.204 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.3 tp -144.1 107.68 4.93 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -74.28 144.09 32.6 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 121.747 1.631 . . . . 0.0 111.202 178.43 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.3 p -149.42 135.41 11.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -85.57 122.65 29.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.239 173.094 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -94.09 113.35 25.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.259 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.408 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 99.1 m-20 -71.57 147.34 92.24 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.214 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 98' ' ' ASP . 85.1 Cg_exo -53.81 129.12 32.5 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 121.66 1.573 . . . . 0.0 111.203 178.369 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 38.3 t0 55.42 62.94 2.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.229 177.052 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 85.5 p -145.6 165.61 28.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.212 178.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -122.54 147.29 46.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.251 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -131.62 144.46 51.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.256 176.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 86.8 m -105.68 119.7 39.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.155 176.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 59.8 tp -112.85 119.91 39.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.242 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.48 113.71 41.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.155 -178.018 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.7 t -91.63 97.55 11.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.248 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 57.5 tp60 -113.51 106.65 54.01 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.183 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_exo -56.46 144.04 85.3 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.69 1.593 . . . . 0.0 111.14 177.454 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 91.02 21.66 35.2 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 176.17 -169.62 42.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 178.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -88.14 150.4 47.22 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.807 0.337 . . . . 0.0 111.215 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -71.99 149.3 52.74 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.685 1.59 . . . . 0.0 111.18 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -106.98 148.66 28.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.224 179.047 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.0 tt -139.9 131.2 26.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 -175.772 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 86.9 t -122.99 129.14 75.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.266 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.62 136.72 37.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.229 178.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -139.68 76.32 29.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.231 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_exo . . . . . 0 C--O 1.2 -1.376 0 C-N-CA 121.681 1.587 . . . . 0.0 111.24 178.761 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo . . . . . 0 N--CA 1.457 -0.626 0 N-CA-C 111.189 -0.35 . . . . 0.0 111.189 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.7 tptp -59.42 119.18 6.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.165 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -1.02 60.07 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 174.375 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 56.7 p -105.22 -177.08 3.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.239 -177.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.19 154.51 51.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.216 178.027 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 74.1 t80 -130.44 132.01 45.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.153 -177.483 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 63.4 t -119.59 126.77 75.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.278 -175.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 85.9 mtt85 -99.81 177.06 5.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.189 170.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ALA . . . . . 0.406 ' HA ' ' O ' ' A' ' 105' ' ' LEU . . . -148.24 155.72 41.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.22 -179.049 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 72.1 t80 -162.76 117.15 1.74 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.117 172.346 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -67.01 107.82 2.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.232 176.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -122.74 25.93 8.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.217 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -95.85 -157.34 31.83 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 47.7 p-10 -114.43 29.58 7.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.279 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.7 p -163.1 162.44 25.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.35 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -85.3 130.37 34.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.223 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.507 ' C ' HD12 ' A' ' 56' ' ' LEU . 4.2 pp -157.35 162.66 39.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.231 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -98.28 148.26 23.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.148 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 99.5 t -127.13 135.33 63.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.197 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 86.8 p -153.96 166.7 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.221 177.751 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 8.4 p -148.72 129.93 5.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.164 176.314 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 62.98 -113.71 6.17 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 -178.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.8 p -112.8 10.84 19.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.982 0.42 . . . . 0.0 111.292 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.9 m -97.08 119.84 36.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.226 -178.495 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 28.8 t -81.39 123.28 28.43 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.193 172.702 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.1 mt -107.25 169.64 8.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.188 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -151.14 177.36 10.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.123 175.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -65.12 119.94 11.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.219 -175.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 89.9 t -106.41 119.47 55.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.153 173.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.93 145.47 92.68 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 -177.118 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -52.2 133.94 48.95 Favored 'Trans proline' 0 C--N 1.328 -0.538 0 C-N-CA 121.617 1.545 . . . . 0.0 111.203 177.67 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 69.3 mt 65.8 23.38 11.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.212 -178.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.71 -166.02 12.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.4 t -166.26 151.91 8.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.884 0.373 . . . . 0.0 111.146 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.1 t -143.79 140.74 30.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.255 177.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -70.04 128.82 37.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.197 -175.184 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -131.57 163.81 27.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.241 174.224 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -63.1 125.35 23.73 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 175.22 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -76.93 144.42 38.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.229 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.2 mt -120.56 140.16 29.97 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.195 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 34.9 Cg_exo -57.99 160.48 15.4 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.699 1.599 . . . . 0.0 111.219 171.134 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.86 151.13 62.56 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 121.599 1.533 . . . . 0.0 111.188 176.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.48 -157.37 25.64 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.353 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.6 t -103.38 109.01 20.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.803 0.335 . . . . 0.0 111.141 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -121.45 109.69 15.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.204 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 87.6 m -64.31 129.06 38.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.235 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -102.7 162.88 12.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.174 176.634 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -129.23 131.97 47.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.138 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -128.56 101.25 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 173.711 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.56 -116.18 7.67 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -174.601 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -99.6 1.32 43.57 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.699 0.285 . . . . 0.0 111.168 177.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.45 170.91 7.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.226 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.9 p -144.01 157.37 44.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.215 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.8 tp -154.42 114.03 2.46 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 -178.133 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.42 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 78.3 Cg_exo -55.0 125.23 18.49 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 121.634 1.556 . . . . 0.0 111.261 175.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 87.3 t -108.06 115.72 49.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.249 177.4 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -80.95 116.62 21.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 175.343 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.3 mt -103.23 114.99 29.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.264 -178.357 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.406 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 95.6 m-20 -95.12 149.31 36.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 175.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 98' ' ' ASP . 73.1 Cg_exo -54.48 133.22 55.39 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.664 1.576 . . . . 0.0 111.339 177.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 55.81 60.59 3.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.213 178.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 83.3 p -146.95 160.37 42.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.229 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -128.83 143.47 50.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.162 -177.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -132.51 154.72 49.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.288 -177.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 87.6 m -128.75 120.78 27.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 170.33 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 48' ' ' ALA . 70.2 tp -104.04 112.96 26.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.121 -178.386 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 33.0 m -117.39 157.95 18.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.189 -176.1 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 80.5 p -90.36 159.68 16.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.156 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 93.9 mm-40 -124.74 155.96 69.06 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 173.182 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -50.53 127.99 22.23 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.731 1.621 . . . . 0.0 111.188 177.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 104.61 -9.69 48.69 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -172.436 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 83.39 42.72 7.76 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -108.66 145.82 32.42 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 111.165 -175.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.5 152.78 30.21 Favored 'Trans proline' 0 C--N 1.328 -0.552 0 C-N-CA 121.643 1.562 . . . . 0.0 111.24 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 68.3 tp60 -151.59 107.69 3.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.22 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 60.6 tp -92.55 118.87 31.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.187 -177.613 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 67.2 t -121.88 113.12 37.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.241 176.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -66.45 129.14 38.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.202 177.145 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.21 73.55 25.83 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo . . . . . 0 C--O 1.201 -1.336 0 C-N-CA 121.817 1.678 . . . . 0.0 111.124 178.273 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo . . . . . 0 N--CA 1.459 -0.523 0 N-CA-C 111.212 -0.342 . . . . 0.0 111.212 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -61.36 129.98 43.86 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.193 175.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.92 3.43 55.91 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 89.3 p -87.97 162.15 17.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.813 0.339 . . . . 0.0 111.116 174.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.33 148.15 24.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.19 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -120.12 138.82 53.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.188 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.6 p -148.16 144.09 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.173 -179.234 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.9 ptt180 -142.93 153.2 42.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.252 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -94.01 155.06 17.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.215 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -135.23 130.62 35.51 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.209 175.182 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 55.7 t-20 -102.67 93.71 5.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.204 -176.51 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.33 70.69 7.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.229 177.1 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.62 177.78 40.89 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -97.88 -7.04 31.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.808 0.337 . . . . 0.0 111.145 -175.61 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 34.8 t -99.88 135.84 40.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.164 178.236 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.1 mp0 -61.77 140.49 58.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.172 176.469 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.0 mt -124.8 144.89 50.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.171 -175.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -106.37 111.05 23.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.244 174.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.97 166.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.192 -177.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.6 p -148.01 158.24 43.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 51.2 t -127.04 85.6 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.243 174.246 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.97 -111.74 4.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -84.86 -12.61 53.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.771 0.319 . . . . 0.0 111.166 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.3 m -84.47 126.24 33.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.25 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.8 t -103.4 119.44 38.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.192 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.6 mt -125.11 67.5 1.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.173 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -91.42 158.82 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.251 -172.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 36.6 t0 55.31 60.49 3.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.213 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.1 t -82.55 130.77 35.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.203 176.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.55 147.08 88.92 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -171.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -54.89 129.23 34.09 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.657 1.571 . . . . 0.0 111.178 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 86.4 mt 50.74 33.53 8.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -177.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -124.84 -162.03 11.25 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.5 p -148.64 166.42 28.37 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.743 0.306 . . . . 0.0 111.34 -177.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.4 t -137.95 100.96 4.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.235 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -76.93 150.85 35.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.201 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -142.82 127.81 18.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 174.331 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -116.42 178.6 4.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.183 -178.231 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 64.46 32.41 11.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.234 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 61.4 tp -102.16 115.26 64.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.084 -179.035 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.481 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 73.8 Cg_exo -54.88 128.33 30.02 Favored 'Trans proline' 0 N--CA 1.457 -0.624 0 C-N-CA 121.787 1.658 . . . . 0.0 111.179 176.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.481 ' HD3' ' HA ' ' A' ' 80' ' ' PRO . 58.7 Cg_exo -56.14 146.48 70.45 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 121.692 1.595 . . . . 0.0 111.225 176.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 156.32 -175.44 33.99 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.8 t -85.78 125.07 32.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.786 0.327 . . . . 0.0 111.107 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -130.24 143.66 50.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.181 176.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.0 m -98.3 110.57 23.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.206 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.446 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -75.58 151.13 37.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 177.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 72.6 tp60 -134.91 117.16 15.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.204 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.3 t -127.37 106.5 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.196 173.41 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.78 -110.14 3.31 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -115.45 18.16 16.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.889 0.376 . . . . 0.0 111.191 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.0 tp60 -126.91 117.05 21.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -90.01 155.6 18.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.29 176.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 97.1 mt -141.2 85.12 12.23 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.142 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -55.35 129.25 34.18 Favored 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 121.677 1.585 . . . . 0.0 111.189 174.684 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -146.71 135.35 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.235 -177.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -86.65 123.72 32.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.188 173.078 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.6 mt -100.02 103.01 14.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.271 -178.258 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -73.68 155.62 88.99 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.188 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.3 149.79 63.98 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 121.782 1.655 . . . . 0.0 111.197 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 55.01 45.23 26.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.13 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -151.58 147.48 26.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.272 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -106.38 140.51 39.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.197 -175.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -129.64 142.17 50.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.273 177.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.5 m -120.6 126.46 50.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.277 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 62.3 tp -94.49 98.91 11.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 176.215 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.5 t -78.42 106.15 8.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.115 -178.268 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 92.6 p -101.82 162.85 12.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -154.42 133.28 7.11 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.112 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.75 101.97 0.12 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 121.717 1.612 . . . . 0.0 111.121 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 71.67 22.54 78.66 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 176.346 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -118.43 -167.63 14.04 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.37 124.32 43.31 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 120.814 0.34 . . . . 0.0 111.251 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -75.49 157.96 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 121.611 1.541 . . . . 0.0 111.265 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -141.37 127.38 19.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.197 -175.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 95.5 mt -76.06 133.98 40.18 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.207 172.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 90.0 t -128.37 125.31 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.228 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.38 135.87 38.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.142 175.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 81.4 mt-10 -128.92 150.55 75.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -178.316 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo . . . . . 0 C--O 1.201 -1.349 0 C-N-CA 121.585 1.523 . . . . 0.0 111.231 178.002 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo . . . . . 0 N--CA 1.457 -0.64 0 N-CA-C 111.238 -0.332 . . . . 0.0 111.238 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -80.24 163.09 24.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.158 177.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 113.64 -20.25 18.13 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -176.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.3 t -154.68 140.59 18.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 0.0 111.165 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.1 151.48 24.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.173 176.113 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -114.9 139.6 49.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.182 -173.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.9 p -140.45 140.39 34.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.131 -178.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 42.1 ttm180 -111.42 112.44 24.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.171 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.56 123.83 33.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.187 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -110.56 134.81 52.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -100.28 104.18 15.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.189 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.65 4.01 53.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.284 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -97.21 -171.28 33.67 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -102.92 2.67 35.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.888 0.375 . . . . 0.0 111.199 178.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.9 p -149.01 167.73 25.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.294 177.128 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -53.95 122.15 9.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.231 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 90.1 mt -107.12 140.18 40.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.309 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -105.84 144.65 32.28 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.231 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.6 p -140.05 137.26 38.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 41.2 t -102.09 105.52 16.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.158 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 61.7 t -102.14 94.15 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.229 -176.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.16 -109.65 3.01 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -175.404 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.7 p -103.33 -7.42 21.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.752 0.31 . . . . 0.0 111.23 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.7 m -120.06 118.61 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.34 -175.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.3 p -89.13 154.63 20.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.251 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.4 mt -120.0 149.03 42.82 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.18 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 32.4 p30 -158.66 -174.9 5.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -178.013 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.3 t0 63.07 46.19 4.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.22 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.1 t -117.49 121.6 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.231 174.647 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -70.59 145.99 93.26 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.136 -175.111 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 82.6 Cg_exo -53.36 131.49 43.65 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.619 1.546 . . . . 0.0 111.285 177.602 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 65.9 mt 66.42 20.17 10.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.169 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.63 -166.93 12.19 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 173.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 84.7 p -155.7 165.08 37.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.724 0.297 . . . . 0.0 111.215 -179.154 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -149.58 143.21 25.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.147 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -93.01 138.59 31.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 -178.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -129.69 161.43 30.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.255 -178.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.425 ' O ' ' HB2' ' A' ' 78' ' ' PHE . 63.4 pttt -158.02 -155.77 0.52 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.24 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.425 ' HB2' ' O ' ' A' ' 77' ' ' LYS . 50.0 m-85 68.35 33.09 4.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.138 -173.342 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.41 HD12 ' HD2' ' A' ' 80' ' ' PRO . 56.0 tp -134.85 116.67 12.59 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.216 -176.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.41 ' HD2' HD12 ' A' ' 79' ' ' LEU . 92.5 Cg_exo -51.67 133.83 45.41 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 121.618 1.545 . . . . 0.0 111.286 179.459 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -55.47 147.81 55.83 Favored 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 121.77 1.647 . . . . 0.0 111.217 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.16 -171.91 30.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.513 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.0 t -103.59 124.74 49.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.796 0.331 . . . . 0.0 111.21 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -127.33 140.52 52.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.243 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 90.6 m -80.4 117.54 21.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -92.26 108.31 19.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.197 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -85.14 113.8 21.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.254 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.9 t -122.66 103.09 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.215 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.65 -118.94 12.44 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -98.29 -0.55 43.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.741 0.305 . . . . 0.0 111.21 177.444 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.5 mm-40 -109.01 168.35 9.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.085 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.6 p -149.08 153.8 38.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.253 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.2 tp -151.76 114.91 3.0 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.273 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -57.37 131.41 44.58 Favored 'Trans proline' 0 C--N 1.326 -0.608 0 C-N-CA 121.613 1.542 . . . . 0.0 111.118 174.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.7 t -123.81 118.49 54.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.223 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -86.31 124.54 32.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 172.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 84.2 mt -118.54 139.03 52.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.175 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -114.82 155.68 45.99 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.32 -176.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -80.08 -19.92 9.08 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 121.788 1.658 . . . . 0.0 111.211 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -92.93 -30.57 15.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.193 -173.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.1 t -126.16 -158.76 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.145 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -149.42 159.23 44.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.192 176.073 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -126.85 141.72 51.74 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.203 177.589 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.4 m -102.16 118.23 36.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.147 -176.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.2 tp -99.52 113.31 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.0 t -81.69 99.29 4.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 177.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -85.22 123.41 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 -176.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -91.43 152.5 43.73 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.232 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.82 68.31 7.21 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.683 1.589 . . . . 0.0 111.24 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.49 -7.37 53.75 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -96.15 -166.41 34.13 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.329 -0.708 . . . . 0.0 111.329 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -87.79 127.73 56.94 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 120.877 0.37 . . . . 0.0 111.16 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -75.88 160.31 37.38 Favored 'Trans proline' 0 N--CA 1.457 -0.634 0 C-N-CA 121.683 1.589 . . . . 0.0 111.232 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -129.02 118.55 22.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.233 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 50.3 tp -85.39 128.03 34.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.18 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.7 126.73 72.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.143 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.76 73.18 5.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.137 179.303 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 119' ' ' PRO . 88.0 tt0 -67.59 129.99 93.32 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.234 -178.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 118' ' ' GLU . 84.1 Cg_exo . . . . . 0 C--O 1.2 -1.42 0 C-N-CA 121.628 1.552 . . . . 0.0 111.161 178.262 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo . . . . . 0 N--CA 1.457 -0.666 0 N-CA-C 111.206 -0.344 . . . . 0.0 111.206 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -63.66 122.8 17.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.175 -176.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.63 5.56 78.24 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 175.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 69.8 m -117.84 160.65 21.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.842 0.353 . . . . 0.0 111.058 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.37 146.75 24.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.262 177.336 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -115.67 130.9 57.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.209 175.488 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 91.5 t -128.07 131.83 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 176.107 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -115.09 104.94 12.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.202 173.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.5 147.27 32.28 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.209 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -138.4 133.88 33.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.064 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -99.2 105.22 17.24 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.255 -178.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -96.22 24.3 5.83 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.204 -174.104 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -125.08 -165.05 12.02 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -115.3 27.33 9.44 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.756 0.313 . . . . 0.0 111.219 -179.294 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 44.8 t -146.6 130.33 17.04 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.199 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -59.91 131.3 50.44 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.12 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.8 mt -116.1 146.99 41.78 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.195 -174.032 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -89.38 111.13 21.91 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.217 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.6 t -96.07 134.32 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.157 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 83.8 p -156.76 167.37 30.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.239 173.302 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.08 130.57 5.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 178.503 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.33 -114.11 6.51 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -114.04 9.11 17.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.5 m -99.87 118.48 36.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.177 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.6 t -78.32 123.95 27.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.236 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 84.2 mt -106.4 173.55 6.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.303 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -73.11 144.9 46.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.217 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.86 150.64 45.58 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.223 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -117.63 123.4 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.106 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -72.82 159.96 84.05 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.2 -178.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_exo -52.69 125.64 18.59 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.713 1.609 . . . . 0.0 111.239 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.3 mt 65.18 22.07 12.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.108 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -112.29 -172.66 18.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 175.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.9 p -152.24 164.16 37.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.855 0.359 . . . . 0.0 111.171 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.9 t -149.39 124.95 10.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.213 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -83.6 137.7 33.7 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.315 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -127.41 118.35 23.92 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.215 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -113.25 168.42 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.19 -177.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 63.81 31.96 13.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.148 174.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.5 mt -86.22 125.88 66.66 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.268 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 74.6 Cg_exo -55.71 116.04 2.88 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.639 1.559 . . . . 0.0 111.227 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -59.87 147.67 91.62 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.714 1.609 . . . . 0.0 111.175 175.246 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.97 -161.99 27.51 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.3 t -103.29 109.69 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.766 0.317 . . . . 0.0 111.249 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -132.78 155.31 49.14 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.345 -177.125 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.9 m -88.83 117.61 27.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.168 178.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -93.23 114.15 26.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.245 -179.223 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.3 tt0 -107.71 131.99 53.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.232 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.04 105.68 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 172.374 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 81.51 -106.66 2.64 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -174.29 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -113.02 -24.48 9.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.773 0.321 . . . . 0.0 111.133 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -98.72 154.0 18.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.277 -177.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 86.7 p -150.76 148.17 28.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.304 -178.02 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 94' ' ' PRO . 87.6 mt -143.0 141.18 19.03 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.247 174.164 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 93' ' ' LEU . 61.1 Cg_exo -55.97 137.09 77.92 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 121.65 1.567 . . . . 0.0 111.136 175.668 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 31.7 m -127.45 150.72 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.237 176.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.74 115.73 30.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.282 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 88.4 mt -107.68 100.04 9.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.204 -177.291 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -88.35 147.12 39.31 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.184 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.78 149.14 53.75 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 121.74 1.627 . . . . 0.0 111.188 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 59.98 43.26 14.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 81.9 p -147.95 161.17 41.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.176 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -114.93 144.74 43.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.196 -175.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -133.85 147.68 51.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.169 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 99.5 m -118.14 129.86 55.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.154 169.34 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 46.8 tp -114.95 101.41 8.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.185 -173.479 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 90.7 t -100.04 128.27 52.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.265 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.5 t -148.91 150.86 33.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.107 -176.197 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -153.48 159.0 32.65 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.232 176.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -54.98 123.72 14.5 Favored 'Trans proline' 0 C--N 1.328 -0.543 0 C-N-CA 121.688 1.592 . . . . 0.0 111.161 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.85 -20.01 47.51 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.204 -0.759 . . . . 0.0 111.204 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -111.08 -171.76 19.45 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -124.06 155.58 67.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 111.178 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -56.58 120.24 7.99 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.594 1.529 . . . . 0.0 111.28 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 60.3 tp60 -104.12 112.43 25.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.186 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 35.7 tp -77.23 129.26 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.222 178.083 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.4 t -115.92 114.03 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.094 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -76.24 132.91 40.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.214 -178.171 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 76.7 mt-10 -139.38 76.13 31.9 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.258 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo . . . . . 0 C--O 1.199 -1.45 0 C-N-CA 121.67 1.58 . . . . 0.0 111.183 179.466 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo . . . . . 0 N--CA 1.456 -0.687 0 N-CA-C 111.217 -0.34 . . . . 0.0 111.217 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -62.19 115.36 4.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.191 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.66 4.27 57.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 28.9 t -65.41 131.24 45.93 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.816 0.341 . . . . 0.0 111.177 -179.103 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.38 145.74 43.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.171 173.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -124.43 135.66 53.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.221 -174.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 67.4 t -124.32 124.81 69.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.241 170.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -110.49 111.7 23.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.199 176.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.11 149.33 29.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.258 175.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -148.42 132.34 17.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.272 177.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.439 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 58.5 t-20 -91.32 99.55 12.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.71 5.13 50.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 -175.614 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.97 -171.95 37.21 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -178.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -115.21 26.22 10.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.198 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -151.37 164.71 36.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.207 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -79.08 128.97 33.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.19 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.82 148.98 51.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.23 -177.279 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -85.24 128.71 34.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.217 176.044 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.9 t -122.78 130.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.204 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 42.1 t -136.46 123.26 21.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.229 -178.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 80.7 t -126.46 107.46 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 178.082 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.5 -116.48 5.78 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -102.26 -6.86 22.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.194 -176.21 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.3 m -115.54 136.08 53.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.133 -177.536 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -142.52 157.79 44.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.139 -174.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.8 tp -137.8 119.72 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.089 175.7 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -88.53 150.43 23.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.238 -175.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 54.51 59.41 4.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.229 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -75.99 120.82 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.12 148.41 97.89 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.227 -173.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -52.11 132.57 43.83 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.728 1.619 . . . . 0.0 111.196 176.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.8 mt 66.59 21.2 10.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.89 -171.15 43.36 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 174.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.1 p -159.77 166.61 30.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.327 . . . . 0.0 111.243 -176.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.8 t -157.89 118.77 3.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.213 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -88.79 139.03 30.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.228 -176.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -121.05 93.84 4.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.149 172.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -98.15 154.89 17.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.243 -164.202 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 67.0 33.73 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.175 166.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 97.5 mt -84.02 137.89 40.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.185 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.47 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 77.6 Cg_endo -72.12 150.2 53.51 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.704 1.603 . . . . 0.0 111.234 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 80' ' ' PRO . 65.4 Cg_exo -57.19 145.0 88.98 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 121.8 1.667 . . . . 0.0 111.192 178.546 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.27 -172.18 28.57 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.4 t -94.6 134.92 36.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.227 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 -125.82 151.18 47.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.195 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.6 m -95.26 118.97 32.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.196 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -108.7 96.02 6.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.216 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -94.9 130.51 41.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.214 -178.638 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.1 t -127.91 119.45 51.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.229 168.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.89 -110.02 3.24 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -178.145 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -108.16 -9.58 15.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.76 0.314 . . . . 0.0 111.177 -175.568 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -113.49 160.27 18.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 -176.365 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 95.5 p -147.69 148.46 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 90.4 mt -135.39 150.04 71.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.23 177.026 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.04 146.6 32.7 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.665 1.577 . . . . 0.0 111.129 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 89.4 t -124.78 126.37 71.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.189 177.575 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -99.11 111.94 24.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.131 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.8 mt -106.39 135.57 47.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.241 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -113.79 162.26 23.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.114 -177.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -51.91 123.28 12.07 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.781 1.654 . . . . 0.0 111.198 175.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 56.02 64.73 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 77.0 p -140.87 157.57 45.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.219 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -118.75 161.2 20.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.197 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.44 149.87 22.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.236 -175.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 97.7 m -127.42 134.73 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.208 179.224 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 63.6 tp -116.02 111.73 20.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.141 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.452 ' HB ' ' HB3' ' A' ' 114' ' ' GLN . 85.9 t -103.38 123.96 57.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.117 -175.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.439 ' HB2' ' HA ' ' A' ' 50' ' ' ASN . 67.8 m -84.91 127.6 34.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.236 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -98.37 148.77 34.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_exo -52.02 131.75 40.13 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.657 1.572 . . . . 0.0 111.179 176.451 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.95 -10.45 57.1 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -177.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.74 67.87 1.34 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 178.331 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.54 130.93 13.62 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-O 120.768 0.318 . . . . 0.0 111.303 175.728 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.61 148.86 33.55 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.742 1.628 . . . . 0.0 111.181 -178.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLN . . . . . 0.452 ' HB3' ' HB ' ' A' ' 106' ' ' VAL . 49.7 tt0 -126.01 125.04 42.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 171.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 94.3 mt -85.51 118.45 25.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.264 -175.703 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 82.9 t -125.9 112.52 30.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.306 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -86.37 136.24 33.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.258 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -100.8 152.78 37.93 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.17 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo . . . . . 0 C--O 1.201 -1.374 0 C-N-CA 121.741 1.628 . . . . 0.0 111.209 -178.562 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo . . . . . 0 N--CA 1.458 -0.595 0 N-CA-C 111.248 -0.328 . . . . 0.0 111.248 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -62.06 124.43 20.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 176.704 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 107.14 -1.61 35.26 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' SER . . . . . 0.441 ' O ' ' N ' ' A' ' 100' ' ' ASP . 86.0 p -68.59 161.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 111.159 -178.645 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -158.23 148.88 20.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.202 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -125.98 142.62 51.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.228 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.21 126.96 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 175.34 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -110.48 100.42 9.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.199 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.28 148.15 50.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.186 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -145.65 131.15 18.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.163 178.412 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.4 t-20 -93.95 100.06 12.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 178.48 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -88.72 4.23 48.05 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.189 -173.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -99.64 -169.19 30.01 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -176.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 -115.32 22.74 13.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.78 0.324 . . . . 0.0 111.161 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 82.5 p -147.04 168.89 20.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.232 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.413 ' HA ' ' O ' ' A' ' 68' ' ' VAL . 99.7 mt-10 -77.17 139.61 39.97 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.179 -173.812 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -115.93 147.9 40.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -106.41 111.51 24.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.211 173.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.6 m -128.44 166.09 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.208 -175.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.2 t -152.97 120.3 5.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.161 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 85.8 t -123.63 125.64 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.146 -173.627 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.61 -116.46 7.43 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -114.03 9.22 17.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.797 0.332 . . . . 0.0 111.231 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.3 m -121.8 115.22 22.25 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.206 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 67.5 m -84.95 149.43 25.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 54.3 tp -144.71 94.45 2.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.149 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -92.9 159.19 15.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.277 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 61.51 48.3 5.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.289 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 55' ' ' GLU . 99.2 t -72.0 118.91 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.273 178.026 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -64.02 145.79 97.7 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.267 -174.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 85.2 Cg_exo -52.95 130.69 39.02 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 121.717 1.611 . . . . 0.0 111.248 177.626 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 59.1 mt 66.17 21.31 11.13 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.177 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.32 177.99 39.77 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 175.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 87.0 p -156.1 164.71 38.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.758 0.314 . . . . 0.0 111.179 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.2 t -161.38 127.37 3.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.192 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -88.21 137.34 32.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.197 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -119.72 134.17 55.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.217 176.286 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -104.2 122.9 46.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.17 -171.609 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -111.07 133.67 53.26 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.207 173.112 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.499 ' HB2' ' HD3' ' A' ' 80' ' ' PRO . 96.3 mt -89.82 -45.52 0.41 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.275 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.499 ' HD3' ' HB2' ' A' ' 79' ' ' LEU . 22.5 Cg_endo -90.0 143.95 4.19 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 121.73 1.62 . . . . 0.0 111.225 -178.251 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_endo -76.48 162.85 32.86 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.689 1.592 . . . . 0.0 111.162 173.55 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.37 -118.45 1.28 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 177.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 87.1 p -166.59 162.61 16.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.812 0.339 . . . . 0.0 111.188 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -160.01 136.11 8.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.23 177.019 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 92.0 m -87.42 111.64 21.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.226 178.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.06 146.26 28.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.223 -176.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.4 tp60 -88.96 120.98 30.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 46.7 t -125.12 80.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.82 -115.3 7.4 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 -176.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.11 -3.24 51.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.86 0.362 . . . . 0.0 111.192 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -107.93 178.04 4.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.208 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -148.97 159.04 44.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.22 176.551 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.417 ' HA ' ' HD2' ' A' ' 94' ' ' PRO . 58.9 tp -135.02 110.94 10.95 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.154 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 93' ' ' LEU . 88.0 Cg_endo -71.83 82.48 1.23 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.766 1.644 . . . . 0.0 111.165 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.4 t -75.05 118.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.162 -175.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -80.98 132.71 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 171.245 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 64.9 mt -111.79 90.64 3.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.25 -175.191 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -72.18 146.22 89.41 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.166 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_exo -54.32 124.33 15.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.761 1.64 . . . . 0.0 111.185 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 43' ' ' SER . 80.7 m-20 54.25 63.11 2.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.128 175.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.1 p -144.4 157.12 44.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.252 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -108.26 150.81 26.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.175 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -136.73 151.98 49.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 177.315 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.401 ' HB ' ' HB ' ' A' ' 116' ' ' VAL . 97.8 m -121.58 137.11 54.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.211 173.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.533 ' C ' HD23 ' A' ' 105' ' ' LEU . 7.1 tt -115.7 104.33 11.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.66 122.34 56.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.199 -178.669 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 90.5 p -142.82 162.73 34.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.199 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -159.82 159.24 27.52 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.257 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -56.49 125.04 17.73 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 121.739 1.626 . . . . 0.0 111.179 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 87.63 -0.14 84.63 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 174.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -120.28 -168.04 13.62 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -124.35 153.59 68.95 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.78 0.324 . . . . 0.0 111.269 179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -69.73 136.59 33.47 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.726 1.617 . . . . 0.0 111.252 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -112.31 125.63 54.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.218 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 58.3 tp -86.77 122.23 30.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 104' ' ' THR . 79.8 t -111.42 118.64 57.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 175.09 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -80.16 132.78 35.98 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.134 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 73.4 mt-10 -139.64 75.06 32.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.217 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo . . . . . 0 C--O 1.201 -1.339 0 C-N-CA 121.685 1.59 . . . . 0.0 111.228 179.339 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo . . . . . 0 N--CA 1.455 -0.769 0 CA-C-O 120.927 0.303 . . . . 0.0 111.318 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.23 130.1 45.3 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.126 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.24 -20.1 26.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -177.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 81.1 p -96.7 166.86 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.823 0.344 . . . . 0.0 111.152 177.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.54 150.76 21.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.272 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -119.06 132.36 56.02 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 97.2 t -129.32 138.25 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -127.56 95.31 4.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 178.214 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.85 151.29 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.148 177.575 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -137.57 134.6 35.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.151 179.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -92.97 93.96 8.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.191 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.95 11.36 25.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.218 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.51 -167.35 36.69 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 74.8 m-20 -116.1 24.59 11.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.742 0.306 . . . . 0.0 111.152 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 84.8 p -157.01 163.24 39.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.196 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 mp0 -64.76 137.11 57.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.233 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -121.56 150.65 41.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.197 -177.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -101.2 119.99 39.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 173.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 97.7 t -115.99 128.65 73.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.984 -172.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.3 t -134.86 106.33 6.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.143 177.783 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.9 t -108.42 114.12 45.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.16 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.57 -111.5 4.02 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 95.9 p -100.62 -5.0 27.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 111.227 178.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 69.7 p -87.44 166.41 14.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 -176.073 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 43.6 t -163.93 126.29 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.231 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 68.5 tp -135.3 118.51 16.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -94.92 156.25 16.42 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.207 -175.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 61.49 49.23 5.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.214 173.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.3 t -74.85 121.11 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.272 175.118 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -64.8 147.81 97.77 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.206 -170.316 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 78.6 Cg_exo -52.94 131.9 44.71 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.637 1.558 . . . . 0.0 111.295 177.1 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 67.7 mt 65.68 21.56 11.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.167 178.17 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -99.14 -170.04 30.78 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 174.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 96.1 p -149.91 162.03 41.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.761 0.315 . . . . 0.0 111.16 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.3 t -140.55 108.04 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.174 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -81.44 137.65 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -120.47 100.5 7.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.212 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -96.99 169.13 10.04 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.157 176.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 55.36 41.22 31.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 55.2 tp -106.58 116.53 58.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.239 -177.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.71 121.56 9.77 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.642 1.562 . . . . 0.0 111.236 -178.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.12 150.56 64.62 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 121.676 1.584 . . . . 0.0 111.214 176.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.04 172.08 19.07 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.6 t -84.84 113.12 21.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.778 0.323 . . . . 0.0 111.169 176.242 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -128.75 147.92 50.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.157 -178.067 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.5 m -93.86 95.17 8.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.237 172.564 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -78.82 146.19 33.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.164 -176.234 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.1 tp60 -112.64 104.52 12.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.069 173.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.97 93.74 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 71.42 -118.59 7.32 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -100.81 4.14 42.64 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.816 0.341 . . . . 0.0 111.155 -177.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -129.25 117.62 21.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.16 -177.191 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 31.1 t -69.35 131.15 44.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.157 172.155 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 84.3 mt -131.85 82.61 59.57 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.257 -178.03 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -70.92 143.62 45.71 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.766 1.644 . . . . 0.0 111.188 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.0 p -161.05 142.27 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 -176.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 59.8 tttm -79.29 119.1 21.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.212 173.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.9 mt -102.49 98.47 8.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.204 -173.376 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -78.52 152.91 78.62 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.201 173.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.46 148.91 61.57 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 121.787 1.658 . . . . 0.0 111.214 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 57.83 45.13 19.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.187 179.144 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.3 t -151.44 145.52 25.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -103.21 132.31 49.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.299 -174.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -123.9 107.32 11.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.267 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 96.7 m -83.87 125.52 32.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.089 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 89.8 mt -112.5 91.24 3.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.209 -178.144 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.4 t -82.81 117.06 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.097 177.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.7 t -112.9 133.55 54.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.261 178.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 -140.77 94.15 8.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.156 -176.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -57.56 119.51 6.81 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 121.79 1.66 . . . . 0.0 111.245 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 84.99 5.44 86.08 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -128.04 -133.08 3.66 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -136.36 121.0 12.87 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.715 0.293 . . . . 0.0 111.234 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.69 163.31 34.04 Favored 'Trans proline' 0 C--N 1.327 -0.586 0 C-N-CA 121.757 1.638 . . . . 0.0 111.167 178.186 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.3 tp60 -145.57 124.83 12.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.258 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.3 mp -102.24 131.22 48.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.191 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.1 t -130.45 120.69 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.238 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.21 132.78 42.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.23 176.27 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -130.96 149.26 73.23 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.205 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo . . . . . 0 C--O 1.199 -1.44 0 C-N-CA 121.641 1.561 . . . . 0.0 111.135 177.544 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.785 0.326 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.32 145.97 88.73 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.214 177.349 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -73.39 144.47 36.6 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 121.705 1.603 . . . . 0.0 111.258 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 66.3 tttp -64.77 132.44 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 109.02 -19.15 30.46 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 94.5 p -72.18 162.57 29.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 111.208 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -141.42 150.34 42.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.253 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -119.21 148.34 43.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.164 -175.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.8 p -146.8 133.79 14.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 176.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -98.6 120.82 39.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.212 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.56 91.22 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 174.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -88.86 125.09 34.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.169 -176.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -95.07 102.89 14.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.203 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -90.65 2.41 55.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -177.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -102.01 -175.29 27.87 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -178.261 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -111.63 28.85 8.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 111.189 -177.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -150.71 157.08 42.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.168 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -62.06 135.36 57.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.215 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 88.1 mt -114.39 141.11 48.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.218 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.71 106.82 17.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.19 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.426 HG22 HG13 ' A' ' 88' ' ' VAL . 96.7 t -92.91 130.46 41.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.141 -174.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.4 t -157.51 117.85 3.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 174.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.6 t -105.46 119.6 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.216 -176.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.04 -113.15 4.04 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -114.85 8.72 16.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.806 0.336 . . . . 0.0 111.21 177.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.6 m -103.41 126.46 50.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.223 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.0 t -81.42 125.32 30.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.165 174.199 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 81.8 mt -113.46 176.42 5.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.224 -175.619 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -75.94 147.29 39.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.166 -175.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -70.68 154.42 41.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 177.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 90.8 t -115.28 133.83 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.124 -178.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -71.41 159.37 85.74 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.231 -175.663 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -53.38 133.64 53.91 Favored 'Trans proline' 0 N--CA 1.458 -0.603 0 C-N-CA 121.752 1.635 . . . . 0.0 111.217 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.8 mt 52.07 34.38 13.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.221 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.89 -163.17 11.74 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.6 p -162.48 159.54 25.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.82 0.343 . . . . 0.0 111.167 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -145.65 129.64 17.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.164 176.304 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.18 134.29 33.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.203 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -128.4 160.9 30.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.241 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -141.37 147.66 38.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.234 -177.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -132.16 139.95 48.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.195 175.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.533 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 60.7 tp -71.84 -48.08 11.51 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.186 179.262 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.533 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 41.5 Cg_endo -83.44 117.12 2.39 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.694 1.596 . . . . 0.0 111.268 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.03 164.36 29.73 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.735 1.624 . . . . 0.0 111.139 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.8 -175.04 23.95 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 177.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 96' ' ' LYS . 29.5 t -84.37 126.36 33.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.782 0.325 . . . . 0.0 111.181 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -130.06 156.54 44.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.189 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 95.6 m -89.74 99.86 12.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 174.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.91 85.11 7.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 -175.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -80.42 124.35 28.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.178 176.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.426 HG13 HG22 ' A' ' 58' ' ' VAL . 51.7 t -127.79 84.65 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.176 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.18 -109.34 2.85 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -86.24 -12.56 49.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.756 0.312 . . . . 0.0 111.16 -176.076 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.91 157.08 18.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.185 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.3 t -157.02 114.11 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.178 176.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.97 141.13 34.85 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.148 -175.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -77.27 67.51 7.67 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.688 1.592 . . . . 0.0 111.218 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.8 t -74.51 116.82 17.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.175 -176.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 88.5 tttt -84.37 126.9 33.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.269 175.078 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 89.1 mt -104.47 95.86 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.179 -177.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -70.63 150.31 95.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.211 174.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.09 144.91 53.73 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.691 1.594 . . . . 0.0 111.209 -178.39 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 59.27 45.75 13.73 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.195 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 45.7 t -151.41 144.65 24.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.201 -177.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 25.3 m-85 -101.93 150.55 23.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.222 176.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -132.26 145.73 51.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.199 176.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 94.0 m -122.68 119.09 29.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.173 171.324 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.7 tp -110.38 111.73 23.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.137 -176.186 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 97.7 t -85.2 114.15 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.217 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.4 t -105.51 109.76 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.208 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -113.18 103.35 55.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.21 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -57.62 117.81 4.57 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.672 1.581 . . . . 0.0 111.183 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.49 84.06 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 176.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -127.09 -134.6 4.0 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -129.96 116.36 17.96 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 120.738 0.304 . . . . 0.0 111.209 -178.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -76.52 159.4 35.84 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.693 1.596 . . . . 0.0 111.225 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -145.09 120.94 10.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.262 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 57.6 tp -96.19 129.87 43.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.238 174.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.3 t -118.67 122.96 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.233 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -84.5 137.78 33.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 176.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -139.91 74.59 31.59 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.228 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_exo . . . . . 0 C--O 1.2 -1.39 0 C-N-CA 121.73 1.62 . . . . 0.0 111.165 178.949 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 96.5 mm-40 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.883 0.373 . . . . 0.0 111.19 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.79 148.32 75.78 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.205 178.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_exo -55.86 151.77 39.06 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.742 1.628 . . . . 0.0 111.186 176.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.9 tptp -57.55 118.71 5.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.211 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.88 -15.99 47.55 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -179.093 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 29.7 t -91.76 141.28 28.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.735 0.302 . . . . 0.0 111.21 -178.001 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.24 146.73 38.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 176.172 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -114.87 110.9 20.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.17 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 76' ' ' PHE . 65.6 t -115.75 127.94 73.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.225 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.4 ttm180 -120.5 113.4 20.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.16 177.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.43 152.6 23.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 176.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -136.6 132.51 35.19 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.21 -178.187 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -93.1 98.03 11.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.274 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.0 5.6 48.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.231 -177.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.44 -164.34 33.22 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -177.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 -124.76 34.77 4.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.777 0.322 . . . . 0.0 111.209 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.6 p -159.06 -179.31 7.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -55.38 125.24 19.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 177.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.437 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 37.3 tp -70.43 126.8 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -112.96 81.4 1.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 90.2 t -134.11 135.28 54.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 -178.161 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 64' ' ' SER . 42.8 t -110.98 116.12 30.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.132 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 64.8 t -106.54 101.48 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.197 -171.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.91 -110.12 3.27 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 176.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.4 p -101.7 -6.58 23.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.784 0.326 . . . . 0.0 111.185 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.9 m -120.68 115.83 24.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.18 -176.041 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 59' ' ' SER . 69.6 m -79.62 144.16 34.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.217 177.141 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 64.6 tp -115.81 115.74 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.183 -175.651 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -130.93 170.97 13.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.24 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 37.3 t0 55.23 59.54 3.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.171 178.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 56' ' ' LEU . 94.4 t -122.01 125.15 72.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.225 176.248 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -69.92 154.68 94.48 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.186 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -52.98 135.92 59.62 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.675 1.583 . . . . 0.0 111.212 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 53.3 mt 67.34 21.72 9.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.186 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -93.26 -168.25 38.82 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 175.427 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.7 p -162.99 167.83 21.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.792 0.329 . . . . 0.0 111.224 -177.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.7 t -155.53 136.88 14.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 177.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -99.9 144.23 29.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.21 -177.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.415 ' HB2' ' HB ' ' A' ' 46' ' ' VAL . 73.7 m-85 -128.47 150.33 50.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.249 179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -123.39 119.96 31.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 -179.156 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -123.29 95.68 4.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.184 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.503 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 63.5 tp -61.23 -48.6 91.15 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.17 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.503 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 49.2 Cg_endo -80.0 118.92 3.81 Favored 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 121.723 1.616 . . . . 0.0 111.206 177.247 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.54 166.49 25.7 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 121.752 1.635 . . . . 0.0 111.178 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.85 -173.38 26.21 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.3 t -83.36 121.27 26.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.787 0.327 . . . . 0.0 111.227 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -121.43 146.79 46.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.192 176.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.8 m -101.64 125.66 48.33 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.203 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -101.46 98.45 8.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.211 172.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -79.28 118.27 21.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.188 -174.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 54.1 t -119.53 78.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.175 -178.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 70.06 -111.2 3.68 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.15 -4.67 48.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.81 0.338 . . . . 0.0 111.169 177.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.9 mm-40 -109.66 172.63 6.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.4 p -158.28 156.11 30.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.115 177.029 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 87.3 mt -117.46 132.46 23.55 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.18 179.051 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -78.04 70.28 7.14 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 121.735 1.623 . . . . 0.0 111.209 177.23 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.4 t -80.02 82.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.227 -169.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -67.38 113.15 5.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.223 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 73.8 mt -95.99 117.1 29.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.211 -174.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -100.19 152.73 37.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.253 172.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -56.71 131.55 46.29 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 121.701 1.601 . . . . 0.0 111.163 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 63.67 23.59 13.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 172.404 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 44.0 t -104.02 148.51 26.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.227 175.068 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -105.61 139.27 40.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.196 -176.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -133.53 142.82 48.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.162 -178.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.8 m -120.69 127.58 52.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.179 173.37 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 68.7 mt -109.94 97.22 6.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.236 -179.115 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.8 t -92.12 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 -177.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.3 t -101.69 106.78 17.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.143 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 55.1 tp60 -115.07 104.95 53.54 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.253 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -55.72 139.45 83.4 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.709 1.606 . . . . 0.0 111.146 177.083 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 103.98 -19.83 42.63 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -142.41 -153.86 6.01 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.33 149.79 36.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.832 0.349 . . . . 0.0 111.231 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -72.08 153.45 57.41 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.665 1.577 . . . . 0.0 111.188 179.428 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.1 mm-40 -107.93 143.44 36.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.215 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 54.7 tp -120.34 111.7 18.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.234 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.5 t -109.01 118.55 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.232 177.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -109.46 138.13 46.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.209 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -126.17 118.5 23.57 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.226 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo . . . . . 0 C--O 1.2 -1.411 0 C-N-CA 121.694 1.596 . . . . 0.0 111.242 178.455 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 . . . . . 0 CA--C 1.523 -0.072 0 CA-C-O 120.84 0.352 . . . . 0.0 111.235 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.413 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . . . -73.88 148.66 87.3 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.234 177.355 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 39' ' ' ALA . 75.3 Cg_exo -55.52 140.1 82.89 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 121.726 1.618 . . . . 0.0 111.133 177.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -57.16 122.62 12.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.211 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 114.98 -23.1 11.83 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.443 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 38.8 t -63.42 130.55 44.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.786 0.327 . . . . 0.0 111.152 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -114.67 146.71 40.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.209 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -125.38 138.94 54.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.196 -176.353 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.8 t -116.64 112.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.164 173.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -89.6 106.0 18.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.227 -176.354 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.62 145.57 30.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.235 178.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -125.61 128.92 48.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.244 178.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -85.78 95.39 9.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.35 9.6 30.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.207 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.78 -169.43 33.88 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -179.06 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -106.85 9.37 30.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.78 0.324 . . . . 0.0 111.213 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.2 p -159.53 178.97 9.33 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.232 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -60.42 126.39 27.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.162 175.328 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 82.3 mt -110.7 147.3 34.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.22 -176.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -79.05 85.08 5.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.174 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.3 t -115.65 128.08 73.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.125 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.0 p -150.66 156.03 40.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 173.291 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.2 t -129.87 123.68 57.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.232 -178.156 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 66.2 -112.73 5.15 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.5 p -114.36 7.22 16.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.835 0.35 . . . . 0.0 111.247 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.8 m -99.57 119.71 38.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.173 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 85.6 p -87.51 169.94 11.77 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.202 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.9 tp -158.14 134.9 9.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.159 178.056 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -149.62 179.51 7.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.193 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.2 t0 60.48 45.7 10.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.154 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.9 t -106.55 119.21 55.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.184 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.92 152.94 86.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.191 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_exo -53.66 133.68 55.01 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 121.709 1.606 . . . . 0.0 111.196 177.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 55.3 mt 66.86 21.07 10.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.224 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -96.67 -167.37 33.61 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 174.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 90.4 p -159.41 161.22 35.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 111.201 -178.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.1 t -160.91 141.72 11.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 177.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.66 132.49 39.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.235 -175.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -91.95 121.56 33.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.188 169.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -95.26 116.67 29.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.17 -174.311 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -126.1 94.45 4.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.241 175.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.513 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 55.3 tp -56.99 -49.83 91.71 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.201 177.004 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.513 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 42.4 Cg_endo -80.16 124.77 5.56 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.692 1.595 . . . . 0.0 111.162 174.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -75.19 164.9 32.14 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.655 1.57 . . . . 0.0 111.284 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.22 -172.42 24.67 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.6 t -86.07 128.1 34.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 111.144 -176.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -130.62 146.1 52.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.232 174.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.8 m -96.31 115.61 27.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -83.27 94.18 7.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.228 177.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.7 tp60 -78.95 120.22 23.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 178.32 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.7 t -131.53 100.47 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.99 -119.31 13.03 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -96.2 -2.61 45.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.744 0.307 . . . . 0.0 111.179 178.464 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -110.19 170.06 8.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.23 -179.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 97.1 p -152.07 154.01 35.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.204 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.3 tp -144.1 107.68 4.93 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -74.28 144.09 32.6 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 121.747 1.631 . . . . 0.0 111.202 178.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.3 p -149.42 135.41 11.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -85.57 122.65 29.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.239 173.094 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -94.09 113.35 25.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.259 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.408 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 99.1 m-20 -71.57 147.34 92.24 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.214 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 98' ' ' ASP . 85.1 Cg_exo -53.81 129.12 32.5 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 121.66 1.573 . . . . 0.0 111.203 178.369 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 38.3 t0 55.42 62.94 2.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.229 177.052 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 85.5 p -145.6 165.61 28.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.212 178.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -122.54 147.29 46.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.251 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -131.62 144.46 51.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.256 176.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 86.8 m -105.68 119.7 39.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.155 176.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 59.8 tp -112.85 119.91 39.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.242 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.48 113.71 41.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.155 -178.018 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.7 t -91.63 97.55 11.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.248 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 57.5 tp60 -113.51 106.65 54.01 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.183 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_exo -56.46 144.04 85.3 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.69 1.593 . . . . 0.0 111.14 177.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 91.02 21.66 35.2 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 176.17 -169.62 42.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 178.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -88.14 150.4 47.22 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.807 0.337 . . . . 0.0 111.215 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -71.99 149.3 52.74 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.685 1.59 . . . . 0.0 111.18 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -106.98 148.66 28.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.224 179.047 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.0 tt -139.9 131.2 26.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 -175.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 86.9 t -122.99 129.14 75.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.266 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.62 136.72 37.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.229 178.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -139.68 76.32 29.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.231 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_exo . . . . . 0 C--O 1.2 -1.376 0 C-N-CA 121.681 1.587 . . . . 0.0 111.24 178.761 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.798 0.332 . . . . 0.0 111.206 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.56 149.87 86.47 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.223 176.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -53.8 144.25 55.53 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.726 1.618 . . . . 0.0 111.189 176.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.7 tptp -59.42 119.18 6.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.165 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -1.02 60.07 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 174.375 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 56.7 p -105.22 -177.08 3.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.239 -177.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.19 154.51 51.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.216 178.027 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 74.1 t80 -130.44 132.01 45.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.153 -177.483 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 63.4 t -119.59 126.77 75.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.278 -175.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 85.9 mtt85 -99.81 177.06 5.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.189 170.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . 0.406 ' HA ' ' O ' ' A' ' 105' ' ' LEU . . . -148.24 155.72 41.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.22 -179.049 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 72.1 t80 -162.76 117.15 1.74 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.117 172.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -67.01 107.82 2.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.232 176.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -122.74 25.93 8.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.217 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -95.85 -157.34 31.83 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 47.7 p-10 -114.43 29.58 7.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.279 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.7 p -163.1 162.44 25.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.35 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -85.3 130.37 34.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.223 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.507 ' C ' HD12 ' A' ' 56' ' ' LEU . 4.2 pp -157.35 162.66 39.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.231 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -98.28 148.26 23.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.148 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 99.5 t -127.13 135.33 63.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.197 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 86.8 p -153.96 166.7 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.221 177.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 8.4 p -148.72 129.93 5.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.164 176.314 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 62.98 -113.71 6.17 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 -178.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.8 p -112.8 10.84 19.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.982 0.42 . . . . 0.0 111.292 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.9 m -97.08 119.84 36.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.226 -178.495 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 28.8 t -81.39 123.28 28.43 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.193 172.702 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.1 mt -107.25 169.64 8.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.188 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -151.14 177.36 10.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.123 175.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -65.12 119.94 11.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.219 -175.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 89.9 t -106.41 119.47 55.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.153 173.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.93 145.47 92.68 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 -177.118 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -52.2 133.94 48.95 Favored 'Trans proline' 0 C--N 1.328 -0.538 0 C-N-CA 121.617 1.545 . . . . 0.0 111.203 177.67 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 69.3 mt 65.8 23.38 11.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.212 -178.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.71 -166.02 12.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.4 t -166.26 151.91 8.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.884 0.373 . . . . 0.0 111.146 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.1 t -143.79 140.74 30.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.255 177.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -70.04 128.82 37.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.197 -175.184 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -131.57 163.81 27.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.241 174.224 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -63.1 125.35 23.73 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 175.22 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -76.93 144.42 38.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.229 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.2 mt -120.56 140.16 29.97 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.195 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 34.9 Cg_exo -57.99 160.48 15.4 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.699 1.599 . . . . 0.0 111.219 171.134 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.86 151.13 62.56 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 121.599 1.533 . . . . 0.0 111.188 176.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.48 -157.37 25.64 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.6 t -103.38 109.01 20.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.803 0.335 . . . . 0.0 111.141 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -121.45 109.69 15.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.204 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 87.6 m -64.31 129.06 38.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.235 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -102.7 162.88 12.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.174 176.634 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -129.23 131.97 47.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.138 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -128.56 101.25 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 173.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.56 -116.18 7.67 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -174.601 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -99.6 1.32 43.57 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.699 0.285 . . . . 0.0 111.168 177.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.45 170.91 7.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.226 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.9 p -144.01 157.37 44.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.215 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.8 tp -154.42 114.03 2.46 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 -178.133 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.42 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 78.3 Cg_exo -55.0 125.23 18.49 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 121.634 1.556 . . . . 0.0 111.261 175.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 87.3 t -108.06 115.72 49.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.249 177.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -80.95 116.62 21.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 175.343 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.3 mt -103.23 114.99 29.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.264 -178.357 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.406 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 95.6 m-20 -95.12 149.31 36.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 175.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 98' ' ' ASP . 73.1 Cg_exo -54.48 133.22 55.39 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.664 1.576 . . . . 0.0 111.339 177.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 55.81 60.59 3.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.213 178.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 83.3 p -146.95 160.37 42.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.229 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -128.83 143.47 50.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.162 -177.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -132.51 154.72 49.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.288 -177.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 87.6 m -128.75 120.78 27.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 170.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 48' ' ' ALA . 70.2 tp -104.04 112.96 26.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.121 -178.386 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 33.0 m -117.39 157.95 18.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.189 -176.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 80.5 p -90.36 159.68 16.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.156 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 93.9 mm-40 -124.74 155.96 69.06 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 173.182 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -50.53 127.99 22.23 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.731 1.621 . . . . 0.0 111.188 177.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 104.61 -9.69 48.69 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -172.436 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 83.39 42.72 7.76 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -108.66 145.82 32.42 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 111.165 -175.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.5 152.78 30.21 Favored 'Trans proline' 0 C--N 1.328 -0.552 0 C-N-CA 121.643 1.562 . . . . 0.0 111.24 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 68.3 tp60 -151.59 107.69 3.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.22 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 60.6 tp -92.55 118.87 31.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.187 -177.613 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 67.2 t -121.88 113.12 37.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.241 176.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -66.45 129.14 38.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.202 177.145 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.21 73.55 25.83 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo . . . . . 0 C--O 1.201 -1.336 0 C-N-CA 121.817 1.678 . . . . 0.0 111.124 178.273 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 . . . . . 0 CA--C 1.524 -0.055 0 CA-C-O 120.806 0.336 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -70.75 146.35 93.32 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.12 178.4 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -55.93 141.14 86.29 Favored 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 121.678 1.585 . . . . 0.0 111.212 179.523 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -61.36 129.98 43.86 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.193 175.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.92 3.43 55.91 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 89.3 p -87.97 162.15 17.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.813 0.339 . . . . 0.0 111.116 174.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.33 148.15 24.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.19 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -120.12 138.82 53.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.188 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.6 p -148.16 144.09 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.173 -179.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.9 ptt180 -142.93 153.2 42.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.252 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -94.01 155.06 17.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.215 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -135.23 130.62 35.51 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.209 175.182 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 55.7 t-20 -102.67 93.71 5.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.204 -176.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.33 70.69 7.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.229 177.1 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.62 177.78 40.89 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -97.88 -7.04 31.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.808 0.337 . . . . 0.0 111.145 -175.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 34.8 t -99.88 135.84 40.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.164 178.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.1 mp0 -61.77 140.49 58.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.172 176.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.0 mt -124.8 144.89 50.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.171 -175.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -106.37 111.05 23.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.244 174.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.97 166.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.192 -177.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.6 p -148.01 158.24 43.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 51.2 t -127.04 85.6 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.243 174.246 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.97 -111.74 4.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -84.86 -12.61 53.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.771 0.319 . . . . 0.0 111.166 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.3 m -84.47 126.24 33.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.25 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.8 t -103.4 119.44 38.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.192 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.6 mt -125.11 67.5 1.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.173 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -91.42 158.82 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.251 -172.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 36.6 t0 55.31 60.49 3.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.213 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.1 t -82.55 130.77 35.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.203 176.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.55 147.08 88.92 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -171.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -54.89 129.23 34.09 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.657 1.571 . . . . 0.0 111.178 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 86.4 mt 50.74 33.53 8.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -177.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -124.84 -162.03 11.25 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.5 p -148.64 166.42 28.37 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.743 0.306 . . . . 0.0 111.34 -177.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.4 t -137.95 100.96 4.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.235 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -76.93 150.85 35.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.201 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -142.82 127.81 18.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 174.331 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -116.42 178.6 4.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.183 -178.231 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 64.46 32.41 11.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.234 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 61.4 tp -102.16 115.26 64.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.084 -179.035 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.481 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 73.8 Cg_exo -54.88 128.33 30.02 Favored 'Trans proline' 0 N--CA 1.457 -0.624 0 C-N-CA 121.787 1.658 . . . . 0.0 111.179 176.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.481 ' HD3' ' HA ' ' A' ' 80' ' ' PRO . 58.7 Cg_exo -56.14 146.48 70.45 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 121.692 1.595 . . . . 0.0 111.225 176.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 156.32 -175.44 33.99 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.8 t -85.78 125.07 32.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.786 0.327 . . . . 0.0 111.107 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -130.24 143.66 50.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.181 176.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.0 m -98.3 110.57 23.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.206 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.446 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -75.58 151.13 37.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 177.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 72.6 tp60 -134.91 117.16 15.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.204 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.3 t -127.37 106.5 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.196 173.41 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.78 -110.14 3.31 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -115.45 18.16 16.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.889 0.376 . . . . 0.0 111.191 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.0 tp60 -126.91 117.05 21.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -90.01 155.6 18.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.29 176.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 97.1 mt -141.2 85.12 12.23 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.142 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -55.35 129.25 34.18 Favored 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 121.677 1.585 . . . . 0.0 111.189 174.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -146.71 135.35 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.235 -177.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -86.65 123.72 32.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.188 173.078 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.6 mt -100.02 103.01 14.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.271 -178.258 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -73.68 155.62 88.99 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.188 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.3 149.79 63.98 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 121.782 1.655 . . . . 0.0 111.197 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 55.01 45.23 26.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.13 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -151.58 147.48 26.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.272 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -106.38 140.51 39.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.197 -175.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -129.64 142.17 50.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.273 177.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.5 m -120.6 126.46 50.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.277 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 62.3 tp -94.49 98.91 11.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 176.215 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.5 t -78.42 106.15 8.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.115 -178.268 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 92.6 p -101.82 162.85 12.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -154.42 133.28 7.11 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.112 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.75 101.97 0.12 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 121.717 1.612 . . . . 0.0 111.121 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 71.67 22.54 78.66 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 176.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -118.43 -167.63 14.04 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.37 124.32 43.31 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 120.814 0.34 . . . . 0.0 111.251 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -75.49 157.96 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 121.611 1.541 . . . . 0.0 111.265 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -141.37 127.38 19.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.197 -175.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 95.5 mt -76.06 133.98 40.18 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.207 172.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 90.0 t -128.37 125.31 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.228 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.38 135.87 38.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.142 175.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 81.4 mt-10 -128.92 150.55 75.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -178.316 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo . . . . . 0 C--O 1.201 -1.349 0 C-N-CA 121.585 1.523 . . . . 0.0 111.231 178.002 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.6 tt0 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.744 0.307 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -80.67 152.55 72.55 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.118 -179.295 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -56.99 134.99 68.16 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.645 1.564 . . . . 0.0 111.238 178.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -80.24 163.09 24.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.158 177.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 113.64 -20.25 18.13 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -176.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.3 t -154.68 140.59 18.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 0.0 111.165 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.1 151.48 24.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.173 176.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -114.9 139.6 49.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.182 -173.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.9 p -140.45 140.39 34.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.131 -178.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 42.1 ttm180 -111.42 112.44 24.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.171 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.56 123.83 33.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.187 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -110.56 134.81 52.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -100.28 104.18 15.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.189 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.65 4.01 53.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.284 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -97.21 -171.28 33.67 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -102.92 2.67 35.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.888 0.375 . . . . 0.0 111.199 178.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.9 p -149.01 167.73 25.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.294 177.128 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -53.95 122.15 9.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.231 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 90.1 mt -107.12 140.18 40.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.309 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -105.84 144.65 32.28 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.231 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.6 p -140.05 137.26 38.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 41.2 t -102.09 105.52 16.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.158 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 61.7 t -102.14 94.15 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.229 -176.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.16 -109.65 3.01 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -175.404 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.7 p -103.33 -7.42 21.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.752 0.31 . . . . 0.0 111.23 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.7 m -120.06 118.61 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.34 -175.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.3 p -89.13 154.63 20.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.251 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.4 mt -120.0 149.03 42.82 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.18 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 32.4 p30 -158.66 -174.9 5.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -178.013 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.3 t0 63.07 46.19 4.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.22 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.1 t -117.49 121.6 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.231 174.647 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -70.59 145.99 93.26 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.136 -175.111 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 82.6 Cg_exo -53.36 131.49 43.65 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.619 1.546 . . . . 0.0 111.285 177.602 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 65.9 mt 66.42 20.17 10.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.169 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.63 -166.93 12.19 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 173.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 84.7 p -155.7 165.08 37.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.724 0.297 . . . . 0.0 111.215 -179.154 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -149.58 143.21 25.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.147 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -93.01 138.59 31.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 -178.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -129.69 161.43 30.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.255 -178.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.425 ' O ' ' HB2' ' A' ' 78' ' ' PHE . 63.4 pttt -158.02 -155.77 0.52 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.24 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.425 ' HB2' ' O ' ' A' ' 77' ' ' LYS . 50.0 m-85 68.35 33.09 4.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.138 -173.342 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.41 HD12 ' HD2' ' A' ' 80' ' ' PRO . 56.0 tp -134.85 116.67 12.59 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.216 -176.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.41 ' HD2' HD12 ' A' ' 79' ' ' LEU . 92.5 Cg_exo -51.67 133.83 45.41 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 121.618 1.545 . . . . 0.0 111.286 179.459 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -55.47 147.81 55.83 Favored 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 121.77 1.647 . . . . 0.0 111.217 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.16 -171.91 30.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.513 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.0 t -103.59 124.74 49.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.796 0.331 . . . . 0.0 111.21 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -127.33 140.52 52.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.243 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 90.6 m -80.4 117.54 21.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -92.26 108.31 19.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.197 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -85.14 113.8 21.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.254 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.9 t -122.66 103.09 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.215 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.65 -118.94 12.44 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -98.29 -0.55 43.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.741 0.305 . . . . 0.0 111.21 177.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.5 mm-40 -109.01 168.35 9.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.085 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.6 p -149.08 153.8 38.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.253 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.2 tp -151.76 114.91 3.0 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.273 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -57.37 131.41 44.58 Favored 'Trans proline' 0 C--N 1.326 -0.608 0 C-N-CA 121.613 1.542 . . . . 0.0 111.118 174.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.7 t -123.81 118.49 54.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.223 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -86.31 124.54 32.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 172.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 84.2 mt -118.54 139.03 52.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.175 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -114.82 155.68 45.99 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.32 -176.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -80.08 -19.92 9.08 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 121.788 1.658 . . . . 0.0 111.211 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -92.93 -30.57 15.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.193 -173.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.1 t -126.16 -158.76 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.145 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -149.42 159.23 44.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.192 176.073 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -126.85 141.72 51.74 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.203 177.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.4 m -102.16 118.23 36.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.147 -176.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.2 tp -99.52 113.31 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.0 t -81.69 99.29 4.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 177.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -85.22 123.41 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 -176.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -91.43 152.5 43.73 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.232 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.82 68.31 7.21 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.683 1.589 . . . . 0.0 111.24 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.49 -7.37 53.75 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -96.15 -166.41 34.13 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.329 -0.708 . . . . 0.0 111.329 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -87.79 127.73 56.94 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 120.877 0.37 . . . . 0.0 111.16 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -75.88 160.31 37.38 Favored 'Trans proline' 0 N--CA 1.457 -0.634 0 C-N-CA 121.683 1.589 . . . . 0.0 111.232 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -129.02 118.55 22.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.233 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 50.3 tp -85.39 128.03 34.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.18 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.7 126.73 72.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.143 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.76 73.18 5.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.137 179.303 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 119' ' ' PRO . 88.0 tt0 -67.59 129.99 93.32 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.234 -178.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 118' ' ' GLU . 84.1 Cg_exo . . . . . 0 C--O 1.2 -1.42 0 C-N-CA 121.628 1.552 . . . . 0.0 111.161 178.262 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.804 0.335 . . . . 0.0 111.243 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -70.39 146.25 94.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.271 177.476 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -56.98 140.46 92.49 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 121.671 1.58 . . . . 0.0 111.206 178.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -63.66 122.8 17.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.175 -176.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.63 5.56 78.24 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 175.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 69.8 m -117.84 160.65 21.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.842 0.353 . . . . 0.0 111.058 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.37 146.75 24.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.262 177.336 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -115.67 130.9 57.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.209 175.488 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 91.5 t -128.07 131.83 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 176.107 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -115.09 104.94 12.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.202 173.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.5 147.27 32.28 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.209 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -138.4 133.88 33.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.064 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -99.2 105.22 17.24 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.255 -178.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -96.22 24.3 5.83 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.204 -174.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -125.08 -165.05 12.02 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -115.3 27.33 9.44 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.756 0.313 . . . . 0.0 111.219 -179.294 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 44.8 t -146.6 130.33 17.04 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.199 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -59.91 131.3 50.44 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.12 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.8 mt -116.1 146.99 41.78 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.195 -174.032 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -89.38 111.13 21.91 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.217 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.6 t -96.07 134.32 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.157 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 83.8 p -156.76 167.37 30.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.239 173.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.08 130.57 5.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 178.503 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.33 -114.11 6.51 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -114.04 9.11 17.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.5 m -99.87 118.48 36.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.177 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.6 t -78.32 123.95 27.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.236 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 84.2 mt -106.4 173.55 6.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.303 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -73.11 144.9 46.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.217 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.86 150.64 45.58 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.223 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -117.63 123.4 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.106 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -72.82 159.96 84.05 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.2 -178.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_exo -52.69 125.64 18.59 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.713 1.609 . . . . 0.0 111.239 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.3 mt 65.18 22.07 12.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.108 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -112.29 -172.66 18.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 175.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.9 p -152.24 164.16 37.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.855 0.359 . . . . 0.0 111.171 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.9 t -149.39 124.95 10.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.213 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -83.6 137.7 33.7 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.315 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -127.41 118.35 23.92 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.215 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -113.25 168.42 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.19 -177.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 63.81 31.96 13.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.148 174.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.5 mt -86.22 125.88 66.66 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.268 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 74.6 Cg_exo -55.71 116.04 2.88 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.639 1.559 . . . . 0.0 111.227 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -59.87 147.67 91.62 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.714 1.609 . . . . 0.0 111.175 175.246 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.97 -161.99 27.51 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.3 t -103.29 109.69 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.766 0.317 . . . . 0.0 111.249 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -132.78 155.31 49.14 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.345 -177.125 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.9 m -88.83 117.61 27.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.168 178.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -93.23 114.15 26.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.245 -179.223 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.3 tt0 -107.71 131.99 53.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.232 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.04 105.68 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 172.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 81.51 -106.66 2.64 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -174.29 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -113.02 -24.48 9.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.773 0.321 . . . . 0.0 111.133 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -98.72 154.0 18.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.277 -177.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 86.7 p -150.76 148.17 28.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.304 -178.02 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 94' ' ' PRO . 87.6 mt -143.0 141.18 19.03 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.247 174.164 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 93' ' ' LEU . 61.1 Cg_exo -55.97 137.09 77.92 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 121.65 1.567 . . . . 0.0 111.136 175.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 31.7 m -127.45 150.72 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.237 176.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.74 115.73 30.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.282 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 88.4 mt -107.68 100.04 9.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.204 -177.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -88.35 147.12 39.31 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.184 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.78 149.14 53.75 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 121.74 1.627 . . . . 0.0 111.188 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 59.98 43.26 14.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 81.9 p -147.95 161.17 41.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.176 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -114.93 144.74 43.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.196 -175.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -133.85 147.68 51.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.169 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 99.5 m -118.14 129.86 55.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.154 169.34 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 46.8 tp -114.95 101.41 8.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.185 -173.479 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 90.7 t -100.04 128.27 52.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.265 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.5 t -148.91 150.86 33.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.107 -176.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -153.48 159.0 32.65 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.232 176.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -54.98 123.72 14.5 Favored 'Trans proline' 0 C--N 1.328 -0.543 0 C-N-CA 121.688 1.592 . . . . 0.0 111.161 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.85 -20.01 47.51 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.204 -0.759 . . . . 0.0 111.204 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -111.08 -171.76 19.45 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -124.06 155.58 67.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 111.178 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -56.58 120.24 7.99 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.594 1.529 . . . . 0.0 111.28 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 60.3 tp60 -104.12 112.43 25.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.186 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 35.7 tp -77.23 129.26 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.222 178.083 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.4 t -115.92 114.03 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.094 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -76.24 132.91 40.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.214 -178.171 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 76.7 mt-10 -139.38 76.13 31.9 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.258 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo . . . . . 0 C--O 1.199 -1.45 0 C-N-CA 121.67 1.58 . . . . 0.0 111.183 179.466 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.2 tp60 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.798 0.332 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.26 149.47 86.93 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.182 177.508 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo -55.51 143.38 78.38 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 121.778 1.652 . . . . 0.0 111.217 177.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -62.19 115.36 4.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.191 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.66 4.27 57.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 28.9 t -65.41 131.24 45.93 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.816 0.341 . . . . 0.0 111.177 -179.103 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.38 145.74 43.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.171 173.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -124.43 135.66 53.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.221 -174.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 67.4 t -124.32 124.81 69.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.241 170.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -110.49 111.7 23.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.199 176.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.11 149.33 29.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.258 175.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -148.42 132.34 17.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.272 177.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.439 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 58.5 t-20 -91.32 99.55 12.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.71 5.13 50.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 -175.614 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.97 -171.95 37.21 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -178.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -115.21 26.22 10.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.198 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -151.37 164.71 36.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.207 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -79.08 128.97 33.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.19 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.82 148.98 51.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.23 -177.279 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -85.24 128.71 34.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.217 176.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.9 t -122.78 130.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.204 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 42.1 t -136.46 123.26 21.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.229 -178.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 80.7 t -126.46 107.46 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 178.082 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.5 -116.48 5.78 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -102.26 -6.86 22.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.194 -176.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.3 m -115.54 136.08 53.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.133 -177.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -142.52 157.79 44.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.139 -174.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.8 tp -137.8 119.72 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.089 175.7 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -88.53 150.43 23.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.238 -175.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 54.51 59.41 4.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.229 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -75.99 120.82 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.12 148.41 97.89 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.227 -173.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -52.11 132.57 43.83 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.728 1.619 . . . . 0.0 111.196 176.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.8 mt 66.59 21.2 10.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.89 -171.15 43.36 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 174.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.1 p -159.77 166.61 30.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.327 . . . . 0.0 111.243 -176.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.8 t -157.89 118.77 3.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.213 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -88.79 139.03 30.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.228 -176.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -121.05 93.84 4.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.149 172.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -98.15 154.89 17.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.243 -164.202 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 67.0 33.73 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.175 166.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 97.5 mt -84.02 137.89 40.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.185 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.47 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 77.6 Cg_endo -72.12 150.2 53.51 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.704 1.603 . . . . 0.0 111.234 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 80' ' ' PRO . 65.4 Cg_exo -57.19 145.0 88.98 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 121.8 1.667 . . . . 0.0 111.192 178.546 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.27 -172.18 28.57 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.4 t -94.6 134.92 36.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.227 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 -125.82 151.18 47.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.195 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.6 m -95.26 118.97 32.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.196 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -108.7 96.02 6.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.216 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -94.9 130.51 41.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.214 -178.638 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.1 t -127.91 119.45 51.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.229 168.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.89 -110.02 3.24 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -178.145 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -108.16 -9.58 15.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.76 0.314 . . . . 0.0 111.177 -175.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -113.49 160.27 18.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 -176.365 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 95.5 p -147.69 148.46 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 90.4 mt -135.39 150.04 71.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.23 177.026 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.04 146.6 32.7 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.665 1.577 . . . . 0.0 111.129 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 89.4 t -124.78 126.37 71.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.189 177.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -99.11 111.94 24.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.131 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.8 mt -106.39 135.57 47.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.241 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -113.79 162.26 23.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.114 -177.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -51.91 123.28 12.07 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.781 1.654 . . . . 0.0 111.198 175.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 56.02 64.73 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 77.0 p -140.87 157.57 45.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.219 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -118.75 161.2 20.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.197 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.44 149.87 22.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.236 -175.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 97.7 m -127.42 134.73 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.208 179.224 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 63.6 tp -116.02 111.73 20.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.141 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.452 ' HB ' ' HB3' ' A' ' 114' ' ' GLN . 85.9 t -103.38 123.96 57.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.117 -175.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.439 ' HB2' ' HA ' ' A' ' 50' ' ' ASN . 67.8 m -84.91 127.6 34.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.236 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -98.37 148.77 34.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_exo -52.02 131.75 40.13 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.657 1.572 . . . . 0.0 111.179 176.451 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.95 -10.45 57.1 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -177.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.74 67.87 1.34 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 178.331 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.54 130.93 13.62 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-O 120.768 0.318 . . . . 0.0 111.303 175.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.61 148.86 33.55 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.742 1.628 . . . . 0.0 111.181 -178.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLN . . . . . 0.452 ' HB3' ' HB ' ' A' ' 106' ' ' VAL . 49.7 tt0 -126.01 125.04 42.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 171.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 94.3 mt -85.51 118.45 25.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.264 -175.703 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 82.9 t -125.9 112.52 30.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.306 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -86.37 136.24 33.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.258 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -100.8 152.78 37.93 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.17 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo . . . . . 0 C--O 1.201 -1.374 0 C-N-CA 121.741 1.628 . . . . 0.0 111.209 -178.562 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.82 0.343 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.2 145.36 88.32 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.156 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -75.72 155.63 39.68 Favored 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 121.653 1.569 . . . . 0.0 111.248 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -62.06 124.43 20.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 176.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 107.14 -1.61 35.26 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.441 ' O ' ' N ' ' A' ' 100' ' ' ASP . 86.0 p -68.59 161.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 111.159 -178.645 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -158.23 148.88 20.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.202 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -125.98 142.62 51.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.228 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.21 126.96 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 175.34 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -110.48 100.42 9.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.199 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.28 148.15 50.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.186 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -145.65 131.15 18.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.163 178.412 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.4 t-20 -93.95 100.06 12.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 178.48 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -88.72 4.23 48.05 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.189 -173.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -99.64 -169.19 30.01 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -176.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 -115.32 22.74 13.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.78 0.324 . . . . 0.0 111.161 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 82.5 p -147.04 168.89 20.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.232 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.413 ' HA ' ' O ' ' A' ' 68' ' ' VAL . 99.7 mt-10 -77.17 139.61 39.97 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.179 -173.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -115.93 147.9 40.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -106.41 111.51 24.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.211 173.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.6 m -128.44 166.09 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.208 -175.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.2 t -152.97 120.3 5.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.161 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 85.8 t -123.63 125.64 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.146 -173.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.61 -116.46 7.43 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -114.03 9.22 17.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.797 0.332 . . . . 0.0 111.231 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.3 m -121.8 115.22 22.25 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.206 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 67.5 m -84.95 149.43 25.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 54.3 tp -144.71 94.45 2.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.149 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -92.9 159.19 15.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.277 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 61.51 48.3 5.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.289 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 55' ' ' GLU . 99.2 t -72.0 118.91 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.273 178.026 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -64.02 145.79 97.7 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.267 -174.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 85.2 Cg_exo -52.95 130.69 39.02 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 121.717 1.611 . . . . 0.0 111.248 177.626 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 59.1 mt 66.17 21.31 11.13 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.177 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.32 177.99 39.77 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 175.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 87.0 p -156.1 164.71 38.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.758 0.314 . . . . 0.0 111.179 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.2 t -161.38 127.37 3.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.192 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -88.21 137.34 32.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.197 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -119.72 134.17 55.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.217 176.286 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -104.2 122.9 46.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.17 -171.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -111.07 133.67 53.26 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.207 173.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.499 ' HB2' ' HD3' ' A' ' 80' ' ' PRO . 96.3 mt -89.82 -45.52 0.41 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.275 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.499 ' HD3' ' HB2' ' A' ' 79' ' ' LEU . 22.5 Cg_endo -90.0 143.95 4.19 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 121.73 1.62 . . . . 0.0 111.225 -178.251 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_endo -76.48 162.85 32.86 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.689 1.592 . . . . 0.0 111.162 173.55 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.37 -118.45 1.28 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 177.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 87.1 p -166.59 162.61 16.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.812 0.339 . . . . 0.0 111.188 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -160.01 136.11 8.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.23 177.019 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 92.0 m -87.42 111.64 21.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.226 178.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.06 146.26 28.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.223 -176.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.4 tp60 -88.96 120.98 30.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 46.7 t -125.12 80.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.82 -115.3 7.4 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 -176.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.11 -3.24 51.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.86 0.362 . . . . 0.0 111.192 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -107.93 178.04 4.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.208 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -148.97 159.04 44.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.22 176.551 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.417 ' HA ' ' HD2' ' A' ' 94' ' ' PRO . 58.9 tp -135.02 110.94 10.95 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.154 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 93' ' ' LEU . 88.0 Cg_endo -71.83 82.48 1.23 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.766 1.644 . . . . 0.0 111.165 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.4 t -75.05 118.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.162 -175.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -80.98 132.71 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 171.245 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 64.9 mt -111.79 90.64 3.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.25 -175.191 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -72.18 146.22 89.41 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.166 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_exo -54.32 124.33 15.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.761 1.64 . . . . 0.0 111.185 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 43' ' ' SER . 80.7 m-20 54.25 63.11 2.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.128 175.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.1 p -144.4 157.12 44.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.252 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -108.26 150.81 26.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.175 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -136.73 151.98 49.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 177.315 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.401 ' HB ' ' HB ' ' A' ' 116' ' ' VAL . 97.8 m -121.58 137.11 54.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.211 173.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.533 ' C ' HD23 ' A' ' 105' ' ' LEU . 7.1 tt -115.7 104.33 11.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.66 122.34 56.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.199 -178.669 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 90.5 p -142.82 162.73 34.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.199 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -159.82 159.24 27.52 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.257 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -56.49 125.04 17.73 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 121.739 1.626 . . . . 0.0 111.179 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 87.63 -0.14 84.63 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 174.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -120.28 -168.04 13.62 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -124.35 153.59 68.95 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.78 0.324 . . . . 0.0 111.269 179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -69.73 136.59 33.47 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.726 1.617 . . . . 0.0 111.252 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -112.31 125.63 54.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.218 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 58.3 tp -86.77 122.23 30.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 104' ' ' THR . 79.8 t -111.42 118.64 57.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 175.09 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -80.16 132.78 35.98 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.134 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 73.4 mt-10 -139.64 75.06 32.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.217 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo . . . . . 0 C--O 1.201 -1.339 0 C-N-CA 121.685 1.59 . . . . 0.0 111.228 179.339 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 . . . . . 0 CA--C 1.522 -0.117 0 CA-C-O 120.928 0.394 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.27 145.91 88.8 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.11 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.9 78.07 1.81 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 121.637 1.558 . . . . 0.0 111.318 178.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.23 130.1 45.3 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.126 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.24 -20.1 26.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -177.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 81.1 p -96.7 166.86 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.823 0.344 . . . . 0.0 111.152 177.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.54 150.76 21.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.272 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -119.06 132.36 56.02 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 97.2 t -129.32 138.25 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -127.56 95.31 4.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 178.214 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.85 151.29 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.148 177.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -137.57 134.6 35.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.151 179.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -92.97 93.96 8.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.191 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.95 11.36 25.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.218 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.51 -167.35 36.69 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 74.8 m-20 -116.1 24.59 11.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.742 0.306 . . . . 0.0 111.152 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 84.8 p -157.01 163.24 39.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.196 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 mp0 -64.76 137.11 57.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.233 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -121.56 150.65 41.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.197 -177.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -101.2 119.99 39.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 173.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 97.7 t -115.99 128.65 73.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.984 -172.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.3 t -134.86 106.33 6.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.143 177.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.9 t -108.42 114.12 45.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.16 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.57 -111.5 4.02 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 95.9 p -100.62 -5.0 27.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 111.227 178.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 69.7 p -87.44 166.41 14.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 -176.073 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 43.6 t -163.93 126.29 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.231 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 68.5 tp -135.3 118.51 16.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -94.92 156.25 16.42 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.207 -175.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 61.49 49.23 5.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.214 173.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.3 t -74.85 121.11 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.272 175.118 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -64.8 147.81 97.77 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.206 -170.316 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 78.6 Cg_exo -52.94 131.9 44.71 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.637 1.558 . . . . 0.0 111.295 177.1 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 67.7 mt 65.68 21.56 11.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.167 178.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -99.14 -170.04 30.78 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 174.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 96.1 p -149.91 162.03 41.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.761 0.315 . . . . 0.0 111.16 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.3 t -140.55 108.04 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.174 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -81.44 137.65 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -120.47 100.5 7.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.212 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -96.99 169.13 10.04 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.157 176.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 55.36 41.22 31.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 55.2 tp -106.58 116.53 58.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.239 -177.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.71 121.56 9.77 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.642 1.562 . . . . 0.0 111.236 -178.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.12 150.56 64.62 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 121.676 1.584 . . . . 0.0 111.214 176.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.04 172.08 19.07 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.6 t -84.84 113.12 21.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.778 0.323 . . . . 0.0 111.169 176.242 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -128.75 147.92 50.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.157 -178.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.5 m -93.86 95.17 8.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.237 172.564 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -78.82 146.19 33.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.164 -176.234 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.1 tp60 -112.64 104.52 12.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.069 173.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.97 93.74 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 71.42 -118.59 7.32 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -100.81 4.14 42.64 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.816 0.341 . . . . 0.0 111.155 -177.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -129.25 117.62 21.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.16 -177.191 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 31.1 t -69.35 131.15 44.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.157 172.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 84.3 mt -131.85 82.61 59.57 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.257 -178.03 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -70.92 143.62 45.71 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.766 1.644 . . . . 0.0 111.188 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.0 p -161.05 142.27 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 -176.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 59.8 tttm -79.29 119.1 21.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.212 173.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.9 mt -102.49 98.47 8.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.204 -173.376 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -78.52 152.91 78.62 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.201 173.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.46 148.91 61.57 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 121.787 1.658 . . . . 0.0 111.214 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 57.83 45.13 19.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.187 179.144 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.3 t -151.44 145.52 25.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -103.21 132.31 49.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.299 -174.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -123.9 107.32 11.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.267 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 96.7 m -83.87 125.52 32.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.089 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 89.8 mt -112.5 91.24 3.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.209 -178.144 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.4 t -82.81 117.06 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.097 177.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.7 t -112.9 133.55 54.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.261 178.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 -140.77 94.15 8.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.156 -176.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -57.56 119.51 6.81 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 121.79 1.66 . . . . 0.0 111.245 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 84.99 5.44 86.08 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -128.04 -133.08 3.66 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -136.36 121.0 12.87 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.715 0.293 . . . . 0.0 111.234 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.69 163.31 34.04 Favored 'Trans proline' 0 C--N 1.327 -0.586 0 C-N-CA 121.757 1.638 . . . . 0.0 111.167 178.186 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.3 tp60 -145.57 124.83 12.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.258 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.3 mp -102.24 131.22 48.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.191 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.1 t -130.45 120.69 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.238 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.21 132.78 42.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.23 176.27 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -130.96 149.26 73.23 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.205 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo . . . . . 0 C--O 1.199 -1.44 0 C-N-CA 121.641 1.561 . . . . 0.0 111.135 177.544 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 N--CA 1.458 -0.601 0 N-CA-C 111.258 -0.324 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 66.3 tttp -64.77 132.44 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 109.02 -19.15 30.46 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 94.5 p -72.18 162.57 29.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 111.208 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -141.42 150.34 42.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.253 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -119.21 148.34 43.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.164 -175.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.8 p -146.8 133.79 14.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 176.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -98.6 120.82 39.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.212 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.56 91.22 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 174.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -88.86 125.09 34.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.169 -176.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -95.07 102.89 14.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.203 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -90.65 2.41 55.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -177.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -102.01 -175.29 27.87 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -178.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -111.63 28.85 8.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 111.189 -177.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -150.71 157.08 42.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.168 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -62.06 135.36 57.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.215 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 88.1 mt -114.39 141.11 48.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.218 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.71 106.82 17.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.19 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.426 HG22 HG13 ' A' ' 88' ' ' VAL . 96.7 t -92.91 130.46 41.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.141 -174.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.4 t -157.51 117.85 3.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 174.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.6 t -105.46 119.6 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.216 -176.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.04 -113.15 4.04 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -114.85 8.72 16.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.806 0.336 . . . . 0.0 111.21 177.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.6 m -103.41 126.46 50.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.223 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.0 t -81.42 125.32 30.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.165 174.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 81.8 mt -113.46 176.42 5.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.224 -175.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -75.94 147.29 39.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.166 -175.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -70.68 154.42 41.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 177.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 90.8 t -115.28 133.83 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.124 -178.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -71.41 159.37 85.74 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.231 -175.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -53.38 133.64 53.91 Favored 'Trans proline' 0 N--CA 1.458 -0.603 0 C-N-CA 121.752 1.635 . . . . 0.0 111.217 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.8 mt 52.07 34.38 13.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.221 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.89 -163.17 11.74 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.6 p -162.48 159.54 25.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.82 0.343 . . . . 0.0 111.167 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -145.65 129.64 17.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.164 176.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.18 134.29 33.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.203 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -128.4 160.9 30.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.241 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -141.37 147.66 38.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.234 -177.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -132.16 139.95 48.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.195 175.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.533 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 60.7 tp -71.84 -48.08 11.51 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.186 179.262 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.533 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 41.5 Cg_endo -83.44 117.12 2.39 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.694 1.596 . . . . 0.0 111.268 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.03 164.36 29.73 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.735 1.624 . . . . 0.0 111.139 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.8 -175.04 23.95 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 177.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 96' ' ' LYS . 29.5 t -84.37 126.36 33.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.782 0.325 . . . . 0.0 111.181 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -130.06 156.54 44.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.189 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 95.6 m -89.74 99.86 12.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 174.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.91 85.11 7.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 -175.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -80.42 124.35 28.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.178 176.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.426 HG13 HG22 ' A' ' 58' ' ' VAL . 51.7 t -127.79 84.65 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.176 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.18 -109.34 2.85 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -86.24 -12.56 49.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.756 0.312 . . . . 0.0 111.16 -176.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.91 157.08 18.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.185 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.3 t -157.02 114.11 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.178 176.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.97 141.13 34.85 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.148 -175.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -77.27 67.51 7.67 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.688 1.592 . . . . 0.0 111.218 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.8 t -74.51 116.82 17.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.175 -176.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 88.5 tttt -84.37 126.9 33.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.269 175.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 89.1 mt -104.47 95.86 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.179 -177.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -70.63 150.31 95.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.211 174.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.09 144.91 53.73 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.691 1.594 . . . . 0.0 111.209 -178.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 59.27 45.75 13.73 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.195 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 45.7 t -151.41 144.65 24.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.201 -177.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 25.3 m-85 -101.93 150.55 23.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.222 176.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -132.26 145.73 51.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.199 176.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 94.0 m -122.68 119.09 29.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.173 171.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.7 tp -110.38 111.73 23.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.137 -176.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 97.7 t -85.2 114.15 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.217 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.4 t -105.51 109.76 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.208 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -113.18 103.35 55.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.21 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -57.62 117.81 4.57 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.672 1.581 . . . . 0.0 111.183 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.49 84.06 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 176.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -127.09 -134.6 4.0 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -129.96 116.36 17.96 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 120.738 0.304 . . . . 0.0 111.209 -178.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -76.52 159.4 35.84 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.693 1.596 . . . . 0.0 111.225 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -145.09 120.94 10.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.262 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 57.6 tp -96.19 129.87 43.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.238 174.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.3 t -118.67 122.96 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.233 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -84.5 137.78 33.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 176.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -139.91 74.59 31.59 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.228 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_exo . . . . . 0 C--O 1.2 -1.39 0 C-N-CA 121.73 1.62 . . . . 0.0 111.165 178.949 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_exo . . . . . 0 N--CA 1.458 -0.609 0 N-CA-C 111.186 -0.351 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.9 tptp -57.55 118.71 5.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.211 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.88 -15.99 47.55 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -179.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 29.7 t -91.76 141.28 28.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.735 0.302 . . . . 0.0 111.21 -178.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.24 146.73 38.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 176.172 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -114.87 110.9 20.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.17 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 76' ' ' PHE . 65.6 t -115.75 127.94 73.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.225 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.4 ttm180 -120.5 113.4 20.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.16 177.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.43 152.6 23.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 176.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -136.6 132.51 35.19 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.21 -178.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -93.1 98.03 11.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.274 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.0 5.6 48.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.231 -177.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.44 -164.34 33.22 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -177.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 -124.76 34.77 4.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.777 0.322 . . . . 0.0 111.209 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.6 p -159.06 -179.31 7.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -55.38 125.24 19.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 177.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.437 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 37.3 tp -70.43 126.8 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -112.96 81.4 1.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 90.2 t -134.11 135.28 54.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 -178.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 64' ' ' SER . 42.8 t -110.98 116.12 30.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.132 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 64.8 t -106.54 101.48 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.197 -171.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.91 -110.12 3.27 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 176.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.4 p -101.7 -6.58 23.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.784 0.326 . . . . 0.0 111.185 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.9 m -120.68 115.83 24.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.18 -176.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 59' ' ' SER . 69.6 m -79.62 144.16 34.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.217 177.141 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 64.6 tp -115.81 115.74 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.183 -175.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -130.93 170.97 13.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.24 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 37.3 t0 55.23 59.54 3.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.171 178.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 56' ' ' LEU . 94.4 t -122.01 125.15 72.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.225 176.248 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -69.92 154.68 94.48 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.186 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -52.98 135.92 59.62 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.675 1.583 . . . . 0.0 111.212 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 53.3 mt 67.34 21.72 9.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.186 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -93.26 -168.25 38.82 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 175.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.7 p -162.99 167.83 21.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.792 0.329 . . . . 0.0 111.224 -177.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.7 t -155.53 136.88 14.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 177.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -99.9 144.23 29.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.21 -177.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.415 ' HB2' ' HB ' ' A' ' 46' ' ' VAL . 73.7 m-85 -128.47 150.33 50.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.249 179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -123.39 119.96 31.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 -179.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -123.29 95.68 4.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.184 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.503 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 63.5 tp -61.23 -48.6 91.15 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.17 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.503 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 49.2 Cg_endo -80.0 118.92 3.81 Favored 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 121.723 1.616 . . . . 0.0 111.206 177.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.54 166.49 25.7 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 121.752 1.635 . . . . 0.0 111.178 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.85 -173.38 26.21 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.3 t -83.36 121.27 26.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.787 0.327 . . . . 0.0 111.227 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -121.43 146.79 46.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.192 176.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.8 m -101.64 125.66 48.33 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.203 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -101.46 98.45 8.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.211 172.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -79.28 118.27 21.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.188 -174.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 54.1 t -119.53 78.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.175 -178.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 70.06 -111.2 3.68 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.15 -4.67 48.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.81 0.338 . . . . 0.0 111.169 177.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.9 mm-40 -109.66 172.63 6.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.4 p -158.28 156.11 30.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.115 177.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 87.3 mt -117.46 132.46 23.55 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.18 179.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -78.04 70.28 7.14 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 121.735 1.623 . . . . 0.0 111.209 177.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.4 t -80.02 82.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.227 -169.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -67.38 113.15 5.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.223 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 73.8 mt -95.99 117.1 29.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.211 -174.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -100.19 152.73 37.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.253 172.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -56.71 131.55 46.29 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 121.701 1.601 . . . . 0.0 111.163 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 63.67 23.59 13.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 172.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 44.0 t -104.02 148.51 26.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.227 175.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -105.61 139.27 40.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.196 -176.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -133.53 142.82 48.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.162 -178.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.8 m -120.69 127.58 52.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.179 173.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 68.7 mt -109.94 97.22 6.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.236 -179.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.8 t -92.12 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 -177.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.3 t -101.69 106.78 17.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.143 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 55.1 tp60 -115.07 104.95 53.54 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.253 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -55.72 139.45 83.4 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.709 1.606 . . . . 0.0 111.146 177.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 103.98 -19.83 42.63 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -142.41 -153.86 6.01 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.33 149.79 36.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.832 0.349 . . . . 0.0 111.231 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -72.08 153.45 57.41 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.665 1.577 . . . . 0.0 111.188 179.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.1 mm-40 -107.93 143.44 36.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.215 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 54.7 tp -120.34 111.7 18.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.234 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.5 t -109.01 118.55 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.232 177.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -109.46 138.13 46.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.209 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -126.17 118.5 23.57 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.226 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo . . . . . 0 C--O 1.2 -1.411 0 C-N-CA 121.694 1.596 . . . . 0.0 111.242 178.455 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo . . . . . 0 N--CA 1.458 -0.574 0 N-CA-C 111.133 -0.372 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -57.16 122.62 12.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.211 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 114.98 -23.1 11.83 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 38.8 t -63.42 130.55 44.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.786 0.327 . . . . 0.0 111.152 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -114.67 146.71 40.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.209 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -125.38 138.94 54.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.196 -176.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.8 t -116.64 112.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.164 173.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -89.6 106.0 18.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.227 -176.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.62 145.57 30.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.235 178.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -125.61 128.92 48.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.244 178.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -85.78 95.39 9.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.35 9.6 30.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.207 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.78 -169.43 33.88 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -179.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -106.85 9.37 30.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.78 0.324 . . . . 0.0 111.213 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.2 p -159.53 178.97 9.33 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.232 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -60.42 126.39 27.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.162 175.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 82.3 mt -110.7 147.3 34.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.22 -176.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -79.05 85.08 5.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.174 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.3 t -115.65 128.08 73.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.125 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.0 p -150.66 156.03 40.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 173.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.2 t -129.87 123.68 57.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.232 -178.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 66.2 -112.73 5.15 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.5 p -114.36 7.22 16.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.835 0.35 . . . . 0.0 111.247 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.8 m -99.57 119.71 38.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.173 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 85.6 p -87.51 169.94 11.77 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.202 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.9 tp -158.14 134.9 9.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.159 178.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -149.62 179.51 7.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.193 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.2 t0 60.48 45.7 10.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.154 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.9 t -106.55 119.21 55.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.184 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.92 152.94 86.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.191 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_exo -53.66 133.68 55.01 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 121.709 1.606 . . . . 0.0 111.196 177.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 55.3 mt 66.86 21.07 10.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.224 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -96.67 -167.37 33.61 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 174.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 90.4 p -159.41 161.22 35.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 111.201 -178.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.1 t -160.91 141.72 11.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 177.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.66 132.49 39.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.235 -175.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -91.95 121.56 33.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.188 169.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -95.26 116.67 29.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.17 -174.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -126.1 94.45 4.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.241 175.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.513 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 55.3 tp -56.99 -49.83 91.71 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.201 177.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.513 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 42.4 Cg_endo -80.16 124.77 5.56 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.692 1.595 . . . . 0.0 111.162 174.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -75.19 164.9 32.14 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.655 1.57 . . . . 0.0 111.284 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.22 -172.42 24.67 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.6 t -86.07 128.1 34.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 111.144 -176.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -130.62 146.1 52.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.232 174.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.8 m -96.31 115.61 27.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -83.27 94.18 7.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.228 177.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.7 tp60 -78.95 120.22 23.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 178.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.7 t -131.53 100.47 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.99 -119.31 13.03 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -96.2 -2.61 45.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.744 0.307 . . . . 0.0 111.179 178.464 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -110.19 170.06 8.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.23 -179.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 97.1 p -152.07 154.01 35.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.204 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.3 tp -144.1 107.68 4.93 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -74.28 144.09 32.6 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 121.747 1.631 . . . . 0.0 111.202 178.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.3 p -149.42 135.41 11.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -85.57 122.65 29.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.239 173.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -94.09 113.35 25.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.259 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.408 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 99.1 m-20 -71.57 147.34 92.24 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.214 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 98' ' ' ASP . 85.1 Cg_exo -53.81 129.12 32.5 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 121.66 1.573 . . . . 0.0 111.203 178.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 38.3 t0 55.42 62.94 2.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.229 177.052 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 85.5 p -145.6 165.61 28.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.212 178.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -122.54 147.29 46.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.251 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -131.62 144.46 51.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.256 176.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 86.8 m -105.68 119.7 39.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.155 176.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 59.8 tp -112.85 119.91 39.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.242 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.48 113.71 41.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.155 -178.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.7 t -91.63 97.55 11.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.248 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 57.5 tp60 -113.51 106.65 54.01 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.183 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_exo -56.46 144.04 85.3 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.69 1.593 . . . . 0.0 111.14 177.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 91.02 21.66 35.2 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 176.17 -169.62 42.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 178.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -88.14 150.4 47.22 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.807 0.337 . . . . 0.0 111.215 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -71.99 149.3 52.74 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.685 1.59 . . . . 0.0 111.18 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -106.98 148.66 28.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.224 179.047 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.0 tt -139.9 131.2 26.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 -175.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 86.9 t -122.99 129.14 75.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.266 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.62 136.72 37.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.229 178.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -139.68 76.32 29.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.231 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_exo . . . . . 0 C--O 1.2 -1.376 0 C-N-CA 121.681 1.587 . . . . 0.0 111.24 178.761 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo . . . . . 0 N--CA 1.457 -0.626 0 N-CA-C 111.189 -0.35 . . . . 0.0 111.189 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.7 tptp -59.42 119.18 6.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.165 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -1.02 60.07 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 174.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 56.7 p -105.22 -177.08 3.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.239 -177.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.19 154.51 51.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.216 178.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 74.1 t80 -130.44 132.01 45.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.153 -177.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 63.4 t -119.59 126.77 75.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.278 -175.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 85.9 mtt85 -99.81 177.06 5.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.189 170.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . 0.406 ' HA ' ' O ' ' A' ' 105' ' ' LEU . . . -148.24 155.72 41.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.22 -179.049 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 72.1 t80 -162.76 117.15 1.74 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.117 172.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -67.01 107.82 2.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.232 176.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -122.74 25.93 8.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.217 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -95.85 -157.34 31.83 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 47.7 p-10 -114.43 29.58 7.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.279 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.7 p -163.1 162.44 25.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.35 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -85.3 130.37 34.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.223 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.507 ' C ' HD12 ' A' ' 56' ' ' LEU . 4.2 pp -157.35 162.66 39.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.231 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -98.28 148.26 23.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.148 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 99.5 t -127.13 135.33 63.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.197 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 86.8 p -153.96 166.7 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.221 177.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 8.4 p -148.72 129.93 5.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.164 176.314 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 62.98 -113.71 6.17 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 -178.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.8 p -112.8 10.84 19.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.982 0.42 . . . . 0.0 111.292 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.9 m -97.08 119.84 36.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.226 -178.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 28.8 t -81.39 123.28 28.43 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.193 172.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.1 mt -107.25 169.64 8.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.188 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -151.14 177.36 10.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.123 175.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -65.12 119.94 11.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.219 -175.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 89.9 t -106.41 119.47 55.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.153 173.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.93 145.47 92.68 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 -177.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -52.2 133.94 48.95 Favored 'Trans proline' 0 C--N 1.328 -0.538 0 C-N-CA 121.617 1.545 . . . . 0.0 111.203 177.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 69.3 mt 65.8 23.38 11.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.212 -178.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.71 -166.02 12.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.4 t -166.26 151.91 8.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.884 0.373 . . . . 0.0 111.146 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.1 t -143.79 140.74 30.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.255 177.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -70.04 128.82 37.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.197 -175.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -131.57 163.81 27.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.241 174.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -63.1 125.35 23.73 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 175.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -76.93 144.42 38.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.229 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.2 mt -120.56 140.16 29.97 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.195 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 34.9 Cg_exo -57.99 160.48 15.4 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.699 1.599 . . . . 0.0 111.219 171.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.86 151.13 62.56 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 121.599 1.533 . . . . 0.0 111.188 176.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.48 -157.37 25.64 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.6 t -103.38 109.01 20.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.803 0.335 . . . . 0.0 111.141 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -121.45 109.69 15.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.204 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 87.6 m -64.31 129.06 38.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.235 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -102.7 162.88 12.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.174 176.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -129.23 131.97 47.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.138 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -128.56 101.25 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 173.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.56 -116.18 7.67 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -174.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -99.6 1.32 43.57 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.699 0.285 . . . . 0.0 111.168 177.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.45 170.91 7.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.226 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.9 p -144.01 157.37 44.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.215 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.8 tp -154.42 114.03 2.46 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 -178.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.42 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 78.3 Cg_exo -55.0 125.23 18.49 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 121.634 1.556 . . . . 0.0 111.261 175.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 87.3 t -108.06 115.72 49.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.249 177.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -80.95 116.62 21.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 175.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.3 mt -103.23 114.99 29.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.264 -178.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.406 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 95.6 m-20 -95.12 149.31 36.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 175.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 98' ' ' ASP . 73.1 Cg_exo -54.48 133.22 55.39 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.664 1.576 . . . . 0.0 111.339 177.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 55.81 60.59 3.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.213 178.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 83.3 p -146.95 160.37 42.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.229 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -128.83 143.47 50.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.162 -177.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -132.51 154.72 49.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.288 -177.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 87.6 m -128.75 120.78 27.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 170.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 48' ' ' ALA . 70.2 tp -104.04 112.96 26.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.121 -178.386 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 33.0 m -117.39 157.95 18.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.189 -176.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 80.5 p -90.36 159.68 16.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.156 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 93.9 mm-40 -124.74 155.96 69.06 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 173.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -50.53 127.99 22.23 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.731 1.621 . . . . 0.0 111.188 177.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 104.61 -9.69 48.69 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -172.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 83.39 42.72 7.76 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -108.66 145.82 32.42 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 111.165 -175.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.5 152.78 30.21 Favored 'Trans proline' 0 C--N 1.328 -0.552 0 C-N-CA 121.643 1.562 . . . . 0.0 111.24 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 68.3 tp60 -151.59 107.69 3.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.22 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 60.6 tp -92.55 118.87 31.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.187 -177.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 67.2 t -121.88 113.12 37.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.241 176.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -66.45 129.14 38.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.202 177.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.21 73.55 25.83 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo . . . . . 0 C--O 1.201 -1.336 0 C-N-CA 121.817 1.678 . . . . 0.0 111.124 178.273 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo . . . . . 0 N--CA 1.459 -0.523 0 N-CA-C 111.212 -0.342 . . . . 0.0 111.212 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -61.36 129.98 43.86 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.193 175.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.92 3.43 55.91 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 89.3 p -87.97 162.15 17.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.813 0.339 . . . . 0.0 111.116 174.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.33 148.15 24.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.19 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -120.12 138.82 53.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.188 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.6 p -148.16 144.09 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.173 -179.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.9 ptt180 -142.93 153.2 42.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.252 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -94.01 155.06 17.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.215 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -135.23 130.62 35.51 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.209 175.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 55.7 t-20 -102.67 93.71 5.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.204 -176.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.33 70.69 7.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.229 177.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.62 177.78 40.89 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -97.88 -7.04 31.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.808 0.337 . . . . 0.0 111.145 -175.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 34.8 t -99.88 135.84 40.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.164 178.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.1 mp0 -61.77 140.49 58.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.172 176.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.0 mt -124.8 144.89 50.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.171 -175.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -106.37 111.05 23.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.244 174.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.97 166.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.192 -177.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.6 p -148.01 158.24 43.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 51.2 t -127.04 85.6 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.243 174.246 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.97 -111.74 4.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -84.86 -12.61 53.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.771 0.319 . . . . 0.0 111.166 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.3 m -84.47 126.24 33.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.25 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.8 t -103.4 119.44 38.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.192 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.6 mt -125.11 67.5 1.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.173 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -91.42 158.82 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.251 -172.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 36.6 t0 55.31 60.49 3.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.213 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.1 t -82.55 130.77 35.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.203 176.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.55 147.08 88.92 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -171.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -54.89 129.23 34.09 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.657 1.571 . . . . 0.0 111.178 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 86.4 mt 50.74 33.53 8.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -177.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -124.84 -162.03 11.25 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.5 p -148.64 166.42 28.37 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.743 0.306 . . . . 0.0 111.34 -177.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.4 t -137.95 100.96 4.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.235 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -76.93 150.85 35.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.201 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -142.82 127.81 18.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 174.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -116.42 178.6 4.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.183 -178.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 64.46 32.41 11.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.234 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 61.4 tp -102.16 115.26 64.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.084 -179.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.481 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 73.8 Cg_exo -54.88 128.33 30.02 Favored 'Trans proline' 0 N--CA 1.457 -0.624 0 C-N-CA 121.787 1.658 . . . . 0.0 111.179 176.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.481 ' HD3' ' HA ' ' A' ' 80' ' ' PRO . 58.7 Cg_exo -56.14 146.48 70.45 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 121.692 1.595 . . . . 0.0 111.225 176.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 156.32 -175.44 33.99 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.8 t -85.78 125.07 32.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.786 0.327 . . . . 0.0 111.107 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -130.24 143.66 50.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.181 176.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.0 m -98.3 110.57 23.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.206 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.446 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -75.58 151.13 37.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 177.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 72.6 tp60 -134.91 117.16 15.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.204 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.3 t -127.37 106.5 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.196 173.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.78 -110.14 3.31 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -115.45 18.16 16.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.889 0.376 . . . . 0.0 111.191 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.0 tp60 -126.91 117.05 21.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -90.01 155.6 18.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.29 176.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 97.1 mt -141.2 85.12 12.23 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.142 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -55.35 129.25 34.18 Favored 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 121.677 1.585 . . . . 0.0 111.189 174.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -146.71 135.35 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.235 -177.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -86.65 123.72 32.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.188 173.078 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.6 mt -100.02 103.01 14.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.271 -178.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -73.68 155.62 88.99 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.188 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.3 149.79 63.98 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 121.782 1.655 . . . . 0.0 111.197 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 55.01 45.23 26.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.13 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -151.58 147.48 26.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.272 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -106.38 140.51 39.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.197 -175.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -129.64 142.17 50.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.273 177.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.5 m -120.6 126.46 50.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.277 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 62.3 tp -94.49 98.91 11.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 176.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.5 t -78.42 106.15 8.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.115 -178.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 92.6 p -101.82 162.85 12.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -154.42 133.28 7.11 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.112 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.75 101.97 0.12 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 121.717 1.612 . . . . 0.0 111.121 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 71.67 22.54 78.66 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 176.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -118.43 -167.63 14.04 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.37 124.32 43.31 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 120.814 0.34 . . . . 0.0 111.251 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -75.49 157.96 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 121.611 1.541 . . . . 0.0 111.265 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -141.37 127.38 19.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.197 -175.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 95.5 mt -76.06 133.98 40.18 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.207 172.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 90.0 t -128.37 125.31 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.228 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.38 135.87 38.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.142 175.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 81.4 mt-10 -128.92 150.55 75.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -178.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo . . . . . 0 C--O 1.201 -1.349 0 C-N-CA 121.585 1.523 . . . . 0.0 111.231 178.002 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo . . . . . 0 N--CA 1.457 -0.64 0 N-CA-C 111.238 -0.332 . . . . 0.0 111.238 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -80.24 163.09 24.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.158 177.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 113.64 -20.25 18.13 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -176.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.3 t -154.68 140.59 18.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 0.0 111.165 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.1 151.48 24.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.173 176.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -114.9 139.6 49.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.182 -173.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.9 p -140.45 140.39 34.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.131 -178.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 42.1 ttm180 -111.42 112.44 24.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.171 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.56 123.83 33.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.187 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -110.56 134.81 52.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -100.28 104.18 15.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.189 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.65 4.01 53.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.284 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -97.21 -171.28 33.67 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -102.92 2.67 35.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.888 0.375 . . . . 0.0 111.199 178.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.9 p -149.01 167.73 25.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.294 177.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -53.95 122.15 9.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.231 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 90.1 mt -107.12 140.18 40.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -105.84 144.65 32.28 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.231 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.6 p -140.05 137.26 38.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 41.2 t -102.09 105.52 16.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.158 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 61.7 t -102.14 94.15 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.229 -176.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.16 -109.65 3.01 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -175.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.7 p -103.33 -7.42 21.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.752 0.31 . . . . 0.0 111.23 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.7 m -120.06 118.61 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.34 -175.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.3 p -89.13 154.63 20.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.251 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.4 mt -120.0 149.03 42.82 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.18 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 32.4 p30 -158.66 -174.9 5.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -178.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.3 t0 63.07 46.19 4.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.22 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.1 t -117.49 121.6 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.231 174.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -70.59 145.99 93.26 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.136 -175.111 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 82.6 Cg_exo -53.36 131.49 43.65 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.619 1.546 . . . . 0.0 111.285 177.602 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 65.9 mt 66.42 20.17 10.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.169 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.63 -166.93 12.19 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 173.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 84.7 p -155.7 165.08 37.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.724 0.297 . . . . 0.0 111.215 -179.154 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -149.58 143.21 25.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.147 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -93.01 138.59 31.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 -178.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -129.69 161.43 30.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.255 -178.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.425 ' O ' ' HB2' ' A' ' 78' ' ' PHE . 63.4 pttt -158.02 -155.77 0.52 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.24 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.425 ' HB2' ' O ' ' A' ' 77' ' ' LYS . 50.0 m-85 68.35 33.09 4.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.138 -173.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.41 HD12 ' HD2' ' A' ' 80' ' ' PRO . 56.0 tp -134.85 116.67 12.59 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.216 -176.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.41 ' HD2' HD12 ' A' ' 79' ' ' LEU . 92.5 Cg_exo -51.67 133.83 45.41 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 121.618 1.545 . . . . 0.0 111.286 179.459 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -55.47 147.81 55.83 Favored 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 121.77 1.647 . . . . 0.0 111.217 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.16 -171.91 30.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.0 t -103.59 124.74 49.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.796 0.331 . . . . 0.0 111.21 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -127.33 140.52 52.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.243 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 90.6 m -80.4 117.54 21.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -92.26 108.31 19.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.197 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -85.14 113.8 21.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.254 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.9 t -122.66 103.09 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.215 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.65 -118.94 12.44 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -98.29 -0.55 43.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.741 0.305 . . . . 0.0 111.21 177.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.5 mm-40 -109.01 168.35 9.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.085 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.6 p -149.08 153.8 38.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.253 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.2 tp -151.76 114.91 3.0 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.273 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -57.37 131.41 44.58 Favored 'Trans proline' 0 C--N 1.326 -0.608 0 C-N-CA 121.613 1.542 . . . . 0.0 111.118 174.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.7 t -123.81 118.49 54.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.223 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -86.31 124.54 32.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 172.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 84.2 mt -118.54 139.03 52.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.175 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -114.82 155.68 45.99 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.32 -176.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -80.08 -19.92 9.08 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 121.788 1.658 . . . . 0.0 111.211 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -92.93 -30.57 15.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.193 -173.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.1 t -126.16 -158.76 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.145 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -149.42 159.23 44.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.192 176.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -126.85 141.72 51.74 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.203 177.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.4 m -102.16 118.23 36.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.147 -176.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.2 tp -99.52 113.31 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.0 t -81.69 99.29 4.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 177.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -85.22 123.41 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 -176.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -91.43 152.5 43.73 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.232 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.82 68.31 7.21 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.683 1.589 . . . . 0.0 111.24 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.49 -7.37 53.75 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -96.15 -166.41 34.13 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.329 -0.708 . . . . 0.0 111.329 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -87.79 127.73 56.94 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 120.877 0.37 . . . . 0.0 111.16 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -75.88 160.31 37.38 Favored 'Trans proline' 0 N--CA 1.457 -0.634 0 C-N-CA 121.683 1.589 . . . . 0.0 111.232 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -129.02 118.55 22.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.233 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 50.3 tp -85.39 128.03 34.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.18 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.7 126.73 72.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.143 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.76 73.18 5.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.137 179.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 119' ' ' PRO . 88.0 tt0 -67.59 129.99 93.32 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.234 -178.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 118' ' ' GLU . 84.1 Cg_exo . . . . . 0 C--O 1.2 -1.42 0 C-N-CA 121.628 1.552 . . . . 0.0 111.161 178.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo . . . . . 0 N--CA 1.457 -0.666 0 N-CA-C 111.206 -0.344 . . . . 0.0 111.206 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -63.66 122.8 17.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.175 -176.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.63 5.56 78.24 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 175.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 69.8 m -117.84 160.65 21.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.842 0.353 . . . . 0.0 111.058 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.37 146.75 24.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.262 177.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -115.67 130.9 57.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.209 175.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 91.5 t -128.07 131.83 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 176.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -115.09 104.94 12.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.202 173.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.5 147.27 32.28 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.209 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -138.4 133.88 33.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.064 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -99.2 105.22 17.24 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.255 -178.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -96.22 24.3 5.83 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.204 -174.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -125.08 -165.05 12.02 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -115.3 27.33 9.44 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.756 0.313 . . . . 0.0 111.219 -179.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 44.8 t -146.6 130.33 17.04 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.199 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -59.91 131.3 50.44 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.12 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.8 mt -116.1 146.99 41.78 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.195 -174.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -89.38 111.13 21.91 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.217 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.6 t -96.07 134.32 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.157 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 83.8 p -156.76 167.37 30.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.239 173.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.08 130.57 5.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 178.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.33 -114.11 6.51 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -114.04 9.11 17.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.5 m -99.87 118.48 36.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.177 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.6 t -78.32 123.95 27.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.236 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 84.2 mt -106.4 173.55 6.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.303 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -73.11 144.9 46.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.217 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.86 150.64 45.58 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.223 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -117.63 123.4 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.106 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -72.82 159.96 84.05 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.2 -178.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_exo -52.69 125.64 18.59 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.713 1.609 . . . . 0.0 111.239 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.3 mt 65.18 22.07 12.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.108 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -112.29 -172.66 18.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 175.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.9 p -152.24 164.16 37.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.855 0.359 . . . . 0.0 111.171 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.9 t -149.39 124.95 10.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.213 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -83.6 137.7 33.7 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.315 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -127.41 118.35 23.92 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.215 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -113.25 168.42 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.19 -177.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 63.81 31.96 13.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.148 174.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.5 mt -86.22 125.88 66.66 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.268 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 74.6 Cg_exo -55.71 116.04 2.88 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.639 1.559 . . . . 0.0 111.227 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -59.87 147.67 91.62 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.714 1.609 . . . . 0.0 111.175 175.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.97 -161.99 27.51 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.3 t -103.29 109.69 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.766 0.317 . . . . 0.0 111.249 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -132.78 155.31 49.14 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.345 -177.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.9 m -88.83 117.61 27.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.168 178.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -93.23 114.15 26.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.245 -179.223 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.3 tt0 -107.71 131.99 53.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.232 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.04 105.68 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 172.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 81.51 -106.66 2.64 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -174.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -113.02 -24.48 9.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.773 0.321 . . . . 0.0 111.133 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -98.72 154.0 18.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.277 -177.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 86.7 p -150.76 148.17 28.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.304 -178.02 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 94' ' ' PRO . 87.6 mt -143.0 141.18 19.03 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.247 174.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 93' ' ' LEU . 61.1 Cg_exo -55.97 137.09 77.92 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 121.65 1.567 . . . . 0.0 111.136 175.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 31.7 m -127.45 150.72 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.237 176.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.74 115.73 30.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.282 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 88.4 mt -107.68 100.04 9.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.204 -177.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -88.35 147.12 39.31 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.184 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.78 149.14 53.75 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 121.74 1.627 . . . . 0.0 111.188 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 59.98 43.26 14.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 81.9 p -147.95 161.17 41.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.176 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -114.93 144.74 43.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.196 -175.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -133.85 147.68 51.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.169 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 99.5 m -118.14 129.86 55.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.154 169.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 46.8 tp -114.95 101.41 8.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.185 -173.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 90.7 t -100.04 128.27 52.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.265 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.5 t -148.91 150.86 33.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.107 -176.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -153.48 159.0 32.65 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.232 176.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -54.98 123.72 14.5 Favored 'Trans proline' 0 C--N 1.328 -0.543 0 C-N-CA 121.688 1.592 . . . . 0.0 111.161 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.85 -20.01 47.51 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.204 -0.759 . . . . 0.0 111.204 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -111.08 -171.76 19.45 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -124.06 155.58 67.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 111.178 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -56.58 120.24 7.99 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.594 1.529 . . . . 0.0 111.28 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 60.3 tp60 -104.12 112.43 25.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.186 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 35.7 tp -77.23 129.26 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.222 178.083 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.4 t -115.92 114.03 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.094 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -76.24 132.91 40.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.214 -178.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 76.7 mt-10 -139.38 76.13 31.9 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.258 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo . . . . . 0 C--O 1.199 -1.45 0 C-N-CA 121.67 1.58 . . . . 0.0 111.183 179.466 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo . . . . . 0 N--CA 1.456 -0.687 0 N-CA-C 111.217 -0.34 . . . . 0.0 111.217 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -62.19 115.36 4.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.191 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.66 4.27 57.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 28.9 t -65.41 131.24 45.93 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.816 0.341 . . . . 0.0 111.177 -179.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.38 145.74 43.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.171 173.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -124.43 135.66 53.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.221 -174.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 67.4 t -124.32 124.81 69.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.241 170.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -110.49 111.7 23.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.199 176.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.11 149.33 29.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.258 175.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -148.42 132.34 17.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.272 177.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.439 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 58.5 t-20 -91.32 99.55 12.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.71 5.13 50.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 -175.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.97 -171.95 37.21 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -178.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -115.21 26.22 10.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.198 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -151.37 164.71 36.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.207 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -79.08 128.97 33.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.19 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.82 148.98 51.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.23 -177.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -85.24 128.71 34.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.217 176.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.9 t -122.78 130.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.204 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 42.1 t -136.46 123.26 21.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.229 -178.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 80.7 t -126.46 107.46 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 178.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.5 -116.48 5.78 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -102.26 -6.86 22.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.194 -176.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.3 m -115.54 136.08 53.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.133 -177.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -142.52 157.79 44.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.139 -174.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.8 tp -137.8 119.72 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.089 175.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -88.53 150.43 23.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.238 -175.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 54.51 59.41 4.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.229 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -75.99 120.82 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.12 148.41 97.89 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.227 -173.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -52.11 132.57 43.83 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.728 1.619 . . . . 0.0 111.196 176.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.8 mt 66.59 21.2 10.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.89 -171.15 43.36 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 174.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.1 p -159.77 166.61 30.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.327 . . . . 0.0 111.243 -176.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.8 t -157.89 118.77 3.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.213 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -88.79 139.03 30.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.228 -176.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -121.05 93.84 4.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.149 172.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -98.15 154.89 17.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.243 -164.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 67.0 33.73 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.175 166.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 97.5 mt -84.02 137.89 40.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.185 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.47 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 77.6 Cg_endo -72.12 150.2 53.51 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.704 1.603 . . . . 0.0 111.234 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 80' ' ' PRO . 65.4 Cg_exo -57.19 145.0 88.98 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 121.8 1.667 . . . . 0.0 111.192 178.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.27 -172.18 28.57 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.4 t -94.6 134.92 36.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.227 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 -125.82 151.18 47.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.195 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.6 m -95.26 118.97 32.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.196 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -108.7 96.02 6.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.216 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -94.9 130.51 41.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.214 -178.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.1 t -127.91 119.45 51.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.229 168.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.89 -110.02 3.24 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -178.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -108.16 -9.58 15.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.76 0.314 . . . . 0.0 111.177 -175.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -113.49 160.27 18.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 -176.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 95.5 p -147.69 148.46 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 90.4 mt -135.39 150.04 71.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.23 177.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.04 146.6 32.7 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.665 1.577 . . . . 0.0 111.129 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 89.4 t -124.78 126.37 71.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.189 177.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -99.11 111.94 24.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.131 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.8 mt -106.39 135.57 47.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.241 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -113.79 162.26 23.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.114 -177.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -51.91 123.28 12.07 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.781 1.654 . . . . 0.0 111.198 175.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 56.02 64.73 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 77.0 p -140.87 157.57 45.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.219 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -118.75 161.2 20.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.197 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.44 149.87 22.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.236 -175.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 97.7 m -127.42 134.73 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.208 179.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 63.6 tp -116.02 111.73 20.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.141 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.452 ' HB ' ' HB3' ' A' ' 114' ' ' GLN . 85.9 t -103.38 123.96 57.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.117 -175.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.439 ' HB2' ' HA ' ' A' ' 50' ' ' ASN . 67.8 m -84.91 127.6 34.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.236 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -98.37 148.77 34.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_exo -52.02 131.75 40.13 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.657 1.572 . . . . 0.0 111.179 176.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.95 -10.45 57.1 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -177.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.74 67.87 1.34 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 178.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.54 130.93 13.62 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-O 120.768 0.318 . . . . 0.0 111.303 175.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.61 148.86 33.55 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.742 1.628 . . . . 0.0 111.181 -178.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . 0.452 ' HB3' ' HB ' ' A' ' 106' ' ' VAL . 49.7 tt0 -126.01 125.04 42.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 171.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 94.3 mt -85.51 118.45 25.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.264 -175.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 82.9 t -125.9 112.52 30.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.306 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -86.37 136.24 33.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.258 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -100.8 152.78 37.93 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.17 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo . . . . . 0 C--O 1.201 -1.374 0 C-N-CA 121.741 1.628 . . . . 0.0 111.209 -178.562 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo . . . . . 0 N--CA 1.458 -0.595 0 N-CA-C 111.248 -0.328 . . . . 0.0 111.248 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -62.06 124.43 20.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 176.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 107.14 -1.61 35.26 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . 0.441 ' O ' ' N ' ' A' ' 100' ' ' ASP . 86.0 p -68.59 161.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 111.159 -178.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -158.23 148.88 20.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.202 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -125.98 142.62 51.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.228 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.21 126.96 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 175.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -110.48 100.42 9.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.199 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.28 148.15 50.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.186 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -145.65 131.15 18.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.163 178.412 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.4 t-20 -93.95 100.06 12.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 178.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -88.72 4.23 48.05 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.189 -173.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -99.64 -169.19 30.01 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -176.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 -115.32 22.74 13.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.78 0.324 . . . . 0.0 111.161 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 82.5 p -147.04 168.89 20.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.232 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.413 ' HA ' ' O ' ' A' ' 68' ' ' VAL . 99.7 mt-10 -77.17 139.61 39.97 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.179 -173.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -115.93 147.9 40.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -106.41 111.51 24.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.211 173.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.6 m -128.44 166.09 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.208 -175.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.2 t -152.97 120.3 5.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.161 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 85.8 t -123.63 125.64 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.146 -173.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.61 -116.46 7.43 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -114.03 9.22 17.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.797 0.332 . . . . 0.0 111.231 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.3 m -121.8 115.22 22.25 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.206 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 67.5 m -84.95 149.43 25.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 54.3 tp -144.71 94.45 2.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.149 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -92.9 159.19 15.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.277 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 61.51 48.3 5.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.289 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 55' ' ' GLU . 99.2 t -72.0 118.91 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.273 178.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -64.02 145.79 97.7 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.267 -174.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 85.2 Cg_exo -52.95 130.69 39.02 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 121.717 1.611 . . . . 0.0 111.248 177.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 59.1 mt 66.17 21.31 11.13 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.177 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.32 177.99 39.77 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 175.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 87.0 p -156.1 164.71 38.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.758 0.314 . . . . 0.0 111.179 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.2 t -161.38 127.37 3.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.192 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -88.21 137.34 32.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.197 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -119.72 134.17 55.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.217 176.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -104.2 122.9 46.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.17 -171.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -111.07 133.67 53.26 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.207 173.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.499 ' HB2' ' HD3' ' A' ' 80' ' ' PRO . 96.3 mt -89.82 -45.52 0.41 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.275 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.499 ' HD3' ' HB2' ' A' ' 79' ' ' LEU . 22.5 Cg_endo -90.0 143.95 4.19 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 121.73 1.62 . . . . 0.0 111.225 -178.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_endo -76.48 162.85 32.86 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.689 1.592 . . . . 0.0 111.162 173.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.37 -118.45 1.28 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 177.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 87.1 p -166.59 162.61 16.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.812 0.339 . . . . 0.0 111.188 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -160.01 136.11 8.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.23 177.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 92.0 m -87.42 111.64 21.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.226 178.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.06 146.26 28.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.223 -176.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.4 tp60 -88.96 120.98 30.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 46.7 t -125.12 80.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.82 -115.3 7.4 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 -176.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.11 -3.24 51.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.86 0.362 . . . . 0.0 111.192 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -107.93 178.04 4.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.208 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -148.97 159.04 44.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.22 176.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.417 ' HA ' ' HD2' ' A' ' 94' ' ' PRO . 58.9 tp -135.02 110.94 10.95 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.154 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 93' ' ' LEU . 88.0 Cg_endo -71.83 82.48 1.23 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.766 1.644 . . . . 0.0 111.165 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.4 t -75.05 118.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.162 -175.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -80.98 132.71 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 171.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 64.9 mt -111.79 90.64 3.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.25 -175.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -72.18 146.22 89.41 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.166 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_exo -54.32 124.33 15.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.761 1.64 . . . . 0.0 111.185 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 43' ' ' SER . 80.7 m-20 54.25 63.11 2.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.128 175.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.1 p -144.4 157.12 44.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.252 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -108.26 150.81 26.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.175 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -136.73 151.98 49.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 177.315 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.401 ' HB ' ' HB ' ' A' ' 116' ' ' VAL . 97.8 m -121.58 137.11 54.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.211 173.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.533 ' C ' HD23 ' A' ' 105' ' ' LEU . 7.1 tt -115.7 104.33 11.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.66 122.34 56.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.199 -178.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 90.5 p -142.82 162.73 34.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.199 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -159.82 159.24 27.52 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.257 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -56.49 125.04 17.73 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 121.739 1.626 . . . . 0.0 111.179 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 87.63 -0.14 84.63 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 174.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -120.28 -168.04 13.62 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -124.35 153.59 68.95 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.78 0.324 . . . . 0.0 111.269 179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -69.73 136.59 33.47 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.726 1.617 . . . . 0.0 111.252 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -112.31 125.63 54.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.218 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 58.3 tp -86.77 122.23 30.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 104' ' ' THR . 79.8 t -111.42 118.64 57.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 175.09 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -80.16 132.78 35.98 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.134 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 73.4 mt-10 -139.64 75.06 32.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.217 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo . . . . . 0 C--O 1.201 -1.339 0 C-N-CA 121.685 1.59 . . . . 0.0 111.228 179.339 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo . . . . . 0 N--CA 1.455 -0.769 0 CA-C-O 120.927 0.303 . . . . 0.0 111.318 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.23 130.1 45.3 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.126 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.24 -20.1 26.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -177.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 81.1 p -96.7 166.86 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.823 0.344 . . . . 0.0 111.152 177.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.54 150.76 21.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.272 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -119.06 132.36 56.02 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 97.2 t -129.32 138.25 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -127.56 95.31 4.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 178.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.85 151.29 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.148 177.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -137.57 134.6 35.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.151 179.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -92.97 93.96 8.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.191 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.95 11.36 25.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.218 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.51 -167.35 36.69 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 74.8 m-20 -116.1 24.59 11.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.742 0.306 . . . . 0.0 111.152 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 84.8 p -157.01 163.24 39.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.196 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 mp0 -64.76 137.11 57.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.233 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -121.56 150.65 41.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.197 -177.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -101.2 119.99 39.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 173.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 97.7 t -115.99 128.65 73.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.984 -172.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.3 t -134.86 106.33 6.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.143 177.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.9 t -108.42 114.12 45.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.16 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.57 -111.5 4.02 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 95.9 p -100.62 -5.0 27.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 111.227 178.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 69.7 p -87.44 166.41 14.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 -176.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 43.6 t -163.93 126.29 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.231 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 68.5 tp -135.3 118.51 16.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -94.92 156.25 16.42 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.207 -175.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 61.49 49.23 5.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.214 173.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.3 t -74.85 121.11 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.272 175.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -64.8 147.81 97.77 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.206 -170.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 78.6 Cg_exo -52.94 131.9 44.71 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.637 1.558 . . . . 0.0 111.295 177.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 67.7 mt 65.68 21.56 11.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.167 178.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -99.14 -170.04 30.78 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 174.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 96.1 p -149.91 162.03 41.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.761 0.315 . . . . 0.0 111.16 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.3 t -140.55 108.04 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.174 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -81.44 137.65 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -120.47 100.5 7.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.212 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -96.99 169.13 10.04 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.157 176.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 55.36 41.22 31.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 55.2 tp -106.58 116.53 58.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.239 -177.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.71 121.56 9.77 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.642 1.562 . . . . 0.0 111.236 -178.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.12 150.56 64.62 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 121.676 1.584 . . . . 0.0 111.214 176.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.04 172.08 19.07 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.6 t -84.84 113.12 21.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.778 0.323 . . . . 0.0 111.169 176.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -128.75 147.92 50.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.157 -178.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.5 m -93.86 95.17 8.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.237 172.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -78.82 146.19 33.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.164 -176.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.1 tp60 -112.64 104.52 12.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.069 173.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.97 93.74 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 71.42 -118.59 7.32 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -100.81 4.14 42.64 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.816 0.341 . . . . 0.0 111.155 -177.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -129.25 117.62 21.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.16 -177.191 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 31.1 t -69.35 131.15 44.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.157 172.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 84.3 mt -131.85 82.61 59.57 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.257 -178.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -70.92 143.62 45.71 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.766 1.644 . . . . 0.0 111.188 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.0 p -161.05 142.27 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 -176.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 59.8 tttm -79.29 119.1 21.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.212 173.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.9 mt -102.49 98.47 8.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.204 -173.376 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -78.52 152.91 78.62 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.201 173.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.46 148.91 61.57 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 121.787 1.658 . . . . 0.0 111.214 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 57.83 45.13 19.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.187 179.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.3 t -151.44 145.52 25.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -103.21 132.31 49.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.299 -174.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -123.9 107.32 11.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.267 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 96.7 m -83.87 125.52 32.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.089 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 89.8 mt -112.5 91.24 3.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.209 -178.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.4 t -82.81 117.06 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.097 177.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.7 t -112.9 133.55 54.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.261 178.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 -140.77 94.15 8.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.156 -176.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -57.56 119.51 6.81 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 121.79 1.66 . . . . 0.0 111.245 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 84.99 5.44 86.08 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -128.04 -133.08 3.66 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -136.36 121.0 12.87 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.715 0.293 . . . . 0.0 111.234 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.69 163.31 34.04 Favored 'Trans proline' 0 C--N 1.327 -0.586 0 C-N-CA 121.757 1.638 . . . . 0.0 111.167 178.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.3 tp60 -145.57 124.83 12.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.258 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.3 mp -102.24 131.22 48.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.191 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.1 t -130.45 120.69 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.238 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.21 132.78 42.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.23 176.27 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -130.96 149.26 73.23 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.205 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo . . . . . 0 C--O 1.199 -1.44 0 C-N-CA 121.641 1.561 . . . . 0.0 111.135 177.544 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.785 0.326 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.32 145.97 88.73 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.214 177.349 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -73.39 144.47 36.6 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 121.705 1.603 . . . . 0.0 111.258 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 66.3 tttp -64.77 132.44 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 109.02 -19.15 30.46 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 94.5 p -72.18 162.57 29.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 111.208 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -141.42 150.34 42.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.253 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -119.21 148.34 43.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.164 -175.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.8 p -146.8 133.79 14.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.166 176.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.7 ttm180 -98.6 120.82 39.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.212 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.56 91.22 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 174.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.4 t80 -88.86 125.09 34.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.169 -176.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -95.07 102.89 14.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.203 -179.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -90.65 2.41 55.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 -177.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -102.01 -175.29 27.87 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -178.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -111.63 28.85 8.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 111.189 -177.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 91.9 p -150.71 157.08 42.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.168 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -62.06 135.36 57.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.215 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 88.1 mt -114.39 141.11 48.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.218 -179.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -86.71 106.82 17.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.19 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.426 HG22 HG13 ' A' ' 88' ' ' VAL . 96.7 t -92.91 130.46 41.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.141 -174.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.4 t -157.51 117.85 3.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 174.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.6 t -105.46 119.6 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.216 -176.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.04 -113.15 4.04 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.7 p -114.85 8.72 16.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.806 0.336 . . . . 0.0 111.21 177.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.6 m -103.41 126.46 50.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.223 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 30.0 t -81.42 125.32 30.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.165 174.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 81.8 mt -113.46 176.42 5.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.224 -175.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -75.94 147.29 39.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.166 -175.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -70.68 154.42 41.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.203 177.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 90.8 t -115.28 133.83 60.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.124 -178.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -71.41 159.37 85.74 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.231 -175.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -53.38 133.64 53.91 Favored 'Trans proline' 0 N--CA 1.458 -0.603 0 C-N-CA 121.752 1.635 . . . . 0.0 111.217 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 84.8 mt 52.07 34.38 13.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.221 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.89 -163.17 11.74 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 86.6 p -162.48 159.54 25.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.82 0.343 . . . . 0.0 111.167 177.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -145.65 129.64 17.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.164 176.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -87.18 134.29 33.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.203 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -128.4 160.9 30.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.241 176.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -141.37 147.66 38.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.234 -177.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -132.16 139.95 48.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.195 175.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.533 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 60.7 tp -71.84 -48.08 11.51 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.186 179.262 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.533 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 41.5 Cg_endo -83.44 117.12 2.39 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.694 1.596 . . . . 0.0 111.268 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.03 164.36 29.73 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.735 1.624 . . . . 0.0 111.139 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.8 -175.04 23.95 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 177.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . 0.433 ' HA ' ' HA ' ' A' ' 96' ' ' LYS . 29.5 t -84.37 126.36 33.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.782 0.325 . . . . 0.0 111.181 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -130.06 156.54 44.34 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.189 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 95.6 m -89.74 99.86 12.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.134 174.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.91 85.11 7.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.136 -175.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -80.42 124.35 28.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.178 176.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.426 HG13 HG22 ' A' ' 58' ' ' VAL . 51.7 t -127.79 84.65 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.176 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.18 -109.34 2.85 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -86.24 -12.56 49.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.756 0.312 . . . . 0.0 111.16 -176.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.91 157.08 18.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.185 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.3 t -157.02 114.11 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.178 176.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.97 141.13 34.85 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.148 -175.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -77.27 67.51 7.67 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 121.688 1.592 . . . . 0.0 111.218 178.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.8 t -74.51 116.82 17.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.175 -176.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 83' ' ' SER . 88.5 tttt -84.37 126.9 33.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.269 175.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 89.1 mt -104.47 95.86 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.179 -177.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -70.63 150.31 95.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.211 174.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.09 144.91 53.73 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.691 1.594 . . . . 0.0 111.209 -178.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 59.27 45.75 13.73 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.195 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 45.7 t -151.41 144.65 24.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.201 -177.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 25.3 m-85 -101.93 150.55 23.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.222 176.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -132.26 145.73 51.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.199 176.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 94.0 m -122.68 119.09 29.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.173 171.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.7 tp -110.38 111.73 23.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.137 -176.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 97.7 t -85.2 114.15 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.217 174.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.4 t -105.51 109.76 21.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.208 177.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -113.18 103.35 55.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.21 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -57.62 117.81 4.57 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.672 1.581 . . . . 0.0 111.183 179.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 79.02 12.49 84.06 Favored Glycine 0 CA--C 1.523 0.555 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 176.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -127.09 -134.6 4.0 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -129.96 116.36 17.96 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 120.738 0.304 . . . . 0.0 111.209 -178.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -76.52 159.4 35.84 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 121.693 1.596 . . . . 0.0 111.225 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -145.09 120.94 10.6 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.262 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 57.6 tp -96.19 129.87 43.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.238 174.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.3 t -118.67 122.96 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.233 177.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -84.5 137.78 33.15 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 176.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -139.91 74.59 31.59 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.228 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_exo . . . . . 0 C--O 1.2 -1.39 0 C-N-CA 121.73 1.62 . . . . 0.0 111.165 178.949 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 96.5 mm-40 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.883 0.373 . . . . 0.0 111.19 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.79 148.32 75.78 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.205 178.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_exo -55.86 151.77 39.06 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.742 1.628 . . . . 0.0 111.186 176.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.9 tptp -57.55 118.71 5.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.211 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 104.88 -15.99 47.55 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -179.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 29.7 t -91.76 141.28 28.84 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.735 0.302 . . . . 0.0 111.21 -178.001 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.24 146.73 38.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.136 176.172 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -114.87 110.9 20.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.17 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.415 ' HB ' ' HB2' ' A' ' 76' ' ' PHE . 65.6 t -115.75 127.94 73.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.225 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.4 ttm180 -120.5 113.4 20.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.16 177.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.43 152.6 23.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.188 176.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -136.6 132.51 35.19 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.21 -178.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 64.8 t-20 -93.1 98.03 11.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.274 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.0 5.6 48.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.231 -177.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.44 -164.34 33.22 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 111.149 -0.781 . . . . 0.0 111.149 -177.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.0 m-80 -124.76 34.77 4.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.777 0.322 . . . . 0.0 111.209 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.6 p -159.06 -179.31 7.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.147 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -55.38 125.24 19.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.179 177.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.437 ' HB3' ' HB ' ' A' ' 68' ' ' VAL . 37.3 tp -70.43 126.8 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.17 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -112.96 81.4 1.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 176.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 90.2 t -134.11 135.28 54.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.188 -178.161 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 64' ' ' SER . 42.8 t -110.98 116.12 30.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.132 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 64.8 t -106.54 101.48 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.197 -171.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.91 -110.12 3.27 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 176.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.4 p -101.7 -6.58 23.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.784 0.326 . . . . 0.0 111.185 -177.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.9 m -120.68 115.83 24.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.18 -176.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 59' ' ' SER . 69.6 m -79.62 144.16 34.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.217 177.141 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 64.6 tp -115.81 115.74 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.183 -175.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -130.93 170.97 13.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.24 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 37.3 t0 55.23 59.54 3.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.171 178.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 56' ' ' LEU . 94.4 t -122.01 125.15 72.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.225 176.248 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -69.92 154.68 94.48 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.186 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -52.98 135.92 59.62 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.675 1.583 . . . . 0.0 111.212 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 53.3 mt 67.34 21.72 9.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.186 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -93.26 -168.25 38.82 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 175.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.7 p -162.99 167.83 21.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.792 0.329 . . . . 0.0 111.224 -177.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.7 t -155.53 136.88 14.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.122 177.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -99.9 144.23 29.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.21 -177.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.415 ' HB2' ' HB ' ' A' ' 46' ' ' VAL . 73.7 m-85 -128.47 150.33 50.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.249 179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -123.39 119.96 31.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 -179.156 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -123.29 95.68 4.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.184 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.503 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 63.5 tp -61.23 -48.6 91.15 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.17 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.503 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 49.2 Cg_endo -80.0 118.92 3.81 Favored 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 121.723 1.616 . . . . 0.0 111.206 177.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -77.54 166.49 25.7 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 121.752 1.635 . . . . 0.0 111.178 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 145.85 -173.38 26.21 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.3 t -83.36 121.27 26.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.787 0.327 . . . . 0.0 111.227 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -121.43 146.79 46.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.192 176.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.8 m -101.64 125.66 48.33 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.203 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -101.46 98.45 8.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.211 172.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -79.28 118.27 21.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.188 -174.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 54.1 t -119.53 78.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.175 -178.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 70.06 -111.2 3.68 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.15 -4.67 48.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.81 0.338 . . . . 0.0 111.169 177.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.9 mm-40 -109.66 172.63 6.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.19 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.4 p -158.28 156.11 30.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.115 177.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 87.3 mt -117.46 132.46 23.55 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.18 179.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -78.04 70.28 7.14 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 121.735 1.623 . . . . 0.0 111.209 177.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.4 t -80.02 82.86 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.227 -169.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -67.38 113.15 5.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.223 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 73.8 mt -95.99 117.1 29.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.211 -174.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -100.19 152.73 37.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.253 172.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -56.71 131.55 46.29 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 121.701 1.601 . . . . 0.0 111.163 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 63.67 23.59 13.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 172.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 44.0 t -104.02 148.51 26.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.227 175.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -105.61 139.27 40.47 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.196 -176.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -133.53 142.82 48.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.162 -178.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.8 m -120.69 127.58 52.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.179 173.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 68.7 mt -109.94 97.22 6.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.236 -179.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.8 t -92.12 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.138 -177.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 31.3 t -101.69 106.78 17.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.143 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 55.1 tp60 -115.07 104.95 53.54 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.253 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -55.72 139.45 83.4 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.709 1.606 . . . . 0.0 111.146 177.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 103.98 -19.83 42.63 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -142.41 -153.86 6.01 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -102.33 149.79 36.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.832 0.349 . . . . 0.0 111.231 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -72.08 153.45 57.41 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 121.665 1.577 . . . . 0.0 111.188 179.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.1 mm-40 -107.93 143.44 36.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.215 -177.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 54.7 tp -120.34 111.7 18.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.234 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.5 t -109.01 118.55 56.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.232 177.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -109.46 138.13 46.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.209 -179.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -126.17 118.5 23.57 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.226 177.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo . . . . . 0 C--O 1.2 -1.411 0 C-N-CA 121.694 1.596 . . . . 0.0 111.242 178.455 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 . . . . . 0 CA--C 1.523 -0.072 0 CA-C-O 120.84 0.352 . . . . 0.0 111.235 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.413 ' HA ' ' HD3' ' A' ' 40' ' ' PRO . . . -73.88 148.66 87.3 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.234 177.355 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 39' ' ' ALA . 75.3 Cg_exo -55.52 140.1 82.89 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 121.726 1.618 . . . . 0.0 111.133 177.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 57.2 tptt -57.16 122.62 12.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.211 -179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 114.98 -23.1 11.83 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 38.8 t -63.42 130.55 44.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.786 0.327 . . . . 0.0 111.152 -178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -114.67 146.71 40.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.209 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -125.38 138.94 54.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.196 -176.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 62.8 t -116.64 112.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.164 173.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -89.6 106.0 18.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.227 -176.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.62 145.57 30.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.235 178.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -125.61 128.92 48.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.244 178.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 50.6 t-20 -85.78 95.39 9.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.137 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.35 9.6 30.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.207 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -96.78 -169.43 33.88 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -179.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -106.85 9.37 30.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.78 0.324 . . . . 0.0 111.213 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 78.2 p -159.53 178.97 9.33 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.232 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -60.42 126.39 27.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.162 175.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 82.3 mt -110.7 147.3 34.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.22 -176.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -79.05 85.08 5.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.174 -179.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.3 t -115.65 128.08 73.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.125 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.0 p -150.66 156.03 40.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 173.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.2 t -129.87 123.68 57.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.232 -178.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 66.2 -112.73 5.15 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 88.5 p -114.36 7.22 16.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.835 0.35 . . . . 0.0 111.247 177.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 96.8 m -99.57 119.71 38.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.173 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 85.6 p -87.51 169.94 11.77 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.202 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.9 tp -158.14 134.9 9.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.159 178.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -149.62 179.51 7.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.193 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.2 t0 60.48 45.7 10.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.154 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 81.9 t -106.55 119.21 55.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.184 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -74.92 152.94 86.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.191 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_exo -53.66 133.68 55.01 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 121.709 1.606 . . . . 0.0 111.196 177.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 55.3 mt 66.86 21.07 10.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.224 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -96.67 -167.37 33.61 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 174.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 90.4 p -159.41 161.22 35.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.776 0.322 . . . . 0.0 111.201 -178.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.1 t -160.91 141.72 11.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.233 177.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -94.66 132.49 39.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.235 -175.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -91.95 121.56 33.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.188 169.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -95.26 116.67 29.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.17 -174.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -126.1 94.45 4.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.241 175.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.513 ' HB3' ' HD3' ' A' ' 80' ' ' PRO . 55.3 tp -56.99 -49.83 91.71 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.201 177.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.513 ' HD3' ' HB3' ' A' ' 79' ' ' LEU . 42.4 Cg_endo -80.16 124.77 5.56 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.692 1.595 . . . . 0.0 111.162 174.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -75.19 164.9 32.14 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.655 1.57 . . . . 0.0 111.284 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 143.22 -172.42 24.67 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.6 t -86.07 128.1 34.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 111.144 -176.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -130.62 146.1 52.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.232 174.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.8 m -96.31 115.61 27.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 -176.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -83.27 94.18 7.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.228 177.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.7 tp60 -78.95 120.22 23.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.165 178.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.7 t -131.53 100.47 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.124 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.99 -119.31 13.03 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -96.2 -2.61 45.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.744 0.307 . . . . 0.0 111.179 178.464 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -110.19 170.06 8.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.23 -179.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 97.1 p -152.07 154.01 35.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.204 177.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.3 tp -144.1 107.68 4.93 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.166 178.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -74.28 144.09 32.6 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 121.747 1.631 . . . . 0.0 111.202 178.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.3 p -149.42 135.41 11.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.206 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -85.57 122.65 29.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.239 173.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -94.09 113.35 25.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.259 -176.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.408 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 99.1 m-20 -71.57 147.34 92.24 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.214 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 98' ' ' ASP . 85.1 Cg_exo -53.81 129.12 32.5 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 121.66 1.573 . . . . 0.0 111.203 178.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 38.3 t0 55.42 62.94 2.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.229 177.052 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 85.5 p -145.6 165.61 28.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.212 178.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -122.54 147.29 46.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.251 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -131.62 144.46 51.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.256 176.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 86.8 m -105.68 119.7 39.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.155 176.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 59.8 tp -112.85 119.91 39.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.242 -178.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.48 113.71 41.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.155 -178.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.7 t -91.63 97.55 11.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.248 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 57.5 tp60 -113.51 106.65 54.01 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.183 -178.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 68.2 Cg_exo -56.46 144.04 85.3 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 121.69 1.593 . . . . 0.0 111.14 177.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 91.02 21.66 35.2 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 178.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 176.17 -169.62 42.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 178.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -88.14 150.4 47.22 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.807 0.337 . . . . 0.0 111.215 179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -71.99 149.3 52.74 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.685 1.59 . . . . 0.0 111.18 -179.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -106.98 148.66 28.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.224 179.047 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.0 tt -139.9 131.2 26.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 -175.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 86.9 t -122.99 129.14 75.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.266 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.62 136.72 37.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.229 178.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 80.0 mt-10 -139.68 76.32 29.85 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.231 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 81.5 Cg_exo . . . . . 0 C--O 1.2 -1.376 0 C-N-CA 121.681 1.587 . . . . 0.0 111.24 178.761 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.798 0.332 . . . . 0.0 111.206 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.56 149.87 86.47 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.223 176.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -53.8 144.25 55.53 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.726 1.618 . . . . 0.0 111.189 176.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 27.7 tptp -59.42 119.18 6.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.165 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 97.45 -1.02 60.07 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 174.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 56.7 p -105.22 -177.08 3.26 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.239 -177.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -135.19 154.51 51.58 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.216 178.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 74.1 t80 -130.44 132.01 45.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.153 -177.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 63.4 t -119.59 126.77 75.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.278 -175.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 85.9 mtt85 -99.81 177.06 5.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.189 170.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . 0.406 ' HA ' ' O ' ' A' ' 105' ' ' LEU . . . -148.24 155.72 41.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.22 -179.049 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 72.1 t80 -162.76 117.15 1.74 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.117 172.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -67.01 107.82 2.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.232 176.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -122.74 25.93 8.46 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.217 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -95.85 -157.34 31.83 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 47.7 p-10 -114.43 29.58 7.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.869 0.366 . . . . 0.0 111.279 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.7 p -163.1 162.44 25.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.35 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -85.3 130.37 34.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.223 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.507 ' C ' HD12 ' A' ' 56' ' ' LEU . 4.2 pp -157.35 162.66 39.09 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.231 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -98.28 148.26 23.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.148 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 99.5 t -127.13 135.33 63.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.197 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 86.8 p -153.96 166.7 32.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.221 177.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 8.4 p -148.72 129.93 5.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.164 176.314 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 62.98 -113.71 6.17 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 -178.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 90.8 p -112.8 10.84 19.21 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.982 0.42 . . . . 0.0 111.292 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.9 m -97.08 119.84 36.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.226 -178.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 28.8 t -81.39 123.28 28.43 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.193 172.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.1 mt -107.25 169.64 8.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.188 -177.094 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -151.14 177.36 10.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.123 175.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -65.12 119.94 11.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.219 -175.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 89.9 t -106.41 119.47 55.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.153 173.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.93 145.47 92.68 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.117 -177.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -52.2 133.94 48.95 Favored 'Trans proline' 0 C--N 1.328 -0.538 0 C-N-CA 121.617 1.545 . . . . 0.0 111.203 177.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 69.3 mt 65.8 23.38 11.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.212 -178.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -123.71 -166.02 12.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 37.4 t -166.26 151.91 8.6 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.884 0.373 . . . . 0.0 111.146 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.1 t -143.79 140.74 30.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.255 177.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -70.04 128.82 37.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.197 -175.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -131.57 163.81 27.21 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.241 174.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -63.1 125.35 23.73 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.149 175.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -76.93 144.42 38.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.229 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.45 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.2 mt -120.56 140.16 29.97 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.195 -176.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 34.9 Cg_exo -57.99 160.48 15.4 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.699 1.599 . . . . 0.0 111.219 171.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -70.86 151.13 62.56 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 121.599 1.533 . . . . 0.0 111.188 176.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.48 -157.37 25.64 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.6 t -103.38 109.01 20.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.803 0.335 . . . . 0.0 111.141 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 57.0 m-85 -121.45 109.69 15.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.204 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 94' ' ' PRO . 87.6 m -64.31 129.06 38.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.235 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -102.7 162.88 12.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.174 176.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -129.23 131.97 47.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.138 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 88.6 t -128.56 101.25 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.264 173.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 67.56 -116.18 7.67 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 -174.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -99.6 1.32 43.57 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.699 0.285 . . . . 0.0 111.168 177.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.3 mm-40 -106.45 170.91 7.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.226 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 91.9 p -144.01 157.37 44.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.215 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.8 tp -154.42 114.03 2.46 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.136 -178.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.42 ' HA ' ' HA ' ' A' ' 85' ' ' THR . 78.3 Cg_exo -55.0 125.23 18.49 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 121.634 1.556 . . . . 0.0 111.261 175.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 87.3 t -108.06 115.72 49.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.249 177.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -80.95 116.62 21.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 175.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.3 mt -103.23 114.99 29.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.264 -178.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.406 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 95.6 m-20 -95.12 149.31 36.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.178 175.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 98' ' ' ASP . 73.1 Cg_exo -54.48 133.22 55.39 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.664 1.576 . . . . 0.0 111.339 177.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 55.81 60.59 3.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.213 178.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 83.3 p -146.95 160.37 42.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.229 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -128.83 143.47 50.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.162 -177.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -132.51 154.72 49.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.288 -177.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 87.6 m -128.75 120.78 27.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.108 170.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 48' ' ' ALA . 70.2 tp -104.04 112.96 26.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.121 -178.386 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 33.0 m -117.39 157.95 18.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.189 -176.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 80.5 p -90.36 159.68 16.49 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.156 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 93.9 mm-40 -124.74 155.96 69.06 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.154 173.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -50.53 127.99 22.23 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.731 1.621 . . . . 0.0 111.188 177.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 104.61 -9.69 48.69 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -172.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 83.39 42.72 7.76 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -108.66 145.82 32.42 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 111.165 -175.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.5 152.78 30.21 Favored 'Trans proline' 0 C--N 1.328 -0.552 0 C-N-CA 121.643 1.562 . . . . 0.0 111.24 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 68.3 tp60 -151.59 107.69 3.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.22 175.215 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 60.6 tp -92.55 118.87 31.44 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.187 -177.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 67.2 t -121.88 113.12 37.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.241 176.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -66.45 129.14 38.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.202 177.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.21 73.55 25.83 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo . . . . . 0 C--O 1.201 -1.336 0 C-N-CA 121.817 1.678 . . . . 0.0 111.124 178.273 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 . . . . . 0 CA--C 1.524 -0.055 0 CA-C-O 120.806 0.336 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -70.75 146.35 93.32 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.12 178.4 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_exo -55.93 141.14 86.29 Favored 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 121.678 1.585 . . . . 0.0 111.212 179.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -61.36 129.98 43.86 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.193 175.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.92 3.43 55.91 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -175.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 89.3 p -87.97 162.15 17.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.813 0.339 . . . . 0.0 111.116 174.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.33 148.15 24.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.19 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -120.12 138.82 53.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.188 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.6 p -148.16 144.09 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.173 -179.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.9 ptt180 -142.93 153.2 42.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.252 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -94.01 155.06 17.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.215 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -135.23 130.62 35.51 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.209 175.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 55.7 t-20 -102.67 93.71 5.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.204 -176.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.33 70.69 7.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.229 177.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 170.62 177.78 40.89 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -97.88 -7.04 31.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.808 0.337 . . . . 0.0 111.145 -175.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 34.8 t -99.88 135.84 40.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.164 178.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 54.1 mp0 -61.77 140.49 58.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.172 176.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 93.0 mt -124.8 144.89 50.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.171 -175.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -106.37 111.05 23.47 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.244 174.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.97 166.96 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.192 -177.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 87.6 p -148.01 158.24 43.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 86' ' ' ALA . 51.2 t -127.04 85.6 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.243 174.246 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 67.97 -111.74 4.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 -176.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -84.86 -12.61 53.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.771 0.319 . . . . 0.0 111.166 178.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 99.3 m -84.47 126.24 33.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.25 -178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.8 t -103.4 119.44 38.88 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.192 179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.6 mt -125.11 67.5 1.12 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.173 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -91.42 158.82 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.251 -172.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 36.6 t0 55.31 60.49 3.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.213 178.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.1 t -82.55 130.77 35.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.203 176.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.55 147.08 88.92 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -171.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -54.89 129.23 34.09 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.657 1.571 . . . . 0.0 111.178 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 86.4 mt 50.74 33.53 8.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.112 -177.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -124.84 -162.03 11.25 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.5 p -148.64 166.42 28.37 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.743 0.306 . . . . 0.0 111.34 -177.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.4 t -137.95 100.96 4.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.235 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -76.93 150.85 35.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.201 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.1 t80 -142.82 127.81 18.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.106 174.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -116.42 178.6 4.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.183 -178.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 64.46 32.41 11.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.234 175.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 61.4 tp -102.16 115.26 64.87 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.084 -179.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.481 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 73.8 Cg_exo -54.88 128.33 30.02 Favored 'Trans proline' 0 N--CA 1.457 -0.624 0 C-N-CA 121.787 1.658 . . . . 0.0 111.179 176.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.481 ' HD3' ' HA ' ' A' ' 80' ' ' PRO . 58.7 Cg_exo -56.14 146.48 70.45 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 121.692 1.595 . . . . 0.0 111.225 176.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 156.32 -175.44 33.99 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 29.8 t -85.78 125.07 32.97 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.786 0.327 . . . . 0.0 111.107 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -130.24 143.66 50.91 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.181 176.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 96.0 m -98.3 110.57 23.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.206 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.446 ' HA ' ' HA ' ' A' ' 60' ' ' VAL . . . -75.58 151.13 37.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 177.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 72.6 tp60 -134.91 117.16 15.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.204 -179.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 61.3 t -127.37 106.5 15.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.196 173.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.78 -110.14 3.31 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -178.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -115.45 18.16 16.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.889 0.376 . . . . 0.0 111.191 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 63.0 tp60 -126.91 117.05 21.77 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -90.01 155.6 18.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.29 176.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 97.1 mt -141.2 85.12 12.23 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.142 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -55.35 129.25 34.18 Favored 'Trans proline' 0 N--CA 1.458 -0.582 0 C-N-CA 121.677 1.585 . . . . 0.0 111.189 174.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -146.71 135.35 15.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.235 -177.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -86.65 123.72 32.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.188 173.078 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 49.6 mt -100.02 103.01 14.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.271 -178.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -73.68 155.62 88.99 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.188 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.3 149.79 63.98 Favored 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 121.782 1.655 . . . . 0.0 111.197 179.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 55.01 45.23 26.81 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.13 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -151.58 147.48 26.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.272 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -106.38 140.51 39.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.197 -175.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -129.64 142.17 50.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.273 177.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 92.5 m -120.6 126.46 50.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.277 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 62.3 tp -94.49 98.91 11.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 176.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.5 t -78.42 106.15 8.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.115 -178.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 92.6 p -101.82 162.85 12.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 66.2 tt0 -154.42 133.28 7.11 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.112 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -57.75 101.97 0.12 Allowed 'Trans proline' 0 N--CA 1.459 -0.547 0 C-N-CA 121.717 1.612 . . . . 0.0 111.121 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 71.67 22.54 78.66 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 176.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -118.43 -167.63 14.04 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.37 124.32 43.31 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 120.814 0.34 . . . . 0.0 111.251 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -75.49 157.96 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 121.611 1.541 . . . . 0.0 111.265 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.5 tp60 -141.37 127.38 19.46 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.197 -175.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 95.5 mt -76.06 133.98 40.18 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.207 172.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 90.0 t -128.37 125.31 63.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.228 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.38 135.87 38.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.142 175.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 81.4 mt-10 -128.92 150.55 75.5 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -178.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo . . . . . 0 C--O 1.201 -1.349 0 C-N-CA 121.585 1.523 . . . . 0.0 111.231 178.002 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.6 tt0 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.744 0.307 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -80.67 152.55 72.55 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.118 -179.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -56.99 134.99 68.16 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.645 1.564 . . . . 0.0 111.238 178.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -80.24 163.09 24.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.158 177.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 113.64 -20.25 18.13 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -176.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.3 t -154.68 140.59 18.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 0.0 111.165 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.1 151.48 24.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.173 176.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -114.9 139.6 49.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.182 -173.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 10.9 p -140.45 140.39 34.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.131 -178.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 42.1 ttm180 -111.42 112.44 24.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.171 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.56 123.83 33.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.187 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -110.56 134.81 52.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -100.28 104.18 15.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.189 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.65 4.01 53.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.284 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -97.21 -171.28 33.67 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -102.92 2.67 35.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.888 0.375 . . . . 0.0 111.199 178.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 86.9 p -149.01 167.73 25.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.294 177.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -53.95 122.15 9.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.231 -178.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 90.1 mt -107.12 140.18 40.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.152 179.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -105.84 144.65 32.28 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.231 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.6 p -140.05 137.26 38.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 178.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 41.2 t -102.09 105.52 16.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.158 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 61.7 t -102.14 94.15 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.229 -176.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.16 -109.65 3.01 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -175.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 98.7 p -103.33 -7.42 21.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.752 0.31 . . . . 0.0 111.23 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.7 m -120.06 118.61 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.34 -175.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.3 p -89.13 154.63 20.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.251 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.4 mt -120.0 149.03 42.82 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.18 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 32.4 p30 -158.66 -174.9 5.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.177 -178.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.3 t0 63.07 46.19 4.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.22 177.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 66.1 t -117.49 121.6 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.231 174.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -70.59 145.99 93.26 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.136 -175.111 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 82.6 Cg_exo -53.36 131.49 43.65 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.619 1.546 . . . . 0.0 111.285 177.602 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 65.9 mt 66.42 20.17 10.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.169 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -127.63 -166.93 12.19 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 173.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 84.7 p -155.7 165.08 37.63 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.724 0.297 . . . . 0.0 111.215 -179.154 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 48.0 t -149.58 143.21 25.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.147 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -93.01 138.59 31.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 -178.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -129.69 161.43 30.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.255 -178.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.425 ' O ' ' HB2' ' A' ' 78' ' ' PHE . 63.4 pttt -158.02 -155.77 0.52 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.24 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.425 ' HB2' ' O ' ' A' ' 77' ' ' LYS . 50.0 m-85 68.35 33.09 4.32 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.138 -173.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.41 HD12 ' HD2' ' A' ' 80' ' ' PRO . 56.0 tp -134.85 116.67 12.59 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.216 -176.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.41 ' HD2' HD12 ' A' ' 79' ' ' LEU . 92.5 Cg_exo -51.67 133.83 45.41 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 121.618 1.545 . . . . 0.0 111.286 179.459 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -55.47 147.81 55.83 Favored 'Trans proline' 0 N--CA 1.457 -0.645 0 C-N-CA 121.77 1.647 . . . . 0.0 111.217 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.16 -171.91 30.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.0 t -103.59 124.74 49.36 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.796 0.331 . . . . 0.0 111.21 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -127.33 140.52 52.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.243 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 90.6 m -80.4 117.54 21.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.187 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -92.26 108.31 19.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.197 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 69.4 tp60 -85.14 113.8 21.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.254 179.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.9 t -122.66 103.09 12.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.215 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.65 -118.94 12.44 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -98.29 -0.55 43.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.741 0.305 . . . . 0.0 111.21 177.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.5 mm-40 -109.01 168.35 9.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.085 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.6 p -149.08 153.8 38.33 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.253 177.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 58.2 tp -151.76 114.91 3.0 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.273 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -57.37 131.41 44.58 Favored 'Trans proline' 0 C--N 1.326 -0.608 0 C-N-CA 121.613 1.542 . . . . 0.0 111.118 174.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.7 t -123.81 118.49 54.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.223 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -86.31 124.54 32.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 172.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 84.2 mt -118.54 139.03 52.09 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.175 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 77.0 m-20 -114.82 155.68 45.99 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.32 -176.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -80.08 -19.92 9.08 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 121.788 1.658 . . . . 0.0 111.211 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -92.93 -30.57 15.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.193 -173.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.1 t -126.16 -158.76 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.145 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 44.4 p90 -149.42 159.23 44.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.192 176.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -126.85 141.72 51.74 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.203 177.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 98.4 m -102.16 118.23 36.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.147 -176.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 64.2 tp -99.52 113.31 25.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.141 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.0 t -81.69 99.29 4.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 177.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 29.1 t -85.22 123.41 30.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.142 -176.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -91.43 152.5 43.73 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.232 177.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.82 68.31 7.21 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 121.683 1.589 . . . . 0.0 111.24 -179.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 102.49 -7.37 53.75 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 178.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -96.15 -166.41 34.13 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.329 -0.708 . . . . 0.0 111.329 -178.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -87.79 127.73 56.94 Favored Pre-proline 0 C--N 1.327 -0.375 0 CA-C-O 120.877 0.37 . . . . 0.0 111.16 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -75.88 160.31 37.38 Favored 'Trans proline' 0 N--CA 1.457 -0.634 0 C-N-CA 121.683 1.589 . . . . 0.0 111.232 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -129.02 118.55 22.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.233 178.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 50.3 tp -85.39 128.03 34.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.18 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.7 126.73 72.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.143 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -78.76 73.18 5.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.137 179.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 119' ' ' PRO . 88.0 tt0 -67.59 129.99 93.32 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.234 -178.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 118' ' ' GLU . 84.1 Cg_exo . . . . . 0 C--O 1.2 -1.42 0 C-N-CA 121.628 1.552 . . . . 0.0 111.161 178.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.804 0.335 . . . . 0.0 111.243 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -70.39 146.25 94.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.271 177.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -56.98 140.46 92.49 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 121.671 1.58 . . . . 0.0 111.206 178.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -63.66 122.8 17.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.175 -176.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.63 5.56 78.24 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 175.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 69.8 m -117.84 160.65 21.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.842 0.353 . . . . 0.0 111.058 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.37 146.75 24.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.262 177.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.6 t80 -115.67 130.9 57.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.209 175.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 91.5 t -128.07 131.83 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.148 176.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -115.09 104.94 12.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.202 173.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.5 147.27 32.28 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.209 -178.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -138.4 133.88 33.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.064 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 51.5 t-20 -99.2 105.22 17.24 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.255 -178.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -96.22 24.3 5.83 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.204 -174.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -125.08 -165.05 12.02 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -115.3 27.33 9.44 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.756 0.313 . . . . 0.0 111.219 -179.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 44.8 t -146.6 130.33 17.04 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.199 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -59.91 131.3 50.44 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.12 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 87.8 mt -116.1 146.99 41.78 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.195 -174.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -89.38 111.13 21.91 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.217 -179.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 87.6 t -96.07 134.32 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.157 -174.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 83.8 p -156.76 167.37 30.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.239 173.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.08 130.57 5.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 178.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 64.33 -114.11 6.51 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.9 p -114.04 9.11 17.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 94.5 m -99.87 118.48 36.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.177 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.6 t -78.32 123.95 27.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.236 174.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 84.2 mt -106.4 173.55 6.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.303 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -73.11 144.9 46.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.217 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -70.86 150.64 45.58 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.223 177.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -117.63 123.4 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.106 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -72.82 159.96 84.05 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.2 -178.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_exo -52.69 125.64 18.59 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.713 1.609 . . . . 0.0 111.239 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.3 mt 65.18 22.07 12.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.108 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -112.29 -172.66 18.96 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 175.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 95.9 p -152.24 164.16 37.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.855 0.359 . . . . 0.0 111.171 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 47.9 t -149.39 124.95 10.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.213 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -83.6 137.7 33.7 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.315 178.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -127.41 118.35 23.92 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.215 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -113.25 168.42 9.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.19 -177.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 63.81 31.96 13.78 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.148 174.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.403 ' HA ' ' HD3' ' A' ' 80' ' ' PRO . 96.5 mt -86.22 125.88 66.66 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.268 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 79' ' ' LEU . 74.6 Cg_exo -55.71 116.04 2.88 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.639 1.559 . . . . 0.0 111.227 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -59.87 147.67 91.62 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 121.714 1.609 . . . . 0.0 111.175 175.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.97 -161.99 27.51 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 177.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 37.3 t -103.29 109.69 21.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.766 0.317 . . . . 0.0 111.249 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -132.78 155.31 49.14 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.345 -177.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.9 m -88.83 117.61 27.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.168 178.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -93.23 114.15 26.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.245 -179.223 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.3 tt0 -107.71 131.99 53.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.232 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.9 t -131.04 105.68 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.149 172.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 81.51 -106.66 2.64 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.109 -0.796 . . . . 0.0 111.109 -174.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.6 mm-40 -113.02 -24.48 9.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.773 0.321 . . . . 0.0 111.133 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -98.72 154.0 18.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.277 -177.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 86.7 p -150.76 148.17 28.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.304 -178.02 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 94' ' ' PRO . 87.6 mt -143.0 141.18 19.03 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.247 174.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 93' ' ' LEU . 61.1 Cg_exo -55.97 137.09 77.92 Favored 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 121.65 1.567 . . . . 0.0 111.136 175.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 31.7 m -127.45 150.72 33.53 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.237 176.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -100.74 115.73 30.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.282 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 88.4 mt -107.68 100.04 9.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.204 -177.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -88.35 147.12 39.31 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.184 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -71.78 149.14 53.75 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 121.74 1.627 . . . . 0.0 111.188 179.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 59.98 43.26 14.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 81.9 p -147.95 161.17 41.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.176 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -114.93 144.74 43.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.196 -175.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -133.85 147.68 51.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.169 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 99.5 m -118.14 129.86 55.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.154 169.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 46.8 tp -114.95 101.41 8.99 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.185 -173.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 90.7 t -100.04 128.27 52.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.265 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 45.5 t -148.91 150.86 33.65 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.107 -176.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -153.48 159.0 32.65 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.232 176.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -54.98 123.72 14.5 Favored 'Trans proline' 0 C--N 1.328 -0.543 0 C-N-CA 121.688 1.592 . . . . 0.0 111.161 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.85 -20.01 47.51 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.204 -0.759 . . . . 0.0 111.204 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -111.08 -171.76 19.45 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -124.06 155.58 67.37 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 111.178 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -56.58 120.24 7.99 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 121.594 1.529 . . . . 0.0 111.28 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 60.3 tp60 -104.12 112.43 25.43 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.186 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 35.7 tp -77.23 129.26 35.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.222 178.083 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.4 t -115.92 114.03 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.094 172.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -76.24 132.91 40.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.214 -178.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 76.7 mt-10 -139.38 76.13 31.9 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.258 177.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo . . . . . 0 C--O 1.199 -1.45 0 C-N-CA 121.67 1.58 . . . . 0.0 111.183 179.466 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 66.2 tp60 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.798 0.332 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.26 149.47 86.93 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.182 177.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo -55.51 143.38 78.38 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 121.778 1.652 . . . . 0.0 111.217 177.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -62.19 115.36 4.07 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.191 179.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.66 4.27 57.07 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 28.9 t -65.41 131.24 45.93 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.816 0.341 . . . . 0.0 111.177 -179.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -116.38 145.74 43.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.171 173.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 85.2 m-85 -124.43 135.66 53.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.221 -174.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 67.4 t -124.32 124.81 69.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.241 170.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -110.49 111.7 23.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.199 176.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.11 149.33 29.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.258 175.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -148.42 132.34 17.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.272 177.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.439 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 58.5 t-20 -91.32 99.55 12.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.71 5.13 50.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.139 -175.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.97 -171.95 37.21 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 -178.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -115.21 26.22 10.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.198 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 88.2 p -151.37 164.71 36.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.207 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -79.08 128.97 33.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.19 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.82 148.98 51.75 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.23 -177.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -85.24 128.71 34.78 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.217 176.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.9 t -122.78 130.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.204 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 42.1 t -136.46 123.26 21.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.229 -178.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 80.7 t -126.46 107.46 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.198 178.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.5 -116.48 5.78 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 97.9 p -102.26 -6.86 22.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.194 -176.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 93.3 m -115.54 136.08 53.43 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.133 -177.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 87.7 p -142.52 157.79 44.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.139 -174.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 69.8 tp -137.8 119.72 15.35 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.089 175.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -88.53 150.43 23.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.238 -175.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 54.51 59.41 4.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.229 177.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 94.1 t -75.99 120.82 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.12 148.41 97.89 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.227 -173.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -52.11 132.57 43.83 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 121.728 1.619 . . . . 0.0 111.196 176.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.8 mt 66.59 21.2 10.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.89 -171.15 43.36 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 174.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 85.1 p -159.77 166.61 30.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.327 . . . . 0.0 111.243 -176.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 43.8 t -157.89 118.77 3.48 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.213 177.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -88.79 139.03 30.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.228 -176.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -121.05 93.84 4.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.149 172.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -98.15 154.89 17.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.243 -164.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 67.0 33.73 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.175 166.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 97.5 mt -84.02 137.89 40.19 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.185 177.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.47 ' HA ' ' HD3' ' A' ' 81' ' ' PRO . 77.6 Cg_endo -72.12 150.2 53.51 Favored 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 121.704 1.603 . . . . 0.0 111.234 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 80' ' ' PRO . 65.4 Cg_exo -57.19 145.0 88.98 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 121.8 1.667 . . . . 0.0 111.192 178.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 148.27 -172.18 28.57 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.4 t -94.6 134.92 36.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.227 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 -125.82 151.18 47.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.195 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 98.6 m -95.26 118.97 32.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.196 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -108.7 96.02 6.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.216 179.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 60.7 tt0 -94.9 130.51 41.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.214 -178.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 95.1 t -127.91 119.45 51.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.229 168.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 66.89 -110.02 3.24 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -178.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -108.16 -9.58 15.55 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.76 0.314 . . . . 0.0 111.177 -175.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -113.49 160.27 18.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.209 -176.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 95.5 p -147.69 148.46 31.05 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.237 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 90.4 mt -135.39 150.04 71.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.23 177.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.04 146.6 32.7 Favored 'Trans proline' 0 N--CA 1.458 -0.594 0 C-N-CA 121.665 1.577 . . . . 0.0 111.129 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 89.4 t -124.78 126.37 71.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.189 177.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -99.11 111.94 24.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.131 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.8 mt -106.39 135.57 47.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.241 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 87.9 m-20 -113.79 162.26 23.58 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.114 -177.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_exo -51.91 123.28 12.07 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 121.781 1.654 . . . . 0.0 111.198 175.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 56.02 64.73 1.63 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.14 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 77.0 p -140.87 157.57 45.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.219 -177.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -118.75 161.2 20.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.197 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.4 t80 -157.44 149.87 22.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.236 -175.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 97.7 m -127.42 134.73 49.86 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.208 179.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 63.6 tp -116.02 111.73 20.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.141 177.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.452 ' HB ' ' HB3' ' A' ' 114' ' ' GLN . 85.9 t -103.38 123.96 57.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.117 -175.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.439 ' HB2' ' HA ' ' A' ' 50' ' ' ASN . 67.8 m -84.91 127.6 34.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.236 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -98.37 148.77 34.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_exo -52.02 131.75 40.13 Favored 'Trans proline' 0 N--CA 1.459 -0.556 0 C-N-CA 121.657 1.572 . . . . 0.0 111.179 176.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 101.95 -10.45 57.1 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -177.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.74 67.87 1.34 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 178.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -140.54 130.93 13.62 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-O 120.768 0.318 . . . . 0.0 111.303 175.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.61 148.86 33.55 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.742 1.628 . . . . 0.0 111.181 -178.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . 0.452 ' HB3' ' HB ' ' A' ' 106' ' ' VAL . 49.7 tt0 -126.01 125.04 42.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 171.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 94.3 mt -85.51 118.45 25.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.264 -175.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 82.9 t -125.9 112.52 30.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.306 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -86.37 136.24 33.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.258 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -100.8 152.78 37.93 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.17 179.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo . . . . . 0 C--O 1.201 -1.374 0 C-N-CA 121.741 1.628 . . . . 0.0 111.209 -178.562 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.82 0.343 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.2 145.36 88.32 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.156 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -75.72 155.63 39.68 Favored 'Trans proline' 0 N--CA 1.458 -0.595 0 C-N-CA 121.653 1.569 . . . . 0.0 111.248 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -62.06 124.43 20.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 176.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 107.14 -1.61 35.26 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.441 ' O ' ' N ' ' A' ' 100' ' ' ASP . 86.0 p -68.59 161.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.904 0.383 . . . . 0.0 111.159 -178.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -158.23 148.88 20.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.202 178.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -125.98 142.62 51.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.228 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.21 126.96 71.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 175.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 41.5 ttm180 -110.48 100.42 9.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.199 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -69.28 148.15 50.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.186 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -145.65 131.15 18.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.163 178.412 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 58.4 t-20 -93.95 100.06 12.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 178.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -88.72 4.23 48.05 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.189 -173.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -99.64 -169.19 30.01 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -176.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 75.7 m-20 -115.32 22.74 13.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.78 0.324 . . . . 0.0 111.161 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 82.5 p -147.04 168.89 20.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.232 177.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.413 ' HA ' ' O ' ' A' ' 68' ' ' VAL . 99.7 mt-10 -77.17 139.61 39.97 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.179 -173.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 96.3 mt -115.93 147.9 40.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -106.41 111.51 24.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.211 173.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 27.6 m -128.44 166.09 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.208 -175.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 45.2 t -152.97 120.3 5.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.161 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 85.8 t -123.63 125.64 71.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.146 -173.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.61 -116.46 7.43 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 87.8 p -114.03 9.22 17.29 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.797 0.332 . . . . 0.0 111.231 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 95.3 m -121.8 115.22 22.25 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.206 -178.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 67.5 m -84.95 149.43 25.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.231 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 54.3 tp -144.71 94.45 2.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.149 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -92.9 159.19 15.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.277 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 61.51 48.3 5.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.289 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 55' ' ' GLU . 99.2 t -72.0 118.91 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.273 178.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -64.02 145.79 97.7 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.267 -174.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 85.2 Cg_exo -52.95 130.69 39.02 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 121.717 1.611 . . . . 0.0 111.248 177.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 59.1 mt 66.17 21.31 11.13 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.177 178.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.32 177.99 39.77 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 175.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 87.0 p -156.1 164.71 38.08 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.758 0.314 . . . . 0.0 111.179 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.2 t -161.38 127.37 3.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.192 179.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 94.9 m-20 -88.21 137.34 32.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.197 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -119.72 134.17 55.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.217 176.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -104.2 122.9 46.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.17 -171.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -111.07 133.67 53.26 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.207 173.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.499 ' HB2' ' HD3' ' A' ' 80' ' ' PRO . 96.3 mt -89.82 -45.52 0.41 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.275 179.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.499 ' HD3' ' HB2' ' A' ' 79' ' ' LEU . 22.5 Cg_endo -90.0 143.95 4.19 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 121.73 1.62 . . . . 0.0 111.225 -178.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_endo -76.48 162.85 32.86 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 121.689 1.592 . . . . 0.0 111.162 173.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.37 -118.45 1.28 Allowed Glycine 0 CA--C 1.523 0.538 0 N-CA-C 111.204 -0.758 . . . . 0.0 111.204 177.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 87.1 p -166.59 162.61 16.66 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.812 0.339 . . . . 0.0 111.188 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -160.01 136.11 8.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.23 177.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 92.0 m -87.42 111.64 21.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.226 178.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -84.06 146.26 28.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.223 -176.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.4 tp60 -88.96 120.98 30.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.216 176.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 46.7 t -125.12 80.88 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 65.82 -115.3 7.4 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 -176.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -94.11 -3.24 51.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.86 0.362 . . . . 0.0 111.192 174.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -107.93 178.04 4.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.208 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 94.6 p -148.97 159.04 44.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.22 176.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.417 ' HA ' ' HD2' ' A' ' 94' ' ' PRO . 58.9 tp -135.02 110.94 10.95 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.154 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' A' ' 93' ' ' LEU . 88.0 Cg_endo -71.83 82.48 1.23 Allowed 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 121.766 1.644 . . . . 0.0 111.165 176.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.4 t -75.05 118.26 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.162 -175.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -80.98 132.71 35.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.181 171.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 64.9 mt -111.79 90.64 3.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.25 -175.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -72.18 146.22 89.41 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.166 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_exo -54.32 124.33 15.79 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 121.761 1.64 . . . . 0.0 111.185 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.441 ' N ' ' O ' ' A' ' 43' ' ' SER . 80.7 m-20 54.25 63.11 2.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.128 175.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 96.1 p -144.4 157.12 44.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.252 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -108.26 150.81 26.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.175 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -136.73 151.98 49.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 177.315 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.401 ' HB ' ' HB ' ' A' ' 116' ' ' VAL . 97.8 m -121.58 137.11 54.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.211 173.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.533 ' C ' HD23 ' A' ' 105' ' ' LEU . 7.1 tt -115.7 104.33 11.58 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 85.8 t -103.66 122.34 56.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.199 -178.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 90.5 p -142.82 162.73 34.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.199 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -159.82 159.24 27.52 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.257 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -56.49 125.04 17.73 Favored 'Trans proline' 0 N--CA 1.458 -0.576 0 C-N-CA 121.739 1.626 . . . . 0.0 111.179 179.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 87.63 -0.14 84.63 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 174.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -120.28 -168.04 13.62 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -124.35 153.59 68.95 Favored Pre-proline 0 C--N 1.327 -0.38 0 CA-C-O 120.78 0.324 . . . . 0.0 111.269 179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -69.73 136.59 33.47 Favored 'Trans proline' 0 C--N 1.328 -0.534 0 C-N-CA 121.726 1.617 . . . . 0.0 111.252 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.6 tp60 -112.31 125.63 54.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.218 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 58.3 tp -86.77 122.23 30.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.134 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 104' ' ' THR . 79.8 t -111.42 118.64 57.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.191 175.09 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -80.16 132.78 35.98 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.134 -179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 73.4 mt-10 -139.64 75.06 32.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.217 179.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo . . . . . 0 C--O 1.201 -1.339 0 C-N-CA 121.685 1.59 . . . . 0.0 111.228 179.339 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 . . . . . 0 CA--C 1.522 -0.117 0 CA-C-O 120.928 0.394 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.27 145.91 88.8 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.11 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.9 78.07 1.81 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 121.637 1.558 . . . . 0.0 111.318 178.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.23 130.1 45.3 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.126 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 110.24 -20.1 26.26 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 -177.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 81.1 p -96.7 166.86 11.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.823 0.344 . . . . 0.0 111.152 177.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -91.54 150.76 21.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.272 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -119.06 132.36 56.02 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 97.2 t -129.32 138.25 54.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.166 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -127.56 95.31 4.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 178.214 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.85 151.29 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.148 177.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -137.57 134.6 35.8 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.151 179.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 57.9 t-20 -92.97 93.96 8.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.191 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -91.95 11.36 25.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.218 -177.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -94.51 -167.35 36.69 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 74.8 m-20 -116.1 24.59 11.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.742 0.306 . . . . 0.0 111.152 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 84.8 p -157.01 163.24 39.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.196 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 mp0 -64.76 137.11 57.6 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.233 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 97.4 mt -121.56 150.65 41.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.197 -177.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -101.2 119.99 39.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 173.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 97.7 t -115.99 128.65 73.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.984 -172.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 44.3 t -134.86 106.33 6.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.143 177.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.9 t -108.42 114.12 45.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.299 -0.409 . . . . 0.0 111.16 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 68.57 -111.5 4.02 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 95.9 p -100.62 -5.0 27.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.753 0.311 . . . . 0.0 111.227 178.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 69.7 p -87.44 166.41 14.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.173 -176.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 43.6 t -163.93 126.29 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.231 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 68.5 tp -135.3 118.51 16.59 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.228 174.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -94.92 156.25 16.42 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.207 -175.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 75.6 m-20 61.49 49.23 5.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.214 173.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 99.3 t -74.85 121.11 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.272 175.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . . . -64.8 147.81 97.77 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.206 -170.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 69' ' ' ALA . 78.6 Cg_exo -52.94 131.9 44.71 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 121.637 1.558 . . . . 0.0 111.295 177.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 67.7 mt 65.68 21.56 11.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.167 178.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -99.14 -170.04 30.78 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 174.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 96.1 p -149.91 162.03 41.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.761 0.315 . . . . 0.0 111.16 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 45.3 t -140.55 108.04 5.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.174 -179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -81.44 137.65 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -120.47 100.5 7.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.212 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -96.99 169.13 10.04 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.157 176.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 55.36 41.22 31.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 55.2 tp -106.58 116.53 58.85 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.239 -177.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -53.71 121.56 9.77 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 121.642 1.562 . . . . 0.0 111.236 -178.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -58.12 150.56 64.62 Favored 'Trans proline' 0 N--CA 1.457 -0.636 0 C-N-CA 121.676 1.584 . . . . 0.0 111.214 176.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.04 172.08 19.07 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 30.6 t -84.84 113.12 21.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.778 0.323 . . . . 0.0 111.169 176.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -128.75 147.92 50.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.157 -178.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 94.5 m -93.86 95.17 8.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.237 172.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -78.82 146.19 33.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.164 -176.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 70.1 tp60 -112.64 104.52 12.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.069 173.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.97 93.74 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.143 -174.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 71.42 -118.59 7.32 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 -177.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 99.7 mm-40 -100.81 4.14 42.64 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.816 0.341 . . . . 0.0 111.155 -177.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 64.7 tp60 -129.25 117.62 21.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.16 -177.191 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 31.1 t -69.35 131.15 44.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.157 172.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 84.3 mt -131.85 82.61 59.57 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.257 -178.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -70.92 143.62 45.71 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 121.766 1.644 . . . . 0.0 111.188 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.0 p -161.05 142.27 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 -176.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' LYS . . . . . . . . . . . . . 59.8 tttm -79.29 119.1 21.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.212 173.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 79.9 mt -102.49 98.47 8.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.204 -173.376 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -78.52 152.91 78.62 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.201 173.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.46 148.91 61.57 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 121.787 1.658 . . . . 0.0 111.214 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 57.83 45.13 19.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.187 179.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.3 t -151.44 145.52 25.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -103.21 132.31 49.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.299 -174.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -123.9 107.32 11.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.267 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 96.7 m -83.87 125.52 32.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.089 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 89.8 mt -112.5 91.24 3.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.209 -178.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 99.4 t -82.81 117.06 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.097 177.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.7 t -112.9 133.55 54.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.261 178.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 -140.77 94.15 8.22 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.156 -176.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_exo -57.56 119.51 6.81 Favored 'Trans proline' 0 N--CA 1.458 -0.578 0 C-N-CA 121.79 1.66 . . . . 0.0 111.245 178.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 84.99 5.44 86.08 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 178.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -128.04 -133.08 3.66 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -136.36 121.0 12.87 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.715 0.293 . . . . 0.0 111.234 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo -75.69 163.31 34.04 Favored 'Trans proline' 0 C--N 1.327 -0.586 0 C-N-CA 121.757 1.638 . . . . 0.0 111.167 178.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 66.3 tp60 -145.57 124.83 12.97 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.258 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.3 mp -102.24 131.22 48.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.191 174.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 78.1 t -130.45 120.69 49.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.238 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -97.21 132.78 42.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.23 176.27 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -130.96 149.26 73.23 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.205 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo . . . . . 0 C--O 1.199 -1.44 0 C-N-CA 121.641 1.561 . . . . 0.0 111.135 177.544 . . . . . . . . 0 0 . 1 stop_ save_